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Abstract
This thesis is concerned with the psychosocial impact of psoriatic arthritis (PsA) - an
inflammatory arthritis associated with psoriasis.
Although an extensive literature exists on the nature and impact of psoriasis, little is known
about the effect that psoriatic arthritis can have on an individual, and the bearing it may have
on their quality of life. In order to address this gap in the literature, this study utilised a mixed
methods research design, employing a qualitative study with semi-structured interviews,
followed by a quantitative, cross-sectional postal survey.
In the qualitative study, interviews were conducted with ten people living with psoriatic
arthritis. Analysis of the data, using Interpretative Phenomenological Approach (JPA; Smith,
2003) resulted in five emerging themes; pain, functionality (including fatigue), emotions
(including depression), coping and treatment experience/management.
The quantitative study used a postal survey to measure the variables of interest and explore the
associations between them. Survey respondents consisted of a sample (n = 313) drawn from
The Psoriasis Association membership and also 44 from a hospital rheumatology clinic. AA
participants completed a piloted questionnaire containing questions about their demographic
characteristics and validated measures of quality of life.
Analysis confirmed that the group with PsA fared less well on all measures of quality of life,
than those with just psoriasis. Correlations identified highly significant relationships between
most study variables, however of note were the relationships between fatigue and current pain
(r = .547) and depression (r = .670). Within the Psoriasis Group correlations of interest
included those between anxiety and social functioning (r = -.606) and DLQI and social
functioning (r = -.546). Comparison of the correlations identified 18 that were significantly
different between the groups. Of these, relationships between physical functioning, pain,
fatigue and self efficacy were of particular interest, whilst in the psoriasis group the
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associations between self efficacy, social functioning and psychological health were
noteworthy.
This research provides some evidence that different psychosocial variables appear to be
involved in the reductions in quality of life experienced by the two clinical populations in this
study.
The results suggest that in rheumatology and dermatology clinics, the routine measurement of
fatigue, self efficacy and psychological health could be used to inform the prescribing of
therapies, psychosocial interventions and drugs to improve emotional functioning, so
impacting on health-related quality of life.
Furthermore, these fmdings have highlighted the need to elucidate the symptom of fatigue in
PsA and position it as an appropriate target not only for clinical management, but also
psychological management. By advocating fatigue as a legitimate concern, this may offer
patients the chance to discuss fatigue explicitly and obtain appropriate health advice.
x
CHAPTER!
INTRODUCTION TO THESIS
1.1 Background
Although an extensive literature exists on the nature and impact of psoriasis, little is known
about the effect that psoriatic arthritis can have on an individual and the bearing it may have
on their quality oflife.
This thesis is concerned with the psychosocial impact of psoriatic arthritis (PsA) - an
inflammatory arthritis associated with psoriasis. Whilst both these chronic conditions warrant
exploration, the focus of this research is PsA, however given that the conditions are linked, the
role of psoriasis is, by necessity, reviewed.
In summary, research examining the psychosocial aspects of PsA has been historically under-
investigated with the vast majority of the published literature consisting of clinical reports and
a limited number of prevalence studies. It is clear that there are substantial gaps in the
literature, and that basic questions about the scope, nature and impact of psychosocial issues
_ among individuals with PsA, remain largely unanswered.
1.2 Research Questions
In order to address these deficiencies and provide a valid and detailed assessment of the
impact of psychosocial issues related to PsA, several research questions are addressed in the
present study:
(1) What is the prevalence and nature of the psychosocial issuess experienced
by people with PsA?
(2) What is the impact of these issues on the quality oflife in people with PsA?
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(3) To what extent do physical and psychosocial issues influence how people
with PsA cope with the disease?
Given that there is a paucity of research concerning the psychological impact of living with
PsA, no specific hypotheses were formulated. Rather, exploratory analyses were conducted to
determine which psychosocial issues were viewed as pertinent by patients, before using
quantitative instruments to measure the impact and determine the presence of any associations.
1.3 Methodology
The methodology adopted, in turn, reflected the nature of these research questions. The
present study utilised a mixed methods research design involving semi-structured interviews
(Study 1) and a cross-sectional postal survey (Study 2).
Study 1: Interviews were conducted with ten people living with psoriatic arthritis.
Study participants were a purposive sample drawn from a hospital rheumatology clinic located
in Liverpool, UK. The inclusion criteria were three-fold: participants had to be aged between
18 and 65; had a new or existing diagnosis ofPsA, and spoke English as their first language.
The sessions were audio taped and tapes transcribed verbatim and, in order to identify
emerging themes, were interpreted using Interpretative Phenomenological Approach (IPA) as
'described by Smith (2003).
Study 2: Survey respondents consisted of a sample (n = 313) drawn from The Psoriasis
Association membership and also 44 from a hospital rheumatology clinic. All participants
completed a piloted questionnaire containing questions about their demographic
characteristics and validated measures of quality of life.
1.4 Structure of thesis
Chapter 2 considers, in broad terms, the impact of chronic illness with particular reference to
inflammatory arthritis and more specifically, psoriatic arthritis. A critical review of the
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existing literature concerning PsA-related psychosocial issues is discussed. However, given
the shortage of published papers in this area, psychosocial functioning in people with
rheumatoid arthritis (RA) and ankylosing spondylitis (AS) is explored with implications for
the current study.
A discussion and justification of the methodology adopted to meet the aims of the current
study is presented in Chapter 3. The design and sampling methods for the research in Study 1
and 2 are described, as is the rationale for using qualitative interviews, rather than focus
groups.
Chapter 4 presents the research design and sampling methods for Study 1. It reports the results
and discusses the findings and their implications for the choice of quantitative measures used
in Study 2.
Chapter 5 reviews the instruments available to measure the psychosocial variables that Study 1
determined were of interest. The chapter concludes with justification for the final choice of
measures to be used in Study 2.
Chapter 6 considers the aims and objectives of Study 2. The research design, sampling method
and results are presented, along with a discussion that interprets the findings.
Chapter 7 considers the findings of both Study 1 and 2 and examines the results in the context
of the current literature concerning PsA and psoriasis. It summarises the major findings of the
study and how they integrate with previous research. The thesis concludes with an overview of
the research process utilised to address the research problem and the methodological strengths
and limitations of the study are also considered. The implications arising from the findings
with respect to clinical practice are discussed along with possible directions for future research.
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CHAPTER2
LITERATURE REVIEW
2.1 Chronic Illness
The latter half of the twentieth century and the dawn of the new millennium has been a period
in which life expectancy in the United Kingdom has increased as modem medicine and
improved sanitation has eradicated many communicable diseases like cholera, while acute
illnesses such as pneumonia are no longer an automatic death sentence.
However, this greater longevity has resulted in the health services having to adapt to meet the
challenges of the increasing burden of conditions such as heart disease, stroke, cancer,
diabetes and arthritis, due to the predominant disease pattern in the UK, and most other
developed countries, now being one of long-term, or chronic, illness rather than acute disease.
This change has created a significant economic cost to the UK health service as 80% of GP
consultations now relate to chronic illness and 60% of hospital bed days result from chronic
illness and related complications (Office of National Statistics, 2008).
The challenges faced by the 17.5 million people in the UK living with a chronic illness are
-many, because not only are they required to contend with physical pain, prolonged medical
treatment, increasing restrictions on their daily activities and psychological distress, but they
face the possibility of making significant changes in their employment status and social and
family relations, all of which has the potential to significantly reduce their quality of life
(Department of Health, 2004)
The impact on quality of life extends to those family members who provide care for the
chronically ill who face an increased fmancial, physical and emotional responsibility.
Research shows that carers who are employed reported missing work, taking days off, and
even retiring early in order to provide care (Lim & Zebrack, 2004). Given that many patients
4
may be unable to continue in employment, chronic illness frequently leads to financial
hardship for patients and their families.
Chronic illnesses are one of the most prevalent and escalating health concerns facing not only
the health service, but also organisations and employers nationwide. With an estimated third
of the workforce managing a chronic illness, the need to find innovative management
strategies that can improve a patient's ability to cope with a long-term condition and manage
symptoms, so as to remain productive at work, is becoming increasingly important.
A chronic illness is a disease that has a prolonged course, does not resolve spontaneously, and
rarely is completely cured. According to the World Health Organisation (2006), they are
diseases that are defined by being permanent, caused by non-reversible pathological alteration,
leave residual disability, require special training of the patient for rehabilitation, or may be
expected to require a long period of supervision, observation or care.
Individuals with a chronic illness experience a permanent alteration in their way of life and a
reappraisal of functional abilities that introduces significant psychosocial stressors and
adaptive demands. Such illness-induced disruptions to lifestyle, activities, and interests have
been shown to compromise psychosocial well-being and contribute to emotional distress in
chronic disease (Devins, 1994).
The most common long-term condition in the UK is arthritis followed by heart conditions
(British Household Panel Survey, 2001). One in four of all GP consultations in the UK relates
to a musculoskeletal problem with arthritis affecting one in five adults (McCormick, Fleming
& Charlton, 1995; Parroy, 2005). This equates to approximately 9 million people with some
form of arthritis, which, according to The Health and Safety Executive, costs the economy
£5.7 billion per year.
Arthritis is a stressful chronic illness which results in persistent pain, joint damage and joint
stiffuess, that may not only produce substantial physical disability, but also negatively
influences individuals' lives as it is detrimental to functional ability, family and social
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relationships, employment, and psychological status (Escalante & Del Rincon, 1999; Yellin &
Callahan, 1995; Katz, 1998). The subsequent loss or reduced independence, role changes and
uncertainty that can result, are compounded by the economic burden that confront many
sufferers as maintaining employment becomes a challenge (Melanson & Downe-Wamboldt,
2003)
There are 200 types of arthritis that are classified into three categories: Inflammatory arthritis
(e.g. rheumatoid arthritis), Non-Inflammatory Arthritis (e.g. osteoarthritis) and Connective
Tissue Disease (e.g. Lupus).
Inflammatory arthritis is the term used to describe a range of conditions including rheumatoid
arthritis (RA), psoriatic arthritis (PsA), ankylosing spondylitis (AS) and juvenile idiopathic
arthritis (JIA). These are autoimmune diseases in which the body's immune system attacks the
joints causing them to become inflamed, and whilst the cause is not exactly known various
factors are thought to playa role, including infection, the environment, trauma and a person's
genetic make-up (Svendsen et al., 2002).
2.2 Inflammatory Arthritis - the size of the problem
The most common form of inflammatory arthritis is rheumatoid arthritis. Approximately
.387,000 adults in the UK have RA, a figure that represents 0.8% of the adult population
(Symmons et al, 2002). Each year there are approximately 12,000 newly diagnosed cases of
this condition that affects three times as many women as men (Arthritis Research Campaign,
2002).
Annually, 200,000 people visit their GP with ankylosing spondylitis (Arthritis Research
Campaign, 2002), whilst estimates for those with psoriatic arthritis vary between 84,000 and
177,000 (Kay et al, 1999). A further 250,000 people have gout, (McCormick et al, 1995)
whilst 12,000 children in the UK have Juvenile Idiopathic Arthritis (Silman, 2001).
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Whilst these figures serve to demonstrate the human cost of inflammatory arthritis in the UK.,
they do not present the complete picture. These are progressive diseases, but are unpredictable
as their pattern and progression varies greatly between individuals. Many people will
experience severe and disabling pain, stiffness and reduced joint function, other organs can be
affected and severe inflammatory arthritis, particularly RA, can shorten life expectancy by
approximately 6-10 years, which is similar to the impact of diabetes, Hodgkin's disease,
strokes and triple coronary artery disease (Arthritis Research Campaign, 2002; Scott et al,
1998).
2.3 EconomicCost of Inflammatory Arthritis
Whilst the costs of the disease are high for the individuals affected and their families, so too is
the cost to the NHS. For example, in 2000, there were 1.9 million GP consultations for
inflammatory arthritis, with almost 46,000 hospital admissions (Arthritis Research Campaign,
2002).
The annual NHS spend for managing RA and complications arising from its treatment is
estimated to be £240 million (Arthritis Care, 2000), whilst the total annual cost of treating RA,
inclUding health costs and lost working days, is estimated to be £1.3 billion (van Jaarsveld et
al,2000).
2.4 Psoriatic Arthritis (PsA)
Associated with psoriasis, psoriatic arthritis is a chronic, inflammatory disease of the joints
and connective tissue with potential for significant joint destruction contributing to pain and
disability. The disease affects men and women almost equally, with a mean age at onset of 36
years.
Although probably frrst described by Alibert in 1818, the association between inflammatory
arthritis and psoriasis was only formally recognised in 1964 when the American Rheumatism
Association classified PsA as distinct from other rheumatic conditions (Mo 11& Wright, 1973;
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Blumberg et aI., 1964) and included it in the group of seronegative spondyloarthropathies - a
family of inflammatory rheumatic diseases that affect the spine, joints, ligaments and tendons.
Other diseases in this group include ankylosing spondylitis (AS), enteropathic arthritis (e.g.
associated with Crohn's disease or ulcerative colitis) and reactive arthritis or Reiter's disease.
2.4.1 Epidemiology
There are few universally agreed diagnostic criteria for PsA, so prevalence is difficult to
estimate, however a study, based on a population of 413,421 patients in the Norwich area,
reported prevalence rates of 3.5 per 100,000 for males and 3.4 per 100,000 for females
(Harrison et al, 1997). In other studies the reported incidence has varied from 3.4 to 8 per
100,000 (Bruce, 2003: Savolainan, 2000; Soderlin, 2002). One Swedish study suggested that
30% of patients with psoriasis had PsA (Zachariae, 2003) whilst another study of patients
attending a psoriasis clinic found 31% to have PsA (Brockbank, 2001). These findings suggest
that prevalence rates for PsA in the general population would be ::::1%.
Occurrence of PsA increases with severity and duration of psoriasis. In 70% of patients,
psoriasis usually precedes onset of PsA by an average of ten years, but PsA can precede the
appearance of the skin condition in up to 20% of cases, by as much as fifteen years. The onset
IS contemporaneous in approximately 20% of cases (Mease & Goffe, 2005; Veale et. al, 1994).
2.4.2 Clinical Features of PsA
Given there is no specific diagnostic test for PsA, diagnosis is made primarily on the basis of
history, physical examination, the usual absence of Rheumatoid Factor, and radiographic
features.
The physical examination includes assessment of number, location and distribution of joints
involved, along with the presence of psoriatic skin lesions (Barth, 1997). Key signs indicative
of PsA include asymmetric joint involvement, enthesitis (inflammation at the site of insertion
of the tendons and ligaments to bone), dactylitis (inflammation of an entire digit, sometimes
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referred to as 'sausage fingers'), distal interphalangeal involvement and spinal inflammation.
Extra-articular manifestations include nail lesions, iritis, mouth ulcers, urethritis, and heel pain
(Mease & Goffe, 2005). Nail involvement occurs in 80% of patients with PsA, causing pitting,
thickening, separation of the subungual bed, and ridging of the nail plate (Bennet, 2001).
2.4.3 Treatments
Drugs for the treatment of psoriatic arthritis can be divided into several categories:
nonsteroidal anti-inflammatory drugs (NSAIDs), disease-modifying anti-rheumatic drugs
(DMARDs) and biologics, which are also considered DMARDs.
NSAIDs help to decrease inflammation, joint pain and stiffness and include over-the-counter
medications such as aspirin and ibuprofen, as well as prescription products.
Disease-modifying antirheumatic drugs (DMARDs) may relieve more severe symptoms and
attempt to slow or stop joint and tissue damage and progression of psoriatic arthritis. Biologics,
such as Enbrel®, Humira® and Remicade®, are highly selective agents that target specific
internal events in the body that trigger the inflammatory response in psoriasis and psoriatic
arthritis .
.Despite the advances in treating PsA, the disease remains incurable and one that can result in
substantial deformities of the affected joints, as demonstrated by the following images:
Images showing PsA
Figure 1: Swelling and deformity of the metacarpophalangeal and distal interphalangeal
Joints in a patient with psoriatic arthritis (www.emedicine.com)
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Figure 2: Severe psoriatic arthritis involving the distal and proximal interphalangeal joints
(www.emedicine.com).
Figure 3: Arthritis mutilans, a typically psoriatic pattern of arthritis, which is associated with a
characteristic "pencil-in-cup" radiographic appearance of digits
(www.emedicine.com)
2.S Psoriasis
Psoriasis is a chronic recurrent immune mediated inflammatory skin condition that can result- " ,
In a significant negative impact on a patient's physical, emotional and psychosocial
functioning (British Association of Dermatologists, 2005).
2.S.1 Prevalence
Epidemiologic studies from around the world have estimated the prevalence of psoriasis to be
0.6% to 4.8%, however, The British Association of Dermatologists estimate the UK incidence
to be 2% (2004), although UK studies typically report rates of 1.5%, whilst in the USA a 2005
population-based survey estimated the lifetime prevalence of self-reported psoriasis in people
18 years or older to be 2.2% (Rapp et al., 1999).
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It is a very diverse skin disease that may present in one of five forms, although approximately
80% of those with the condition are diagnosed with Plaque Psoriasis (scientific name being
Psoriasis Vulgaris). This form is characterised by raised, inflamed, red lesions, covered by a
silvery white scale and is typically found on the elbows, knees, scalp and lower back (see
Figure 4).
Inverse psoriasis (see Figure 5) first shows as very red lesions that usually lack the scale
associated with plaque psoriasis and appears smooth and shiny. As it is located in the armpits,
groin, under the breasts, and in other skin folds around the genitals and the buttocks, it is
particularly subject to irritation from rubbing and sweating and tends to be more common and
troublesome in overweight people and people with deep skin folds.
Erythrodermic Psoriasis is a particularly inflammatory form of psoriasis that often affects most
of the body surface and is characterized by periodic, widespread, fiery redness of the skin (see
Figure 6). The erythema (reddening) and exfoliation (shedding) of the skin are often
accompanied by severe itching and pain. Erythrodermic psoriasis causes protein and fluid loss
that can lead to severe illness. Edema (swelling from fluid retention), especially around the
ankles, may also develop along with infection. The body's temperature regulation is often
disrupted, producing shivering episodes. People with severe cases of this condition often
require hospitalisation as infection, pneumonia and congestive heart failure brought on by
er)rthrodermic psoriasis can be life threatening.
Guttate psoriasis is a form of psoriasis that often starts in childhood or young adulthood. This
form of psoriasis resembles small, red, individual spots on the skin. Guttate lesions usually
appear on the trunk and limbs, although the spots are not usually as thick as plaque lesions
(see Figure 7). Guttate psoriasis often comes on quite suddenly and a variety of conditions
have been known to bring on an attack, including upper respiratory infections, streptoccocal
infections, tonsillitis, stress, injury to the skin and the administration of certain drugs
(including antimalarials and beta-blockers). A streptococcal infection of the throat (strep throat)
IS a common guttate psoriasis trigger.
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Pustular psoriasis, primarily seen in adults, is characterized by white pustules (blisters of non-
infectious pus) surrounded by red skin (see Figure 8). It tends to go in a cycle, with reddening
of the skin followed by formation of pustules and scaling. The pus consists of white blood
cells. It is not an infection, nor is it contagious. Whilst it may be localized to certain areas of
the body, for example, the hands and feet, this form can also be generalized, covering most of
the body. Pustular psoriasis reportedly may be triggered by internal medications, irritating
topical agents, overexposure to UV light, pregnancy, systemic steroids, infections, emotional
stress and sudden withdrawal of systemic medications or potent topical steroids.
2.5.2 Treatments
There are a variety of different treatments available to help control psoriasis, including topical
creams, phototherapy and systemic medications.
Topical treatments refer to medications that are applied to the skin and are usually the first line
of defence. They include products available over the counter, such as tar and salicylic acid, as
well as prescription topicals such as Dovonex cream and topical steroid creams.
Light therapy, involves exposing the skin to wavelengths of ultraviolet light under medical
supervision. There are three types of treatment, UVB phototherapy, PUVA and lasers. UVB
involves exposing the skin to an artificial UVB light source. PUVA is an acronym for psoralen
(a light-sensitising medication) combined with exposure to ultraviolet light A (UVA). UVA,
like UVB, is found in sunlight. However, UVA alone is relatively ineffective unless used with
a light-sensitising medication such as psoralen. Targeted UVB treatment and pulsed dye
lasers can be used to treat chronic, localised plaque lesions.
Systemic medications, such as cyclosporine and methotrexate, are prescribed medications that
affect the entire body and are reserved for patients with moderate to severe psoriasis who are
not responsive to conventional topical medications or UV light treatments.
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Figure 4: Plaque Psoriasis Figure 5: Inverse Psoriasis
Biologics are a fairly new type of systemic medication, and whilst seemingly very effective,
they are still being evaluated, as their long-term effects are not fully known. Biologics are
developed from living sources, such as cells, rather than the combination of chemicals found
in traditional drugs. To date, there are several available to treat psoriasis (National Psoriasis
Foundation).
Images of Psoriasis
Figure 6: Erythrodermic Psoriasis Figure 7: Guttate Psoriasis
Figure 8: Pustular Psoriasis
(All images courtesy ofwww.emedicine.com)
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2.6 The Psychosocial Impact of Psoriasis
Most chronic rheumatological disorders require some form of adaptation, both physical and
psychological, by the patient in order that they may come to terms with a painful, disabling
condition that often has an unpredictable course and no cure.
Psoriasis and psoriatic arthritis are inflammatory, immune-mediated skin and joint conditions
with significant visible manifestations such as thickened, scaly plaques, local or widespread
lesions, significant joint deformities and permanent disability, all of which may not only
contribute to decrements in patients' physical functioning, but may cause a distorted
perception of their self image and embarrassment about their appearance, with the cumulative
effects impacting negatively on their health related quality of life.
Although associated with deformities and joint destruction, PsA had been considered a milder
disease in terms of articular erosions, when compared to RA, however, it is now thought to be
much more aggressive than previously believed and is considered as severe as other
arthropathies, with one study of PsA patients reporting that 57% of participants had erosive
arthritis and 19% had pronounced physical limitations (Torre Alonso et at, 1991).
The Course of PsA is unpredictable with periods of relapse and remission, and because
severity fluctuates over time, so does the impact of the disease. However, given that the
symptoms of PsA, such as joint pain, pain at insertions of tendons and ligaments, stiffuess and
fatigue combine with visible physical signs of disease such as joint swelling, 'sausage digits'
and joint deformities, the psychological burden of the disease may always be present. The skin
component of this condition contributes to this burden, as patients may have to endure the
physical discomfort and disfigurement that can occur as a result of psoriasis (Rapp et at,
1999).
Traditionally, research has tended to focus on the physical aspects of these diseases, however,
m recent years there has been a growing interest in the psychosocial impact, as evidenced by
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an increasing number of researchers adopting a biopsychosocial approach as they strive to
explore the interaction between physical, psychological and social factors.
Such an approach was adopted for the purpose of the current study, as it aims to identify and
explore, in patients with PsA and psoriasis, the role of psychosocial factors.
Given that the majority of individuals with PsA also endure the legacy of living with psoriasis,
it is appropriate to briefly examine the experience that those with psoriasis undergo - an
experience that, research findings suggest, is detrimental to physical, social and psychological
health.
2.6.1 Psoriasis and Psychosocial Issues
Various studies have documented the impact that physical symptoms associated with psoriasis
can have. For example, Fleisher et al. (1996) surveyed 317 patients with a diagnosis of
Psoriasis Vulgaris and reported that 95% experienced pruritus, 86% sore skin and 81%
burning skin and that the average time spent in daily psoriasis care was 68 minutes. In addition,
69% (219 participants) reported joint pain, over half the respondents, 163, stated they had
arthritis, whist 64 (20%) reported they had PsA. The prevalence of PsA in this group mirrors
that cited by Stem (1985), and Zanolli & Winkle (1992). It is of note that arthritis in general
.
was a common condition in this group, however the authors do not elucidate to the possibility
that a portion of these had undiagnosed PsA.
Physical symptoms, such as pruritus, were found in a study by Koo (1996) to be the worst or
second worst aspect about having psoriasis - a finding that supported the results of a survey by
Gupta et al. (1988), in which psoriasis patients reported pruritus as one of the most distressing
symptoms. This study further reported that increased pruritus was associated with increased
severity of depression, whilst Rapp et al. (1999) concluded that pruritus and skin soreness
were the symptoms associated with a decrease in the mental component of health related
quality of life, as measured by a non-disease specific instrument.
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In 1998, in order to better understand how psoriasis affects the quality of life of individuals,
the National Psoriasis Foundation (NPF), the largest organisation of psoriasis patients in the
United States, undertook a two-part survey of their patient membership. They aimed to
explore patients' perspectives of the impact of psoriasis on their lifestyle, emotional well-
being, employment and social conditions (Krueger et al, 2001).
Surveys were mailed to 40,350 members and a response rate of 43% (17,488) was achieved.
Those respondents meeting the criterion for severe psoriasis (6,194) were entered into a
database, and once a representative sample had been created, 502 telephone interviews were
conducted.
Findings from the mail survey clearly demonstrate the psychosocial impact of psoriasis across
all age ranges (18-34y; 35-54 and ~ 55y). A total of 43% reported difficulties in the workplace,
36% believed psoriasis affected their interaction with family and friends and 20% had
contemplated suicide. Obtaining a job (12%) and exclusion from a public facility (21%) also
accounted for some of the difficulties faced by this patient group. Many activities of daily
liVingwere affected such as walking and performing job duties, but the greatest impact was on
sleeping (64%) and sexual activities (67%).
The results of the follow-up telephone survey in the NPF study lend further weight to these
fuidings as 79% of respondents reported that severe psoriasis had an overall negative impact
on their lives. In addition to the practical implications of living and managing the disease,
serious emotional issues were noted with 54% of the sample feeling depressed.
The NPF study undoubtedly provides compelling evidence that individuals with psoriasis
believe that the disease has a profound emotional, social and physical impact on their quality
of life.
This finding was re-enforced by the results of a large Italian study that explored the prevalence
of depressive symptomatology among Italian patients with the most common form of psoriasis,
psoriasis vulgaris, more commonly referred to as plaque psoriasis (Esposito et al., 2006). In
16
this study, the researchers mailed five thousand patients the Centre for Epidemiological
Studies Depression Scale (CES-D) questionnaire, a 20-item instrument developed for use in
epidemiological studies of depressive symptomolgy in the general population. Of the 2,391
that were returned completed and usable, 63.9% (1,528) were from men. Overall, depressive
symptoms were observed in 62% of the respondents, a figure that represented 61% of the
males and 63% of the females, however, it was males under the age of forty who were
significantly more likely to report depressive symptoms.
The Italian study serves to support numerous findings that report a high prevalence of
depressive symptoms among patients with dermatological conditions, but notably, psoriasis.
Comparison studies invariably highlight that a higher percentage of psoriasis patients exhibit
general psychiatric morbidity, compared with patients suffering with other types of skin
diseases. For example, a study by Sharma et al., (2001) that used the General Health
Questionnaire to assess the psychiatric morbidity of psoriasis and vitiligo patients found that
53.3% of psoriasis patients recorded scores indicating the presence of psychiatric illnesses,
such as depression, anxiety and sleep disturbance. Furthermore, a study exploring life events
and psychological distress in three dermatological disorders, specifically, psoriasis, chronic
urticaria and fungal infections, reported that patients with psoriasis and urticaria had higher
depression, anxiety, and inadequacy scores than patients with fungal infections (Fava et al.,
1980).
The literature indicates that researchers comparing psoriasis patients with general population
norms consistently report higher degrees of depression in psoriasis patients than controls. For
example, a Turkish study comprising fifty psoriasis patients and fifty healthy controls, with no
history of skin and psychiatric disease, were matched for sex, age and education and were
administered various measurement instruments, including the Beck Depression Inventory
(BDI). It was found that significantly higher levels of depression were present in psoriasis
patients than the healthy controls (Mean BDI score of 16.96 and 5.48 respectively), and that
the BDI scores were strongly correlated with the severity of the psoriasis symptoms.
Interestingly the researchers also noted that the length of illness was inversely related to the
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BDI score and they suggest that this may be due to individuals adapting and learning to cope
with the psychosocial effects of the disease (Devrimci-Ozguven et al., 2000).
Disease severity in psoriasis is traditionally assessed in terms of the physical appearance of the
lesions and total body surface area involved. However, it is clear that, using these measures,
the clinical severity as determined by a physician, does not necessarily bear any relationship
with the patient reported degree of impairment. With this in mind, Krueger et a!. (2000), in a
position paper, argued that severity of psoriasis is predominantly a quality of life issue, and
that conflicts between clinical severity ratings and the actual disability experienced by the
patient can be reconciled, if both the physical and psychosocial effects of psoriasis are taken
into account.
There is evidence that both joint and skin (psoriasis) manifestations contribute to psychosocial
and physical disability and take a substantial physical and emotional toll on patients. Indeed,
Rapp et al. (1999) measured health-related quality of life in patients with psoriasis and found
that not only did the impact on physical function correlate with joint pain, but also that
patients experienced significant reductions in physical and mental function (compared with
healthy adults) similar to patients with cancer, diabetes, hypertension, heart disease and
depression. Furthermore, another study found that in those people with psoriasis, quality of
life was impaired in terms of bodily pain and social functioning (Heydendael et al., 2004),
The significant psychosocial morbidity and decreased health-related quality of life found in
psoriasis patients was highlighted by Gupta et al, (1993) when they explored depression and
suicidal ideation in dermatology patients. They found a 9.7% prevalence of a death wish and a
5.5% prevalence of acute suicidal ideation in those individuals with psoriasis, both of which
were associated with higher depression scores and higher patient self-ratings of psoriasis
severity. These rates are more than double that found in the general community (Olfson et al,
2002). A later study by Gupta & Gupta (1998) found that psoriasis patients recorded
depression scores that were in the range for clinical depression and the rate of suicidal ideation
among 79 outpatients being treated for psoriasis was 2.5% - a figure consistent with that seen
in other populations with chronic illness (Cooper-Patrick, 1994).
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Substance abuse is known to be an independent risk factor for suicide so it is of some note that
a further study by Gupta & Gupta (1996) reported an 18% prevalence of alcoholism among
patients with psoriasis, compared with 2% among patients with other dermatological
conditions.
Indeed, research has shown that simply receiving a diagnosis of psoriasis can result in
significant psychological sequelae, with one study by Fried et aI. (1995) reporting that half of
the participants were depressed and anxious following a diagnosis of psoriasis.
Whilst the clinical implications of psoriasis and psoriatic arthritis are well documented,
research into the psychosocial impact of these conditions is heavily biased towards psoriasis, a
disease which, as the evidence above demonstrated, impacts negatively on quality of life.
2.6.2 PsA and Psychosocial Issues
When considering the psychosocial impact of living with PsA, it is apparent that compared
with the plethora of psoriasis studies, the literature exploring PsA is less well developed, as
much of the research has been undertaken using a medical model which utilises clinical
measures, such as counting the number 0f tender and swollen joints in a patient, inflammation
markers and physician assessed global health (Mease et aI., 2005). These outcome measures
have primarily been borrowed from the assessment of RA and AS and are used in clinical
trials and with clinical registries of PsA patients. Yet, where much of the research examining
RA, AS and psoriasis includes measures for quality of life, fatigue, function, depression and
mood, this is not the case with PsA, as these have not yet been established as core domains in
PsA research.
In his paper 'Psoriatic Arthritis Update' (2006), Mease argues that 'a challenge ofPsA therapy
is addressing the multiple clinical domains involved in the disease: arthritis, enthesitis,
dactylitis, spine disease, skin, and the significant impairment of function and quality of life
that may occur'. If therapies are to target these domains, then outcome measures need to be
19
used in clinics to allow for the assessment of psychosocial domains in order to establish the
efficacy of treatments.
Given the paucity of studies exploring and measuring the psychosocial impact of living with
PsA, it is difficult to ascertain which factors, if any, may play a role in the lives of those
affected by the disease. However, some understanding of the consequences that may result
from living with other chronic, rheumatoid conditions may be obtained by examining studies
undertaken with RA and AS patients.
The following sections outline and explore various psychosocial factors and are considered in
the light of research relating to RA, AS, and where available, PsA.
2.6.3 Quality of Life
One way of capturing the personal and social context of patients is to use quality of life
measures. Increasingly in the field of health, and in particular, chronic, disabling conditions,
quality of life measures are used to supplement objective clinical or biological measures of
disease severity. Whilst no definitive definition of quality of life has been agreed upon it is
usually regarded as existing relative to individual or cultural expectations and goals (Carr &
Higginson, 2001). In an attempt to clarify the position, the World Health Organisation (WHO),
described quality oflife as:
'individuals' perception of their position in life in the context of the
culture and value systems in which they live and in relation to their
goals, expectations, standards and concerns. It is a broad ranging
concept affected in a complex way by the person's physical health,
psychological state, level of independence, social relationships,
personal beliefs and their relationship to salient features of their
environment '.
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In the health care literature, quality of life is associated with function and health status, and is
invariably referred to as health related quality of life (HRQOL). Functional status is not just
concerned with physical ability, but considers the degree to which an individual can perform
chosen roles without limitation in three key areas - physical, social and psycho cognitive
function. Seemingly, quality of life is a broad concept, indeed Mount and Scott (1983) likened
the assessment of it to assessing the beauty of a rose: no matter how many measurements are
made (for example of colour, smell and height), the full beauty of the rose is never captured.
Given that a substantial body of research supports the view that physical fmdings and disease
severity do not always correlate with patient self-report about quality of life, it is becoming
progressively more important to assess health using multi-dimensional outcome measures
(Corinsky, 1999).
In one of the very few studies to explore PsA-related quality of life, a study undertaken in
Canada by Husted and colleagues (2001), compared the health-related quality of life of
patients with PsA and RA and, as would be expected, both patient populations experienced
lower physical health when compared with that of a general population. Based on the
emerging belief that PsA is more aggressive than previously thought, Husted expected to find
that PsA affects quality of life to a similar extent as RA.
From two outpatient clinics of the University of Toronto Rheumatic Disease Unit, the
researchers recruited 107 PsA patients and 43 with RA. In addition to a number of clinical
measures, all the participants completed the Health Assessment Questionnaire (HAQ) and the
SF-36 in order that particular dimensions of health-related quality of life could be assessed.
Although the RA patients had more active inflammatory disease at the time of the assessments,
the PsA patients, even after adjustments were made for differences in demographic and
clinical characteristics, recorded higher levels of vitality. The researchers suggested this result
might relate to fibromyalgia as in a previous study they had found patients with RA had higher
frequency of fibromyalgia with more tender points than PsA patients. After adjusting for the
observed difference in vitality, it was the PsA patients who reported more role limitations due
to emotional problems and more bodily pain, a result that supports the researchers' earlier
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work, in which they found approximately 47% of a sample of 118 PsA patients described
mood disturbances or low self-esteem related to changes in appearance due to psoriasis
(Husted et aI., 1995).
The 2001 study by Husted and her colleagues revealed meaningful differences in quality of
life between PsA and RA. The higher vitality reported by those with PsA may indicate that
PsA is a less disabling arthropathy than RA, although it is of note that those with PsA
experienced greater bodily pain and role limitations due to emotional problems, a result the
researchers suggest may be due to unique disabilities associated with the psoriasis dimension
ofPsA.
In 2001 Sokoll and Helliwell also reported the findings of their study that compared severity,
disability, and quality of life in patients with PsA and RA matched primarily for disease
duration. Forty-seven patients were matched for disease duration with the Median duration for
those with PsA being five years, and those with RA seven years. Function and QOL data was
gathered using the Health Assessment Questionnaire (HAQ) and the EuroQol-5D, respectively,
whilst recent radiographs of hands and feet were read blinded to diagnosis in order to establish
the extent and severity of disease. The researchers found that peripheral joint damage was
significantly greater in RA than in PsA, but that function and quality of life scores were the
same for both groups and they concluded that this result may reflect the additional burden of
skin disease in those with PsA.
Similarly, another study that explored quality of life and the prevalence of arthritis in Nordic
psoriasis patients concluded that those with arthritis exhibited reduced psoriasis-related quality
of life, longer disease duration and greater self-reported disease severity for psoriasis, with
important predictors for arthritis-related quality of life being pain, number of affected joints
and restriction of joint mobility. Interestingly, this research also indicated that the prevalence
of arthritis in patients with psoriasis might be far higher than the previously accepted average
of 7%, as in their study of 5,795 members of the Nordic Psoriasis Associations, the prevalence
was found to be 30% (Zachariae et al, 2002).
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2.6.4 Depression
The World Health Organisation defines depression as 'a common mental disorder that presents
with depressed mood, loss of interest or pleasure, feelings of guilt or low self-worth, disturbed
sleep or appetite, low energy, and poor concentration' .
Different forms of depression exist and can manifest in different grades of severity. Tamminen
(1993) observed that throughout the history of psychiatry a number of different classifications
have existed, however contemporary epidemiological surveys conceptualise depression as a
diagnosis based on the criteria of diagnostic systems such as the DSM-IV (edition four of the
Diagnostic and Statistic Manual of Mental Disorders) and ICD-I0 (International Classification
of Diseases) as endorsed by the WHO.
Evidence in the chronic pain literature suggests that symptoms of depression, and indeed
clinical depression, often develop secondary to pain (Fishbain et aI., 1997).
The incidence of depression has been found to be higher among those with rheumatological
disorders than in the general population, with a rate similar to that found in individuals with
other chronic conditions (De Vellis, 1993). Although the reasons for the elevated incidence of
depression and depressed mood may be multi-faceted, research with RA patients indicates that
pain is associated with depression (Hawley & Wolfe, 1988) although the direction of causality
between the two is debatable (Brown, 1990; Parker et aI., 1992). Depression has been found to
have an effect on disability, with one study reporting that RA patients were more impaired
than those who were not depressed (Katz & Yelin, 1993) whilst another found that
psychological factors were a better predictor of disability than traditional measures of disease
activity (McFarlane & Brooks, 1988).
In a meta-analysis of 12 studies, Dickens et al. (2002) found that depression was significantly
more common among RA patients than healthy individuals and the levels of pain influenced
this.
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These findings support earlier studies that conclude, even when careful methods of assessment
are applied, major depressive disorder affects between 13% and 17% of patients with RA
(Frank et al., 1988; Murphyet al., 1988; Creed, 1990).
Although much of the research relates to patient samples with chronic RA, there are a number
of studies that have documented rates of depression that are at least as high for patients
recently diagnosed with RA compared to those with chronic RA. In one study considering the
clinical and health status of patients with recent-onset RA, the scores on all clinical and health
status measures indicated substantial disease effects in the group with recent-onset RA, with
an effect size similar in magnitude to those with more established disease (Meenan et al.,
1991).
Interestingly, evidence suggests that RA patients who are depressed early in the disease rarely
adjust with medical intervention alone. Evers and colleagues (1997) reported that depression
and anxiety measured at Time 1 were highly predictive of subsequent deterioration in those
measures, suggesting that patients showed little evidence of adaptation to their disease. Their
findings also suggested that social support networks were predictive of positive changes in
depressed mood.
In a study of 110 patients with ankylosing spondylitis that examined the associations between
disease and psychological status, the authors reported that anxiety, depression, internality and
health status all correlated significantly with disease status scores. Indeed, 25% of the group
were clinically anxious and 15% clinically depressed (Martindale et al., 2006), figures that
reflect those reported in an earlier study by Barlow et al. (1993), who found one third of AS
patients revealed symptoms of depression.
2.6.5 Pain
The International Association for the Study of Pain describes pain as 'an unpleasant sensory
and emotional experience associated with actual or potential tissue damage, or described in
terms of such damage' (IASP, 1994).
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Pain is usually experienced as an unwanted physical stimulus located in a specific anatomical
region and was, up until about 1895, considered a direct consequence of physical injury with
the intensity generally believed to be proportional to the degree of tissue damage (Brannon &
Feist, 2000). However, towards the end of the nineteenth century, a different view of pain
began to emerge as Strong (1895) hypothesised that two factors were implicated in the
experience of pain - the sensation and the person's reaction. The suggestion that psychological
factors and organic causes may be of equal importance has lead researchers to suggest pain is
a psychological and physical phenomenon that is mediated by personal perception.
Increased knowledge regarding the physiology of the brain and spinal cord supports the notion
that the experience of pain includes a psychological element and has paved the way for
researchers to employ a biopsychosocial approach in which the role of factors such as anxiety,
depression, social support, self efficacy and functionality, to name but a few, can be assessed
and their impact on a person's perception of pain, evaluated.
Given that pain is the most prominent symptom in people with musculoskeletal disorders and
the most common reason for patients to seek medical help (Kazis et al., 1983), the literature
contains a broad array of studies which contemplates how pain may be perceived, affected or
mediated by factors such as depression, coping, fatigue, personality traits and catastrophising
(a set of negative emotional and cognitive processes), to name but a few.
Indeed catastrophising, with its construct that incorporates magnification of pain-related
symptoms, feelings of helplessness, rumination about pain, and pessimism about pain-related
outcomes, has been increasingly implicated in the experience of pain and associated with
various adverse outcomes such as pain severity, depression, and disability (Edwards et al.,
2006). Among patients with RA, cross-sectionally, higher pain severity has been found to
relate to catastrophising (Covic et al, 2000) whilst several prospective studies have reported
the longitudinal association of catastrophing with pain - using daily diaries studies, RA
patients who exhibited greater catastrophising reported more day-to-day pain and also
attention to pain than low catastrophisers (Lefebvre et al., 2002). Other RA studies have
established that catastrophising predicts disability even after controlling for pain severity
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(Covic et al, 2000; Thastum et a1., 2005) suggesting that the degree of physical disability
experienced by patients in not just a function of pain intensity or frequency, but also of the
degree of catastrophising.
Much of the literature examining pain in individuals with PsA utilises clinical outcome
measures and generally fails to include any psychosocial assessment of pain. Traditionally
researchers measure pain in this patient group with a view to establishing the efficacy of
various treatments. For example, Chenglong and colleagues (2007), employed the SF36 to
compare the health-related quality of life (HRQoL) of patients with moderate-to-severe RA,
PsA and AS, and then compared the effect of treatment with Infliximab (a biologic Anti-
Tumour Necrosis Factor agent) or a placebo on the HRQoL of these patients. After adjustment
for age, sex and disease duration, at baseline, the physical HRQoL, which includes physical
functioning, role physical and bodily pain, was similar for all three groups. After treatment
with Infliximab, all three showed significantly greater improvement from baseline to the first
assessment time point in all physical scales of the SF-36, compared with patients who received
the placebo. In each of the three diseases, the greatest improvements were observed in bodily
pain and role physica1. Whilst the study clearly shows the beneficial affect of such treatment,
the possible impact or mediating role of psychosocial factors on pain was not assessed.
Whilst there may be dearth of studies exploring PsA using a biopsychosocial approach,
lessons may be learnt from RA and AS, given that many of their physical characteristics are
shared with PsA. Research has shown that pain and functional limitation associated with RA
negatively affects a patient's ability to engage in everyday activities (MacKinnon et a1., 1994)
and results in diminished levels of physical activity (Eurenius et a1., 2005). Furthermore, other
studies, for example, Katz 1998, have concluded that patients with RA report pain, fatigue
unpredictability of symptoms, functional impairment and changes in joint appearance as
having a significant impact on their lives.
Although not the case for psoriatic arthritis, numerous studies have documented the
contribution of emotion and cognitive processes to the experience of chronic pain (Keefe et a1.,
1992; Turner & Romano, 1985). Indeed, research investigating chronic pain and emotion
26
typically conclude that chronic pain is highly associated with depressive mood (Mikail &
Fisher, 1992; Turner & Romano, 1985)
A prospective study investigating the course of depression for patients recently diagnosed (less
than two years) with RA assessed twenty-two patients on a variety of measures at six different
time points over twenty-one months. The researchers found that the patients became
significantly more depressed over time and that a set of five factors - initial level 0f depression,
pain, disability, coping strategies and consequences of arthritis - consistently predicted
depression at the following assessment. Although only a small sample size was used, these
results support much of the previous literature that suggests complex interrelationships exist
between pain, depression and other psychosocial factors (Sharpe et al., 2001). For example, a
five month, weekly study of 188 older women with RA and osteoarthritis reported that levels
of pain and reactivity to perceived stress were affected by depression (Zautra & Smith, 2001),
whilst a study by Covic et al. (2000) concluded that both pain and depression were predicted
by physical disability and that the relationship was mediated by passive coping and
helplessness.
In 2003, Covic et al. hypothesised a biopsychosocial model that used physical disability,
helplessness and passive coping to predict pain and depression in RA. The results indicated
that physical disability, helplessness and passive coping were significant contributors to the
levels of pain and depression experienced in RA and interestingly, that helplessness was a
stronger predictor of pain than passive coping - a finding which suggests that the perception
that one has no control over one's disease can affect the levels of pain.
In a survey of 295 AS patients, 65% rated fatigue as a major symptom and in these patients,
pain, functional disability and stiffness were significantly associated with the level of fatigue
(Jones et al., 1996). Similarly, studies using RA patients have shown that pain severity may be
a significant predictor of subsequent sleep disturbances and this in turn may impact on levels
of fatigue (Drewes et al., 1998, 2000). An investigation by Pollard et al (2006) explored the
amount of fatigue experienced by patients with RA, and its relationship to pain, synovitis and
other common clinical features. They reported that pain is strongly associated with fatigue
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and that patients with active RA had high levels of fatigue, however multiple regression
analyses showed this relationship was less important than the association with pain.
2.6.6 Fatigue
In healthy people, fatigue occurs as a normal and temporary phenomenon resulting from
identifiable events such as physical exercise, emotional tension or lack of sleep. It is generally
considered to playa purposeful and protective role, as it is self-limiting and relieved by sleep
or rest (Mayoux-Benhamou, 2006). However, in people living with a chronic condition,
fatigue may become a disabling, life-and activity-limiting experience impacting on quality of
life, as it is a poorly managed symptom for which there are few pharmacological solutions.
Fatigue is not simply a general symptom of disease activity, but is a complex, disruptive
stressful and subjective personal experience (Repping- Wuts et al, 2007) and whilst there is
little consensus regarding its definition, Piper (1993) suggested that it is an abnormal
experience that has negative effects on bodily function and daily life. Rather than being a
temporary phenomenon, fatigue may have a gradual onset, is cumulative and persists over
time (Ream & Richardson, 1996) unlike the fatigue which most people experience in their
daily lives which is usually related to some form of short-duration exertion that is relieved by
a good night's sleep.
Although incidence of fatigue is unknown, Pawlikowska et aI. (1994) studied a population
they assessed as being without chronic conditions and reported a prevalence of 18.3%, whilst a
later American study by Addington et al (2001) reported lifetime prevalence in the community
of 20%. However, these may be conservative estimates given that fatigue is a chronic
symptom that manifests itself in a multitude of chronic and somatic disorders, including
multiple sclerosis, cancer, Parkinson's disease and rheumatic diseases, to name but a few (Bol
et aI., 2008; Goldstein et aI., 2006; Friedman & Chou, 2004; Wolfe et al., 1996).
Common in many major diseases, fatigue is especially prevalent in pain disorders such as
osteoarthritis (Fishbain et aI., 2003), fibromyalgia syndrome (Wolfe, 1999) and rheumatoid
arthritis (Sing et aI., 2003), with pain patients rating fatigue as a key factor leading to
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decreased quality of life (Swain, 2000). Indeed, in 1996, a study by Wolfe et al. reported that
clinically significant fatigue has been reported by over 40% of patients with osteoarthritis (OA)
and rheumatoid arthritis (RA), and by 76% of patients with fibromyalgia syndrome (FMS).
Although their report was essentially a psychometric analysis, van Tubergen et aI. (2002)
assessed fatigue in patients with ankylosing spondylitis (AS) and concluded that it is a major
symptom that negatively influences different aspects of quality of life and appears to be
associated with the level of disease activity, functional ability, global well-being and mental
health status. Its emerging role as a major symptom was highlighted in an earlier study when
57% of RA patients reported that fatigue was the most problematic aspect of their disease
(Tack, 1990), whilst a study by Hendriksson et al. (1992) exploring pain and daily fatigue
among FMS patients, concluded that fatigue constituted a greater impediment to the
accomplishment of daily tasks than did pain.
In their paper, Zautra et al. (2007) examined reports of fatigue among American patients with
chronic pain, all of who had a diagnosis of OA, RA and FMS. They found considerable
variance in levels of fatigue both between patients and over time and comparison of the three
chronic pain conditions revealed group differences in both the average level of fatigue and
also extent of day-to-day variability. Pain was among the strongest predictors of fatigue, with
those individuals with higher average levels of pain reporting greater fatigue, with daily
increases in pain related to daily increases in fatigue and elevated fatigue levels the next day.
The researchers concluded that as a symptom, fatigue is central to ail three conditions,
although the fatigue response observed in the participants' diaries suggests that the actual type
of chronic pain condition is implicated. Given the different etiologies of OA, RA and FMS, it
seems the underlying causes of fatigue may also be distinct across disorders.
Research by Krupp et al (1990) concluded that fatigue is one of the most frequently reported
and often the most disabling symptom experienced by individuals with systemic lupus
erythematosus (SLE) - an autoimmune disease which falls under the umbrella of rheumatic
diseases. Krupp reported that up to 80% of this patient group report fatigue, yet the cause
remains largely unknown. However, findings from various studies suggest it is likely that
fatigue results from a combination of factors such as disease activity (Zonana-Nacach et al,
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2000), mood disorder (Wysenbeek et al, 1993) and associated fibromyalgia (Taylor et al,
2000).
Qualitative research by Hewlett et al., (2005) explored the experience of fatigue in patients
with RA in the United Kingdom. RA fatigue was viewed as different from normal tiredness
because it is extreme, often not earned, and unresolving and participants attributed it to
inflammation, working the joints harder and unrefreshing sleep. Physical, cognitive and
emotional components were described along with the far-reaching effects on physical
activities, emotions, relationships and social and family roles. Whilst clearly highlighting that
RA fatigue is an important, intrusive and overwhelming symptom, this study revealed that
participants perceive that fatigue is dismissed by professionals and assume it cannot be treated,
so do not raise the issue in clinic. Such reluctance supports an earlier study of the general
population that found 74% of women attending their family practice had fatigue, but only 22%
discussed it (De Rijk et al., 2000).
In 2005, a study by Kralik, Telford, Price and Kock, exploring women's experiences of fatigue
in chronic illness, reported the finding of data which were generated via email group
conversations between the researchers and thirty women with diverse chronic diseases such as
psoriatic arthritis, osteoarthritis and fibromyalgia. Common themes emerged as participants
described extreme fluctuations in their levels of fatigue throughout each day and from day to
day. They also reported how the severity and unpredictable nature of fatigue disrupted their
lives and caused them to re-evaluate the way in which they related to family, friends and the
community. Despite the consequences of living with fatigue, the issue was rarely raised when
attending appointments, as there was a general belief that health care professionals fail to
acknowledge or recognise fatigue as a legitimate concern.
It seems clear from the literature that whilst there is no 'gold-standard' definition of fatigue,
there is consensus that it is a complex, stressful and disruptive subjective personal experience.
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2.6.7 Coping
Coping, according to Lazarus and Folkman (1984), consists of cognitive and behavioural
efforts to manage stressors, and is an ongoing, dynamic process concerned with what an
individual actually thinks or does in a specific context, as well as changes in these thoughts
and actions across encounters.
Most people use various forms of coping in stressful situations, however, problem-focused and
emotion focused coping are the two major functions. Problem-focused coping involves
activities that aim to change elements of the stressful situation, whereas emotion-focused
coping involves activities that modify one's emotional reactions that result from the stressful
situation and make life bearable by avoiding situations that, if confronted directly, can be
overwhelming (Lazarus & Folkman, 1984).
Whilst different forms of coping are effective for different people and situations, Lazarus
suggests that there is a greater association between unsuccessful coping and the use of
emotion-based strategies such as avoidance, self-blame and wishful thinking (Lazarus, 1990).
The Transactional Model of Stress and Coping developed by Lazarus & Folkman (1984)
considered appraisal and coping as processes but failed to allow for the importance of social
support on coping. Researchers, in order to address these limitations, have combined other
models with the original in order to achieve a more rounded framework. Most notably,
Schwarzer (1998) suggested perceived self-efficacy was a personal coping resource for
managing a stressful event and incorporated this into the model, maintaining that having the
belief that one can master difficult scenarios by means of adaptive action, and an optimistic
view of one's capacity to deal with stress, plays a vital role in determining both how an
individual is motivated to act and how they cope. Furthermore, Social Support is included in
the model as researchers view it as a resource that affects an individual's appraisal ofstressors.
Various definitions exist for social support, however it is generally considered to be a generic
construct that includes social networks and social interactions (Schreurs & Ridder, 1997).
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Cohen and Syme (1985) suggest that it comprises the resources provided by informal supports,
such as that provided by family, extended family, friends, relatives, work acquaintances, and
neighbours, whilst formal support refers to that which is paid for or provided by the health
care system (Chappell, 1992).
The mechanisms through which social support and self-efficacy influence coping and
psychological well-being have been explored by researchers, and both self-efficacy and social
support have been found to affect patients' appraisals of their situations and in turn, their
coping behaviours in various chronic illnesses (Hagger & Orbell, 2003; Manne & Zautra,
1989; Merluzzi & Martinez-Sanchez, 1997; Ptacek et aI., 2002; Shaw, 1999).
Cognitive appraisal, personal (e.g., self-efficacy), and situational (e.g., social support)
variables are identified in the literature as predictors of coping and HRQOL in individuals
with chronic illness, such as cancer, multiple sclerosis, and rheumatoid arthritis (Weber et aI.,
2007; Riazi et al., 2004; Cross et aI., 2006).
Using a cross-sectional study to analyse the extent to which coping strategies and illness
perceptions were associated with levels of daily functioning (that is, physical, social and role
functioning), Scharloo et al. (1998) recruited patients with RA (n=84), psoriasis (n=80) and
chronic obstructive lung disease (n=80) and found that coping by seeking social support, and
beliefs in controllability and curability of the disease, were significantly related to better
functioning.
Quite how social support affects psychological adjustment is still not fully understood,
although two theoretical models have been proposed. The stress-buffering model that Cohen
and Willis (1985) proposed, suggests social support has a beneficial effect on adaptation to
chronic illness by acting as a buffer against a stressful situation, so reducing the negative
effects of the illness. In the case of chronic rheumatoid diseases, this theory suggests that
social support, in the form of family and friends would protect the patient against stressors
such as pain and disability, so reducing the patient's distress. Alternatively, the direct effects
model maintains that support is beneficial regardless of the level of stress experienced.
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Several studies have compared these two models among RA patients. Brown et al. (1989)
found evidence for both models - the existence of a direct effects model was underpinned as
greater support was associated with lower depression for people at all levels of pain, whilst the
stress-buffering model was given credence as psychological depression was greatest in those
patients with high levels of pain and low satisfaction with emotional support received from
family and friends. Affleck et al. (1988) also reported modest evidence of a stress-buffering
effect in 129 RA patients - the researchers found psychological adjustment was lowest among
individuals with functional disability who also reported dissatisfaction with support. However,
a number of studies report only evidence for the direct effects model, such as Fitzpatrick et al.
(1998) who found that regardless of disability, greater social support was related to lower
depression and greater self-esteem. Similarly, another study of 101 recently diagnosed RA
patients concluded that the more support patients received, the less depression they
experienced, regardless of physician-rated disease severity (Revenson et al., 1991).
Whilst evidence to support these different models would lead us to conclude that overall,
social support is beneficial for individuals coping with varying amounts and types of arthritis-
related stress, it should be noted that some researchers maintain that receiving, using or
requesting social support has costs as well as benefits and that it is important to understand
how support can both help and hinder adjustment to rheumatic disease (Revenson, 1990). A
small number of studies in RA have concluded that social support is not always conducive to
health. Dissatisfaction with support may have a negative impact on psychological well-being,
as demonstrated by Newsome and Schulz (1998) who found that distress was the response to
being helped by a family caregiver. Such findings may be due to the individual feeling that the
support is unwanted, excessive, inconsistent with their needs, or coming from the 'wrong'
support providers (Lanza et al., 1995).
The evidence does suggest that social support and coping are inextricably linked, but the
mechanism by which they interact and impact on psychological health in those individuals
with chronic disease is still not fully understood, although it may be that support is effective in
enhancing an individual's well-being because it acts as coping assistance. It is possible that
when a person is faced with a stressful situation, such as chronic illness, social support may
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help them alter the meaning of the situation, their emotional or behavioural response to the
situation, or even the situation itself (Holtzman et aI., 2004).
A brief review ofthe coping literature suggests that emotion-focused coping strategies (that is,
avoidant or passive) are linked to poorer outcomes when compared with active and adoptive
problem-focused coping techniques. For example, Evers et al. (1998) undertook a study
examining the psychosocial predictors of functional change in 91 recently diagnosed RA
patients and found that a decrease in all measures of functional status within the first year after
diagnosis could be predicted by the initially more frequent use of the passive pain-coping
strategies of resting and worrying. In addition, the researchers also found that a decrease in
mobility could be predicted by an initially smaller social network, independent of what could
be explained by the initial functional status, demographic variables or by the disease itself.
Conversely, individuals who engage in more active coping, such as the use of positive
statements or ignoring symptoms, report better outcomes as effective coping strategies have
been found to reduce pain and emotional distress. Keefe et al. (1991) examined pain in RA
patients and concluded that patients who were active copers had the ability to control and
decrease the pain, rarely engaged in catastrophising, and experienced low levels of
psychological distress.
Efficacy beliefs in those with a rheumatic condition impact on appraisals regarding the
potential ability and success of coping efforts, and may playa pivotal role in determining the
level of adjustment to stressful events surrounding the illness (Affleck & Tennen, 1996).
Smith and Wallson (1996) undertook an analysis of coping profiles and adjustment in 171 RA
patients to establish whether any particular group of coping strategies influenced
psychological adjustment. Patients were grouped as active, passive, self-blaming or minimal
copers depending on the techniques they typically used to manage their arthritis. The active
and passive groups reported similar levels of pain, the self-blamers reported more pain than
the overall sample, whilst the minimal copers, who had relatively little use of the various
coping strategies, reported lower pain levels than the rest of the sample.
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The results infer that the four groups differed in psychological adjustment to their RA, with
greater levels of negative affect and depressive symptoms and lower levels of positive affect
and life satisfaction reported by the passive copers and self-blamers. The contrast in
adjustment profiles of the active and passive copers is of note, given both groups reported
similar levels of pain and disability, this, the researchers suggest, is evidence for the
hypothesised role of pain coping as an influential mediator of the relationship between pain
and adjustment in rheumatic conditions. In addition, Smith and Wallson argue that the positive
psychological adjustment found in the active copers group lends support to the proposition
that an active approach to coping with pain is often adaptive, whereas a more passive approach
is maladaptive.
2.7 Summary
Despite evidence demonstrating that those with PsA may experience reduced health-related
quality of life resulting in role limitations and reduced physical functioning (Husted et aI.,
1997) there remains a lack of consensus with regard to the role and impact of various
psychological factors. Indeed, the limitations of many existing studies are their failure to
include measurements for psychosocial factors that have been shown to have good predictive
value in other conditions. It is surprising that to date, the role of such factors and their
potential impact has been largely ignored in PsA.
The evidence from previous studies exploring the role of psychosocial issues and psoriasis,
suggests the landscape emerging is somewhat blurred. Studies have focussed on quality of life
issues, but generally have not been patient driven, at a time when there is a move in the Health
Service to include the opinions of service users. Eminent dermatologist and researcher,
Professor Chris Griffiths has suggested that 'involvement of patient groups and an
understanding of the psychosocial aspects of psoriasis, particularly its significant impairment
of quality of life, are keys to progress' (Griffiths, 2004).
In their report, 'The Expert Patient: A New Approach to Chronic Disease Management for the
21st Century', the Department of Health acknowledges that chronic disease and its effects are
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now a major challenge. Due recognition is given to the physical and psychological difficulties,
socio-economic problems, reduced quality of life and possible social exclusion that those with
a chronic condition are faced with, but they also suggest that although people have problems
specific to their individual illness, there is also a core of common needs, including developing
strategies to deal with the psychological consequences of the illness.
Given the lack of such research and paucity of patient driven studies relating to PsA, the aim
of the first phase of this research was to explore, from the patients' perspective, the impact that
PsA and psoriasis has on an individual's quality of life. By identifying and establishing which
psychosocial issues impact on this patient group, it may be possible to improve the
management of the condition and contribute to the future development of strategies that lead
to improved functioning and inform the content of interventions to lead to improved quality of
life.
The following chapter outlines the rationale for the methodology employed in the current
study.
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CHAPTER3
RATIONALE FOR METHODOLOGY FOR STUDY 1
3.1 Introduction
A review of the literature relating to PsA failed to identify any robust studies that clearly
demonstrate the psychosocial impact experienced by individuals who live with this disease. As
a result, there is limited understanding within the health system and wider society on how best
to support these patients.
In order improve understanding and gain deeper insight or a new perspective of a phenomenon
about which little is known, Strauss & Corbin (1999) suggested that qualitative methods may
offer a way of discovering new information that would otherwise be difficult to capture using
quantitative methods.
3.2 A Qualitative Approach
Qualitative research is concerned with the nature of the phenomenon, rather than producing
aggregate data and is aimed at discovering the meaning that events have for the individuals
who experience them. As a consequence, the results deal with the emotional and contextual
aspects of human response, rather than with objective measurable behaviours and attitudes.
The goal of qualitative research is to discover patterns that emerge after close observation,
careful documentation and detailed analysis of the research topic. Researchers collect
qualitative data from the individual by means of several techniques - typically interviews with
participants, either on an individual basis or in a focus group, diaries (audio, written or video)
and various forms of writing. The data can then be analysed in different ways, such as
discourse analysis, narrative analysis, grounded theory and interpretative phenomenological
analysis (IPA).
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3.3 Justification for use
Unlike quantitative research, a qualitative approach offers the researcher an opportunity to
obtain depth and detail and see the worldview of those people that are studied. It allows for an
openness that can generate new theories and recognise phenomena that have been ignored by
previous researchers and literature. A qualitative approach is undoubtedly the preferred choice
where the goal is to try and present people on their own terms and from their own perspective
and to give the participant a voice.
Despite its strengths, it must be acknowledged that fewer participants are usually studied when
a qualitative approach is utilised, meaning that the results are less easily generalised to the
wider population and, because it is difficult to aggregate data, systematic comparisons may not
be possible. It may also be argued that qualitative data collection is dependent upon a
researcher's personal attributes and skills, although this is also true when a quantitative
method is used, although it may not be as easy to evaluate their skills.
Given that the initial research aim of the current study was to explore the nature of
psychosocial issues experienced by people with PsA, a qualitative approach was appropriate.
A qualitative method particularly suited to understanding the lived experiences of an
individual is Interpretative Phenomenological Analysis (IPA), a framework developed and
described by Smith et al. (1995, 1997, 1999), that is concerned with trying to understand lived
experience and how individuals make sense of their experiences, particularly with regard to
living with a medical condition. Although a relatively new approach, it is now being widely
used by researchers in various disciplines, including health, clinical and social psychology.
IPA has its origins in health psychology (Smith et al, 1995) and is theoretically rooted in
critical realism (Bhaskar, 1978) and the social cognition paradigm (Fiske & Taylor, 1991).
Critical realism accepts there are stable and enduring features of reality that exist
independently of human conceptualisation and that differences in the meanings individuals
attach to experiences are possible because they experience different parts of reality.
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Meanwhile, the social cognition paradigm suggests human speech and behaviour reflects these
differences in meaning either directly or indirectly, thus explaining why the analysis of
interview data is considered an appropriate method of accessing and developing an
understanding of such differences.
Concerned with human understanding, the concept of Phenomenology was put forward in
1936 by Edmund Husserl (Husserl, 1970) as he rejected the view that empirical science is the
basis for gaining an understanding of the world, instead stressing the importance of lived
experience. He posited that what is really there in the world, can be understood by perceiving
it in a manner that is uncontaminated by an individual's past experiences and viewpoints.
Traditionally researchers undertaking phenomenological research attempt to 'bracket out' their
preconceptions (Moustakas, 1994) using formal reflexive techniques (Duck, 1992), however,
Caelli (2001) argued that respondents too, should engage with such reflexive techniques in
order to give a more accurate representation of the way in which they see the world pre-
cognitively. This viewpoint could imply that IPA has been incorrectly labelled as
'phenomenological', however Smith et al (1999) stress that the aim of IPA is to attempt to
gain an insider perspective of the phenomenon being studied, whilst acknowledging that the
researcher is the primary analytical tool and that the researcher's beliefs are not to be viewed
as biases to be eliminated, but rather as being necessary for making sense of the experiences of
others. To this end, reflexivity is not viewed as an essential technique for removing bias, but
as an optional tool, enabling the researcher to formally acknowledge their interpretive role.
Smith et al (1999) maintain that IPA is phenomenological as it seeks an insider perspective on
the lived experiences of individuals and it is interpretive in that it acknowledges the
researcher's personal beliefs and encompasses the view that understanding requires
interpretation.
In the current study, the researcher chose to use IPA as it aims to capture and explore
experiences of the individual without testing hypotheses or making assumptions about the
meaning of the topic being studied (Reid, Flowers & Larkin, 2005). It was anticipated that by
giving the patients 'a voice' and gaining an understanding of their experience of living with
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psoriasis and PsA, various themes would emerge during analysis that would drive the choice
of quantitative measures that could be used in a second study.
The following chapter outlines, in detail, Study 1.
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CHAPTER4
STUDY 1
4.1 Introduction
In broad terms, this study aims to explore the lived experience of individuals with PsA and
psoriasis and whilst no specific hypothesis were formulated, the objective was to identify the
nature of any psychosocial issues that patients perceive as impacting on their daily lives.
Given the exploratory quality of this initial study, semi-structured interviews and subsequent
Interpretative Phenomenological Analysis (IPA) were utilised in order to achieve this aim
4.2 Design
Semi-structured interviews were conducted with ten individuals who had a diagnosis of
psoriasis and psoriatic arthritis.
The previous chapter detailed the rationale for the qualitative design employed, however, to
summarise, semi-structured interviews were chosen as they allow for the interviewer to probe
and explore, and they offer flexibility that enables the participant to change the direction of the
interview as issues arise that the researcher may not have thought of when designing the
interview schedule (Smith & Osborn, 2003). They also make good use of interview time and
make interviewing multiple participants more systematic and comprehensive.
4.3 Participants
A purposive sampling strategy was employed to ensure that views were represented from
individuals of different age and gender. The criteria for inclusion into the study was that
participants be aged between 18 and 65, have a new or existing diagnosis of psoriatic arthritis
and/or psoriasis and that English was their first language - the clinical staff who were
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identifying potential participants for the study checked and confirmed that participants
fulfilled these criteria before passing their contact details to the researcher.
Smith, Jarman & Osborn (1999) suggest ten participants is the higher end of the desired
sample size for IPA studies. The sample for the current study is within the recommended
sample size and consisted of ten adults - five women with ages ranging between 37 and 65
years (M = 48.2 years) and five men aged between 30 and 64 (M = 46.0 years). Participant
characteristics are summarised in Table 4.1.
Table 4.1: Characteristics of participants who were interviewed
(n=10) PsA Psoriasis
Alias Gender Age Married Employed Duration Duration
(yrs) (yrs)
Annie F 37 Y N 19 20
Beryl F 65 Y N 40 43
Chris F 49 Y N 8 10
Debbie F 38 N Y 11 11
Ellie F 52 Y N 16 17
Frank M 30 N N 6 10
Gary M 46 Y Y 10 12
Henry M 64 Y N 15 16
Ian M 39 Y Y 5 5
Jack M 51 Y N 20 20
4.4 Ethical Approval
Approval was sought and granted from Liverpool John Moores University and Liverpool NHS
ethics committees. Research Governance was granted by Aintree University Hospitals (see
Appendix 8)
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4.5 Procedure
Participants were recruited from a local NHS University Teaching Hospital. Following ethical
approval the researcher had briefed the clinical staff about the nature of the study and provided
them with information sheets that were to be given to potential participants.
Initially, clinical staff in the rheumatology out-patients department identified patients
attending the PsA clinic and, after confirming that they had a diagnosis ofPsA, provided them
with an information sheet (see Appendix 1) and explained the nature of the study. Verbal and
written information was given to all eligible parties stating that their participation was not
mandatory to receive health care within the clinic. Participants were also informed that declining
participation would not have any deleterious effect on the receipt of their care. Any patients who
expressed interest in taking part in the study gave verbal consent for their contact details to be
given to the researcher and were advised that the researcher would contact them within the
next fourteen days.
The clinical staff provided patient names, date of birth and contact details to the researcher,
who then contacted the patients by telephone in order to further explain the study and arrange
a convenient time and place to conduct an interview.
Before the interview commenced, the researcher explained the purpose of the study and
ensured participants were fully aware of their right to withdraw from the study at any time.
They were given the opportunity to ask questions about the study before the researcher
obtained their informed, written consent to take part in the study and also to allow for the
interview to be recorded and transcribed. Participants were given a copy of their signed
consent form and an information sheet that included a contact telephone number and email
address for the researcher (see Appendix 1-3).
The audio-taped interviews were transcribed and analysed. Following ten interviews, no
further themes were being generated and the analysis was deemed to have reached saturation.
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4.6 Interviews
All interviews were conducted in participants' own homes. The interviews were audio-taped
and ranged in duration between forty-five and eight-five minutes. The interviews were semi-
structured with the researcher utilising a basic interview schedule (see Appendix 5) to ensure
that relevant topics were covered, such as effects on everyday function, pain, and ability to
work. The questions were asked in no prescribed order, but were included at appropriate
points within the dialogue. This allowed for flexibility within the interview and an opportunity
for the participant to introduce aspects of living with the disease that held importance for them
and enabled the researcher to explore any of these in greater depth.
4.7 Analysis
The tapes were transcribed verbatim and analysed using Interpretive Phenomenological
Analysis (IPA) as described by Smith (2003). This method strives to fully preserve people's
perceptions of the world and ensure their unique view is reflected, so capturing the quality of
individual experience.
IPA identifies subordinate and overarching themes within and across transcripts through a
process of reading and re-reading the texts. In order to obtain the richest representation of the
transcripts the following steps were followed:
1. The first interview transcript was read several times and brief notes made of any
associations or early interpretations.
2. Emergent themes were identified from the transcript and researcher's notes and were
assigned appropriate labels.
3. These themes were then reordered and organised into groups. Connected themes were
clustered together to create superordinate themes, which were then included in a
preliminary table of themes (see Table 4.3).
4. This process was then repeated with each of the remaining transcripts. New examples
of each of the already identified themes were noted and any new emergent themes
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identified. Previous transcripts were re-read to check for instances of the new themes.
All the themes were reviewed and any not well represented, were excluded.
5. Finally all the cluster themes were integrated across transcripts in order to identify
shared themes that captured the essence of the participants' experience of living with
PsA and psoriasis. A table of quotes from across all interviews was constructed to
illustrate each theme and demonstrate that the themes were supported verbatim within
the texts. An example of a quote table for a theme is provided in Appendix 6.
In order to increase validity and reliability of the analysis, the first and third transcripts were
reviewed independently by the researcher's supervisor. Both discussed the transcripts and
concurred on the emerging themes and categories. In addition, 40% (four) of the transcripts
were analysed by a researcher familiar with the topic area, which again supported the validity
of the analysis. Osborn & Smith (1998) suggest that such a process serves to ensure that
analysis is systematic and provides results that are supported by the data (see Appendix 7 for
an example of a participant transcript).
4.8 Results
Given the epidemiology of PsA, is it is generally the case that people with PsA invariably
have psoriasis, so it was not unexpected that a1l10 participants had both conditions. However,
it is also the case that some of the treatments for PsA improve psoriasis to such an extent that
the skin manifestations completely clear. At the time of the interviews, it was apparent the
impact of PsA was far greater than that of psoriasis, with participants having very little to say
about the effects of living with psoriasis. In three instances this was due to the fact the
psoriasis had cleared as a result of treatment for PsA, but in others it was simply the case that
PsA was viewed as far more detrimental to quality of life.
Analysis of the data revealed various themes that were concordant across the sample. That is
not to say that every participant gave evidence of every theme, but that common patterns of
meaning emerged both within and across the transcripts. A brief example of the development
of the superordinate theme of pain is shown in Table 4.2.
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Pain is comprised of smaller ordinate themes such as pain descriptors, pain intensity, pain
measurement and impact of pain. The development of these themes is developed and
supported by data from the transcripts.
Table 4.2: Superordinate category of pain comprising four ordinate themes
PAIN Annie Jack Chris
• Description "it's just sharp, "fizzy pains .. .like "it's like a nagging tooth-ache, it's
constant' bubble" there all the time"
• Intensity "different day to "it's there in the "even with pain killers, I don't get
day ... " background" relief from it"
• Measuring "you can't put an
average on pain"
• Impact "it's too painful" "some days I "I've had to ask my husband to cut
can't even wipe my food up"
my bottom"
During the analysis, five emergent themes were identified within the transcripts: pain,
functionality, emotions, treatment experience/management and coping (see Table 4.3). For
ease of presentation these are discussed as separate themes, although it is clear that they are all
interlinked and a full appreciation of each can only be achieved through an understanding of
the others and their connections.
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Table 4.3: Themes supporting development of five superordinate themes
PAIN EMOTIONS FUNCTIONALITY TREATMENT COPING
EXPERIENCE/
MANAGEMENT
Description Psychopathology Employment Regimen Adaptation
Intensity Strong feelings Immobility Side-effects Distraction
Measuring Shame Planning Consequences Help
Impact Pessimism Activity Other sufferers Alienation
Optimism Sleep Staff Withdrawing
Loss Tired Desperation Friends
Comparing Fatigue Clinic Social
Normality Information
Futility
4.8.1 Pain
Given that all the participants interviewed had a chronic musculoskeletal disease, it was,
perhaps, to be expected that pain would emerge as a major symptom and key theme.
All of the participants reported experiencing pain and their descriptions of it varied
considerably and certainly serve to emphasise that it is a subjective sensation. One said the
pain was "like a pair of tight shoes", whilst another characterised it as "fizzy ... like bubbles"
(Jack), whilst another characterised it as "being stabbed with pins" (Henry). Whether it was
"sharp and constant" (Annie) or "crippling" (Ian), it's impact shared similarities that were
reflected in their reduced ability to perform simple activities due to pain always being "there
in the background" (Jack). On some days the pain was so bad that Annie, "couldn't get out of
bed", whilst Ellie, "couldn't open a tin offood" and Gary had to come "down the stairs on my
backside". This detrimental effect on mobility was undoubtedly a source of distress for all the
participants, for example, Annie commented, "I can't get on the floor and play with the kids",
a comment similar in vein to Ian's reflection that, "I couldn't kick afooty round with my lads".
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There was a consensus that the pain and its intensity was unpredictable and was "different day
to day" (Annie). This resulted in participants reflecting on how "not knowing what it's going
to be like one hour to the next " (Debbie) impacts on the activities they can undertake on any
given day. It seems the presence, or possible presence, of pain informs their decisions about
going out to the shops or visiting friends. There was a shared view that "making plans is a
waste of time " (Ellie) because "you never have an idea of what you're going to be like ... it
can be too painful or sore to go out"(lan). This loss of spontaneity was the cause of a great
deal of sadness for participants, with typical reflections being, "cos I'm in pain it makes it
difficult to just go and meet up with friends" (Debbie) and "I can't just pop out, maybe,
like ...go for a drink ...! need to know I can sit down when I get there" (Henry).
It was apparent that participants assessed their pain levels each day and used this as a
benchmark to determine what their activities would be for the day. Annie reported, "I can't
say I'll go out tomorrow 'cos I don't know what it's going to be like until I get up", whilst
Ellie commented, "I never know if I'll manage without a wheelchair ...sometimes I just need to
be able to sit to help my pain". The participants conveyed a deep sense of frustration when
discussing their unpredictable pain levels and it was clear that the impact of pain was
implicated in every aspect of their lives.
Having talked about varying pain levels, it seemed particularly pertinent that several
participants identified pain measurement within the outpatient clinic as a troublesome issue.
Annie, looking emotional and angry as she spoke, described her typical visit to clinic,
"you go in and it's blah, blah, blah, how are youfeeling? It's
like, what really makes me angry, honestly Ifeel like hitting
them sometimes, they've got this, like a ruler thing, put the
arrow on that to tell me where your pain is over the past week,
that really, really makes me angry that, it's stupid, how can
you describe how your pain is on a ruler"
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This particular participant commented that instead of giving an average rating for her pain, she
really wanted to be able to tell the health professionals, "in the morning it was this way or in
the night, on Tuesday / couldn't move ...how can you put an average on pain?"
For most participants, living without pain was a distant memory, illustrated by comments such
as, " ...not sure / can remember a time when / didn't feel pain" (Ellie) and, "I can't remember
not being in pain". This sense that pain was an integral part of their lives was further
emphasised by one person stating "pain is part of me... it becomes part of you and part of your
life" (Debbie).
Generally, medication was not a satisfactory solution, "even with pain-killers / don't get relief
from it" (Chris), meaning the constant presence of pain, "like a nagging toothache" (Chris),
was a shared experience for all the participants.
Pain appeared to define their emotions for the day and to a large extent dictated whether or not
they enjoyed any social interaction. It certainly determined the level of activities they were
able to manage and had an undeniable impact on their degree of ability to perform what are
best described as everyday activities - opening a bag of cornflakes or a tin of food, playing
with their children or walking down the stairs.
4.8.2 Emotions
This category is comprised of various smaller themes that are used to describe the feelings
experienced by the participants, including anger, frustration, depression, shame and loss.
Many expressed anger and frustration, often citing their restricted mobility as the reason, with
comments such as, "I'm angry all the time ...! can't move easily" (Ian) and, "I'm so
angry ...useless ...itfrustrates me" (Chris). Annie remarked that, "Lfeel like I'm being punished
for something ...you feel angry, you need something to blame", whilst Jack said, "I feel I've
if "got some sort 0 curse .
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Other participants remarked on feeling anger and believed it was due their disease being
misunderstood by others, "people who haven't got it just have no idea and it makes me mad
that they don't understand" (Debbie), whilst Annie remarked, 'feels like you're the only
person with it" and went on to comment,
"I actually feel angry with everyone, don't know why, it's like
you're not getting heard, you feel like shouting, I lose my
temper very quickly, not with the kids or anything, just angry
all the time"
Individuals reported feeling, "scared" (Ian) and 'frightened of losing everything" (Henry).
Whilst others described feeling, "utterly useless" (Ellie) saying there was, "no point to my life
anymore" (Ellie). Most acknowledged feeling depressed at some point, with a typical
comment being "I'd gone into another little dark hole again" (Jack) and, "I was going
through depression" (Gary). Chris commented that she had, "been on depression pills for
years", whilst Annie said, "depression ... that's the way it makes you feel". Indeed, the severity
of the low mood experienced by Annie was clearly demonstrated when she remarked that she,
"wanted to go to bed, fall asleep and not wake up", a feeling echoed by Frank when he stated,
"I wanted to kill myself".
Interestingly, the majority of participants reported feelings of shame, "I was so ashamed of it
(the arthritis)" (Jack), whilst some associated this with being too young to have a chronic,
disabling condition 'feel ashamed, probably because I'm young" (Annie) and the belief that
"arthritis is an old person's disease" (Ellie). Others report, "hanging my face in shame"
(Chris) and being, "embarrassed" (Jack).
4.8.2.1 Loss
The theme of loss emerged and comprised four different components as participants talked
about their losses in terms of their life, their goals, their identity and their body image.
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Living with PsA caused many to view their life as being over, commenting that "it's just a life
no more" (Annie) and " ...sometimes my life seems pointless 'cos I can't do what I want to
do" (Ian). Annie observed, "It's ruined my life, that's it now, that is my life ", whilst Debbie
questioned the purpose of her life, "not sure what I'm supposed to do with my life now".
This sense of loss spilled over into a feeling that the participants had lost their future. Annie
talked about her future and said, "I can't see one ", whilst Chris observed, "you don't know
what's going to happen in the future".
It seems the consequences of living with this chronic disease impacted directly on people's
goals and ambitions, with remarks such as, "I gave up on everything" (Henry) and "I felt I
had just lost it all" (Ian) reflecting the views of most of the participants. Indeed, for Beryl the
ambition to have more children was thwarted as she shared the opinion of her consultant "I
was told I couldn't have anymore because of the state I was in ",
It seems the impact was so severe that careers were affected, or had to be stopped altogether,
"I couldn't work no more ...had to give it all up" (Henry). In two instances, employment had
continued, but the individuals had to change their occupational role, "I couldn't lift as my
hands had lost their strength so they put me in the office ...in truth even that was a struggle
some days, but at least I had a wage" (Ian). Participants reflected on their loss of employment,
with several stating that it was responsible for creating a void in their lives, "my work was
taken away, I loved my job but just couldn't do it and was left with nothing to fill all that
space ...Ifeel I lost a lot" (Debbie).
The sense of loss was compounded for many participants as they described how they lost their
sense of identity, or, as one person reflected, "You become a different person" (Jack). Another
participant, visibly emotional when speaking, believed her friends thought of her in a
completely different light, "it's not Annie anymore, it's Annie with arthritis ". Similarly, Frank
commented about his friends, "they knew it's not me". This sense of having two identities was
conveyed by Debbie as she stated, "it was like there was the healthy me...that was one identity,
and then the unhealthy me...I had become someone else ... the old me was lost ". Whilst Ian
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believed, "I'm treated different by my friends, I think sometimes they don't know what to say
to me...! can't play footy with them now, but it's still me on the inside".
This image of dual identities was further emphasised by comparisons between their 'old self
and their 'new self as participants evoked memories of what they used to be able to do, thus
highlighting elements of their lives that had been lost, "I used to play sport" (Annie) and "I
can't work out anymore, I've lost muscle in my legs ... lost my six-pack" (Frank).
At times there was a great sense of sadness conveyed by participants as they took time to draw
comparisons between their old and new self, "I used to walk miles, I was outgoing ...now I
spend most of my time sitting" (Chris), whilst Gary remarked, "losing my sport affected me ...I
was on a real downer at the time, with being so fit for my age ",
It seems that the loss of identity overlapped with the loss of body image. One woman, who
previously had a reputation for buying shoes, said, "I can't wear proper shoes anymore, my
feet are too sore, I always used to be the enry of my friends as I bought lovely shoes ... but that
was the old me ...! had to give up buying them" (Ellie), whilst Jack commented, "I couldn't
put shoes on, so had to change my style ".
Experiencing loss was undoubtedly an experience shared by all those interviewed, whether the
loss related to life, identity, goals or body image, it seemed that, as one male participant
succinctly concluded, psoriasis and psoriatic arthritis is "all about loss" (Jack).
4.8.3 Functionality
This category was composed of two dimensions, physical impact and social impact.
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4.8.3.1 Physical Impact
This theme encompasses various smaller categories that were labelled as immobility, activity,
employment, planning, sleep and fatigue, all of which relate to the impact on physical function
experienced by the interviewees.
As expected, immobility emerged as a theme and was a problem for all the participants,
affecting not only their ability to walk, "I couldn't walk" (Jack), but also to perform
household tasks - "on a good day] can do a meal" (Chris) and be in employment, "would
love to work but there's no chance ...days when] can't move my hands properly" (Chris).
All participants expressed a desire to be able to return to work but were aware that their
physical limitations, combined with their need to plan before they do anything, were major
obstacles - "I can't say ]'11go out tomorrow, 'cos] don't know what it's going to be like until
I get up" (Annie). Another participant stated wistfully that he would "love to be out working"
(Henry), whilst Chris mourned the fact that, in order to go out the house, she "has to wait for a
good day, or get all kinds of equipment out to help me ".
The impact on employment opportunities was clearly demonstrated by one young male
participant who "had theformsfilledfor a police officer ... used to Thai box, run, jog, football,
swim ...can't do nothing now" (Frank).
The majority of the interviewees reported severely compromised mobility, some using simple
yet stark phrases as descriptors - "I could hardly walk" (Gary), "that stiff] could hardly
move" (Chris) and "sometimes need help to get out ofbed" (Henry), whilst others explained
their lack of mobility within the context of being unable to perform everyday tasks. These
ranged from being unable to "hold the iron" (Debbie), or prepare food, "I couldn't open a bag
of cornflakes ...my little lad did it" (Frank). Being unable to prepare food was a shared concern ,
particularly amongst those who had children, "makes me feel horrible, to watch my daughter,
aged nine, doing dinner" (Frank).
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The everyday tasks were often referred to as the, "normal things" (Ellie), "stupid things"
(Debbie) or "just life's usual kind of things" (Henry), yet they were all tasks that the
participants expressed great difficulty achieving. Annie said she just wanted to be able to walk
"down the street without having to walk next to a wall ...so you've got something to grab on
to" and went on to reflect about those tasks she longed to manage, "opening a tin, turning
over in bed without waking up in pain, stupid things".
The consequence of the lack of sleep - generally caused as Annie describes, by waking up due
to pain, "I can't sleep, you turn over and you're waking up again" - was a permanent feeling
of being, "tired all the time" (Ian). Without exception all participants experienced difficulties
sleeping, "I'm awake a lot through the night" (Chris). Disrupted sleep was viewed as the
norm rather than the exception, "just let me have one full night's sleep" (Chris), whilst Ellie
commented, "IfI get two hours without waking then that's a good night".
However, generally participants reported coping with the tiredness, with one male saying,
"you get used to it and learn to manage" (Henry), whilst Debbie remarked, "like most things,
you adapt and cope ...! cat nap when I can and get by on that". However, the lack of sleep
inevitably had an affect on psychological status and general feeling ofwell-being, with several
participants admitting to the regular use of alcohol in an attempt to induce sleep, "I couldn't
sleep ...! was drinking vodka" and "I needed a drink ...! was in that much pain (Gary).
Although disrupted sleep was considered responsible for tiredness, participants remarked on
feeling, "just sheer fatigue" (Henry) and were able to differentiate between the two
experiences, "I know if I go out shopping, I come back tired, it takes it out of me, but some
days Ijustfeel so weary, even when I've not shopped or done things" (Debbie). Ian described
being "beyond tired", whilst Ellie reported having "no energy to move", "completely drained
of everything" and having a "need to just sit and not move at all because you feel that you
can't".
None of the respondents reported having consistent fatigue, but described it as "something
that appears ...sometimes from nowhere" (Henry) and "sort of comes and goes ... bit
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unexpected" (Ian). Although it may be transient in its nature, fatigue undoubtedly has an
impact on those that experience it, for as Debbie observed, "it's so consuming, you can't read,
concentrate ...! can't even watch telly when it really gets me...!just have to stop everything".
4.8.3.2 Social Impact
Living with psoriasis and PsA had negative consequences with regard to enjoying a fulfilling
social life, with several participants reporting that they are regularly "making excuses ... to get
out of it (parties) " (Annie), whilst Chris said, "we don't go out much anyway ...l can't be
bothered, any excuse ".
Feelings of isolation and alienation were typical, particularly once the diagnosis had been
made, "you're left to get on with it" (Jack) and the feeling that, "everyone wants to help at
first, then nothing" (Annie). However, there was a sense that participants were actively
withdrawing from friends and were "pushing them away" (Annie) and, "had difficulty
interacting with other people" (Jack). Ian remarked that, "I often avoid going out because I'm
too tired and can't be bothered", whilst Frank said, "last time I went out was December last
year (11 months previously) ",
Many of the participants held a strong conviction that they would not ask friends for help "if
family don't help, that's it, you either do without or do it yourself" (Chris), whilst Annie said,
"I won't ask anyone outside the house ...! wouldn't lower myself". Such views may have been
tied up with the perception of some that they were too young to be chronically disabled and
would be ashamed to ask for help.
Gary reported being, "more of a loner than I was ", and Henry said, "I think not working
causes some isolation because all that contact has gone ",
4.8.4 Treatment ExperiencelManagement
There was connnon concern about the long-term effects of the drug treatments, with some
participants overwhelmed by the sheer quantity of different medications they were prescribed.
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Chris laughingly remarked that, "some people go in the chemist and get a small paper bag, I
go and get a carrier bag!" although she later expressed concern regarding the volume of
medication she required, "when] get my pills out it seems to be never ending".
The regimen of drugs was a source of anxiety for participants as some were worried about the
side-effects. Indeed, Annie said,
"I wonder what it's doing to my body ...what frightened
me more was when all the nurses had to start wearing
glasses and gloves ...! thought that's going into my body ...
don't want to take tablets no more, fed up ...when you've
taken your tablets, you're feeling sick".
Jack also commented, "I feared going on it, the side-effects ... ". However, there was a belief
that taking the medications enabled the participants to have, "a level of control" over the
disease.
Most had experienced the consequences of non-adherence at some time and had come to terms
with the realisation that mobility was dependant on their drugs, and so could not contemplate
life without their medication - "if you don't take it ...end up in a wheelchair" (Jack). All
participants seemed to appreciate the consequences of not taking their medication, for as
Annie said, "you miss them, you know you've got to pay for it", a view endorsed by Frank, "If
I don't take my tablet ... couldn't move the next day", and Gary, "I thought]' d miss a couple of
days, but I was terrible, had to go back on them", adding that currently, "I stick to all my
medication by the book".
Regular hospital visits were generally viewed as a part of the treatment plan and as such were
tolerated, although Chris commented that she had, "missed lots of my appointments ...! get fed
up with them", whilst Ellie remarked that, "sometimes it's such an effort to get there and when
I do, parking is bad and] can't walkfar, it can be tough".
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Some participants found being in a clinic with other PsA patients helpful as "you get
understanding there" (Beryl) and obtain a sense of being, "in the same club" (Jack), although
Annie had a more negative view of visiting the clinic, stating that she, "thought I would find
someone I could relate to, but I haven't, they are all older than me", whilst Chris remarked of
the other sufferers, "I never pay attention to them".
These mixed views regarding hospital appointments continued to be reflected as participants
talked about the staff Jack found it was beneficial just chatting about his condition to someone
in the clinic, even if it was another patient, "doesn't have to be a professional, just someone to
give you the time", whilst Annie believed, "you don't get enough time ...you feel like you're
wasting her time", a feeling echoed by Gary, "sometimes Ifeel, God, I'm wasting their time".
Of all the participants it was Gary who experienced the major benefits of treatment as he
stated, "I was like a new man" (after starting treatment), ''the treatment has been great ... new
tablets ... fantastic", but this was tempered with concern about the future, "I do worry about
what my joints are going to be like".
Several of the participants, whilst reflecting on appointments at the rheumatology clinic, felt
there was more that could be offered by the clinic by way of more informal help. Jack talked
about visits to the hydrotherapy pool and acknowledged that because it is a limited resource
and always in use, the hospital could, "organise a venue ...so people could go and swim" and
then suggested, that PsA patients, "should have coffee clubs ...a group getting people involved,
need to be more active, cope with the disease". This view was shared by Debbie, "I think it
would be good to have a get-together with others in the same situation and share what we do
to manage ... a group or something at the hospital would be good".
4.8.5 Coping
This final category encompassed strategies that the participants tried to employ in order to
help them cope with their condition. Unsurprisingly, physical adaptation was a common theme
as participants, such as Chris, had changed their lifestyle to cope with their condition ("I have
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a wheelchair when] go out"), although the scale of adaptation varied from, "learning how to
move your body" (Annie) to "the occupational therapists got my taps changed, shower seat
and the rail up the stairs" (Frank) and "I've got a car now, I've just learnt to drive, so I've
had to change" (Beryl). What is pertinent, however, is that all reported the requirement for
some form of change in order for their daily life to continue.
In order to try and cope with the pain participants used various techniques, including drinking
alcohol, "I had a drink to help me sleep" (Henry), because as Beryl suggested, "I was
drinking ... it helps sometimes ... with the pain". Jack reported trying not to think about his pain
"if] zone in on it, think about it and touch it, I'd go through the roof". A more extreme form
of distraction was demonstrated by Annie as she, "started getting tattoos 'cos] could control
the pain". It seems for the first time in years Annie was able to experience a feeling other than
the pain associated with her PsA, as she commented that even though it was still pain, "you're
concentrating on a different pain ... that you know will stop". As a result she had, at the time of
interview, received three tattoos and was contemplating another in the coming weeks. As a
method of pain control such action may appear extreme, but it is of note that this participant
experienced intense pain that made her, "want to go to bed, fall asleep and not wake up".
Itwas clear that participants had developed their own ways of coping with the restrictions that
PsA imposed on them; for example, Jack discussed how he coped with reading a book,
"even that's difficult, a simple thing, holding a book
so I tend to prop it up on a couple of cushions, but] can't
sit then, you know how you lose yourself in a book for a
couple of hours? I couldn't, it would have to be in spates
of like half an hour and then put it down 'cos I've stiffened
up again"
Similarly, Ian commented that he tried, "to control the condition by changes to how] sit, how
I do things, just small changes", whilst Beryl said, "if] can keep myself going and keep
moving around and when it's bad, stop and rest ....find that happy medium".
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4.9 Reliability and Validity of Data
The researcher believes that the aims of this qualitative study (explicitly articulated at the
outset as being the exploration of the lived experience of individuals with PsA and psoriasis,
and the identification of the nature of any psychosocial issues that patients perceive impact on
their daily lives) have indeed been achieved, as the resulting evidence clearly lends some
authenticity to claims that the views of the participants are being represented as they describe
the impact that the disease has on their lives.
It is imperative that such claims are based on reliable data that has been obtained through the
use of a transparent process that can be easily replicated, although there continues to be much
debate concerning the most appropriate methods to use when establishing the reliability and
validity of data in studies conducted within a qualitative framework (for example, Mays &
Pope, 2000; 2005 & Fossey, Harveyet al., 2002).
In order to provide a full demonstration of evidence from the data, the use of quotations, (that
is, the participants own words), juxtaposed with the researcher's description and interpretation
enables the reader to authenticate the researcher's claims about the data.
Researcher triangulation, that is, the use of several researchers in the analytical process,
further enhanced the validity and reliability of the data as this concept allows for a more
complex and nuanced understanding of the possible interpretations. The transcripts were
analysed by the researcher, whilst a sample were also analysed by the researcher's supervisor
and also by a clinical researcher familiar with both the field of rheumatology and dermatology.
There was a high level of consensus when all three researchers compared their analysis, which
served to corroborate the overall interpretation of the data.
Given that such triangulation enables the themes and categories identified by each researcher
to be compared and discussed, there is sound justification for having more than one researcher
analyse data, however, Barbour (2001) maintains that what is in fact important in this process,
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is not the level of consensus, but the opportunity for discussion among analysts to provide
opportunities for developing further coding.
Mays and Pope (2000) advocate that procedural rigour, that is, a clear exposition of the
methods of data collection and analysis, is important because it enables the reader to formulate
their own judgement as to whether the interpretation offered by the researcher is trustworthy
and evidenced by the data.
In the current study, such transparency was demonstrated through descriptions which detail
the way in which the research was conducted and the methodological steps which inform the
reader about participant recruitment, how data were collected, recorded, transcribed, coded
and analysed.
Furthermore, the reflexivity account provided by the researcher acknowledges her own actions
and decisions that will inevitably have impacted upon the meaning and context of the
experience described by the participants. This self-awareness of potential biases and
predispositions enhances the transparency of the overall research process and provides the
reader with sufficient information to allow them to identify the foundations upon which the
fmdings of the study have been grounded.
Whilst there is no one method to prevent errors occurring in qualitative research, use of the
above criteria facilitates the validity and reliability of the research data. Although other criteria,
such as respondent validation or attention to negative cases, may also be employed, Mays and
Pope (2000) suggest that researchers should modify their choice of assessment criteria to take
account of the distinct goals of the research whilst Rolfe (2006) argues that rather than utilise
an overarching set of criteria to judge the validity of qualitative research, each study should be
appraised on its own merits.
Due to the voluminous pages of transcripts that result from qualitative interviews, sample sizes
of participants are usually small and selection biases proportionately greater. The validity and
reliability of the data may be affected by the size and representitiveness of the sample and the
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nature of the population from which it is taken. In this study, the researcher was reliant on the
clinical staff acting as 'gatekeepers' for the recruitment process as they undertook the initial
identification of PsA patients. This process may have created an opportunity for selection bias
to occur as staff may have identified patients who they had previously cared for or who they
had some knowledge of, and as such, were patients who they believed would be willing
participants, or on the contrary, would not feel empowered to refuse their request. It is also
possible that the patients recruited generally had greater disease severity as they were
accessing secondary care services. However, the sample obtained did reflect equal numbers of
males and females and included a broad range of ages and the duration that patients had been
diagnosed with the disease.
As is generally the case with qualitative research, only a small sample size was required
meaning that not all patients attending the clinic were approached and included in the study.
Although potentially this could have created bias and resulted in some experiences not being
identified, interviews were conducted until saturation was achieved and the researcher
considers that saturation of themes may be a valid indicator of the inclusion of all significant
viewpoints.
Whilst acknowledging that the recruitment for this qualitative study was conducted at a single
site, it should be noted that it is a regional centre of excellence, and draws patients from a wide
geographical area so potentially increasing the representitiveness of the population.
Finally, the role of the researcher is recognised, as it is possible that the interviewer had an
effect on the respondents. As may be the case with any interview situation, the participant may
mistrust the interviewer and give misleading answers or provide answers that they think the
interviewer wants to hear. However, in order to reduce such bias occurring, the researcher
took time to explain the purpose of the study to participants, allowed sufficient time to conduct
the interviews and to answer any questions raised and assured the participants that any data
collected would remain confidential.
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Determining the best methods to appraise the reliability and validity of qualitative data
remains a topic of much debate, however the present study employs mixed methodology and
advocates that qualitative and quantitative data collection can extend the range of information
collected and can compensate for their relative weaknesses.
4.10 Conclusions
The aim of this initial qualitative study was to explore the lived experience of those people
with PsA and psoriasis and to establish the nature of any psychosocial issues that they
perceive as impacting on their quality of life.
People clearly indicated that living with psoriatic arthritis resulted in greater consequences
than psoriasis. Whilst this may be due to the severe physical discomfort associated with PsA,
it seems an additional explanation may be that participants can make some attempt to conceal
their psoriasis, "if my scalp's bad, the old hat goes on" (Jack).
As expected, pain was a major factor, with all participants reporting their functional abilities
frequently challenged by both the presence and intensity of pain, with the consequence being
varying levels of disability. Although little exploration has been undertaken with PsA patients
and the psychosocial impact of pain, it is of note that research with RA patients has reported a
complex interrelationship between pain, depression and physical disability, with physical
disability predicting levels of both (Covic, 2000). Furthermore, in studies of patients with RA,
pain severity is thought to predict subsequent sleep disturbances (Drewes et aI., 2000).
Of those people with psoriasis who responded to the 2005 National Psoriasis Foundation
surveys, 49.5% reported that psoriasis interfered with sleep at least once per month, and 11.3%
reported that psoriasis interfered with sleep more than fifteen days per month (Hom, 2007).
This may be due to pruritus (a sometimes painful sensation in the skin that elicits the desire to
itch) from psoriasis, as it is associated with poor sleep quality and frequent awakening from
sleep (Yosipovitch et aI., 200).
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This finding could shed light on the sleep disturbance reported in the current study,
particularly as patients with PsA may also have varying amounts of psoriasis and therefore
pruritis, which may interfere with sleep.
Physical functionality was severely impaired for all participants, with most unable to work and
with simple everyday tasks sometimes presenting enormous challenges. Functionality and
emotions were entwined as feelings of frustration and uselessness were frequently expressed,
whilst participants told of their sense of loss, as comparisons were made with the "old self'.
Reduced mobility appeared to be central to many of the emotions reported whilst several
participants viewed it as the trigger for their depressive symptoms. This may add further
support to a study by Husted et al (2005) that compared the health-related QOL (assessed
using a generic health status measure) of patients with PsA and RA. The authors reported that
those with PsA recorded higher levels of vitality yet they experienced higher levels of bodily
pain and more role limitations due to emotional problems, leading them to conclude that there
maybe unique disabilities associated with the psoriasis dimension ofPsA.
In this study, fatigue emerged as a common component of pain - the impact of this warrants
further investigation as research with rheumatoid arthritis patients has found that different
aspects of fatigue selectively explained different dimensions of health related quality of life
(Rupp, Boshuizen, Jacobi, Dinant, & van den Bos, 2004).
All participants reported consistent tiredness attributable to disturbed sleep. This finding is
important given that sleep disturbance has deleterious effects on health, including daytime
fatigue and an increased risk of depression (Malik & Kaplan, 2005).
Whilst all participants experienced various negative emotions that were all clearly associated
with living with PsA, it was symptoms of depression that emerged as a key theme.
Interestingly, the incidence of depression has been found to be higher among those with
rheumatological disorders than in the general population, indeed the rate is similar to that
found in individuals with other chronic conditions (DeVellis, 1993). Depression has been
found to have an effect on disability, with one study reporting that RA patients were more
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impaired than those who were not depressed (Katz & Yelin, 1993), whilst another found that
psychological factors were a better predictor of disability than traditional measures of disease
activity (McFarlane & Brooks, 1988).
The impact on social functioning was of interest as the majority of those interviewed reported
a conscious effort to avoid social events, withdraw from friendship groups and would only
seek practical or emotional support from immediate family members ("I couldn't lower myself
to ask anyone" - Chris). Despite social invitations and offers of help from outside of their
families, these same people report feelings of isolation and alienation. Such findings may have
wider implications as social support is classically conceived as a protective factor for health,
with a wide variety of studies documenting it's protective role with respect to both physical
and psychological health (Cohen, 2000). Indeed, in one study of patients with RA, chronic
obstructive pulmonary disease and psoriasis, coping by seeking social support was
significantly related to better functioning (Scharloo et aI., 1998).
There was evidence that various lifestyle changes were necessary for participants to cope with
their arthritic condition, whether it be incorporating a seat in the shower or using a wheelchair
when out shopping. However, coping strategies extended to dealing with pain, with various
methods of distraction being employed by the participants.
4.11 Implications of Findings
This study has clearly indicated that, whilst the physical manifestations of psoriasis are
unpleasant, it is PsA that has a major impact on patients' health-related quality of life, with
symptoms resulting in impaired physical functioning and occupational capability and a severe
negative affect on psychosocial domains.
An important finding to emerge from this study was that some problems, for example
depression and lack of social support, are not routinely discussed in the outpatient clinic where
the majority of those with PsA are seen. This warrants further exploration.
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The findings of this study, with it's focus on PsA and the identification of potential domains
requiring assessment, broadly supports that of the OMERACT group of experts (Outcome
Measures in Rheumatology) who recently established, by means of a consensus exercise, that
pain, physical function, QOL, and 'participation' were rated as the most pertinent factors
(Gladman, 2005). However, the current study, somewhat uniquely, focused on patients
perspectives and in addition to the aforementioned factors identified the following areas as
important for assessment: emotions, treatment experience, fatigue and coping.
Whilst caution should be applied to the findings of a small study that drew participants from
one source of referral, it would be prudent to determine the extent of such difficulties in the
wider PsA population. Substantial implications may be revealed by confirmation of Study 1
results with a larger sample, for example, a potential gap in the care of such patients
suggesting that health professionals may require additional training to engage patients in
appropriate discussion and be able to offer advice or interventions as a way of reducing the
psychological impact ofPsA.
There are few studies exploring the psychosocial issues affecting individuals with psoriasis
and psoriatic arthritis. The majority of research has been driven from a dermatology
perspective and considers quality of life issues associated with psoriasis whilst the impact of
PsA has been generally disregarded or overlooked. A review of the literature failed to identify
studies exploring the impact of psychosocial factors from the patient's perspective and perhaps
explains the current lack of consensus regarding which psychosocial domains should be
included in a core set of outcome measures when assessing the impact of both psoriasis and
PsA on an individual's quality oflife.
This qualitative study has addressed the latter point and successfully identified, from the
patient's perspective, which psychosocial factors are considered most pertinent. Study 2 will
utilise instruments to measure the domains that patients indicated, in Study 1, were most
pertinent to them. This will address some of the limitations of previous research and should
also add to the work currently underway by OMERACT, as the study will consider the
psychosocial variables in combination, not in isolation, as has previously been the case.
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In order to develop a suitable test battery to measure the identified domains of pain,
functionality, coping, fatigue and emotions, a review of existing outcome measures was
undertaken and is described in the following chapter.
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CHAPTERS
REVIEW OF OUTCOME MEASURES
5.1 Why measure patient outcomes?
In 2008, the Office of Health Economics (OHE) Commission reported that, each year the NHS
receives over £100 billion of taxpayers' money and that this figure increases by 10% per
annum. Given the aim of the NHS is to improve the health of the UK population, relatively
little is known about how the health of the nation is actually improving as a result of such
massive expenditure.
In order to address this, the Commission stated that routine measurement and analysis of
health care outcomes for patients is required. They also suggested that generic measures of
patients' health related quality of life before, during and after treatment should be collected
alongside disease-specific measures. It is their opinion that generic measures are essential to
permit comparison between different types of treatment for different groups of patients, and to
enable assessment of the overall productivity of the NHS (OHE, 2008).
Measuring the efficacy of a treatment or medical intervention traditionally involves the use of
physician-based outcomes such as blood tests, x-rays and MRI scans, however, given that
many of these clinical measures do not adequately capture the overall impact of the disease on
individuals, there is increasing utilisation of patient-based outcomes in order to gain a patient's
perspective of their health, illness and the efficacy of health-care interventions (Marra et aI.,
2005).
Across the broad spectrum of health and disease, accurate measurement of outcomes has
become an important medical and social issue, as their use is not limited to the assessment of
treatments, health promotions and disease prevention programmes. Indeed, outcome measures
may be used to establish the cost-effectiveness of treatments and interventions, determine the
67
health needs of individuals or groups and monitor those needs, influence an individual's
choice of a specific treatment plan and, ultimately, inform the development of health policy.
In most cases, the accepted "goal of healthcare is to protect, promote, and maintain the health
status of people" (Steinwachs & Cagney, 1996, pp. 747), and whilst treatments and
interventions aim to improve health, research suggests that physiological measures may
change without individuals feeling better and conversely, individuals may report feeling better
without their physiological function showing any measurable change. This being the case,
there is a clear need to be able to include instruments that measure the health of patients from
the patient's perspective, and which compliment conventional clinical measures and thus
provide a more complete assessment of health.
There are two basic approaches to measurement that researchers utilise when assessing the
impact of disease on areas such as health-related quality of life (HRQoL), pain or fatigue. The
first involves the use of instruments that are specific to a disease (e.g. lung cancer, diabetes,
PsA, etc.) a population (e.g. children) or a clinical problem such as pain, whilst the second
approach uses generic instruments that measure broad aspects of, for example, HRQoL and
provide a general sense of the effects of an illness, rather than assessing HRQoL relative to a
particular medical condition.
5.2 Disease Specific Measures versus Generic Measures
5.2.1 Disease-Specific Measures
Disease-specific measures are likely to be more sensitive and clinically relevant as they are
targeted to specific conditions, thus resulting in a measure that is more responsive to clinically
important changes in health that result from interventions (Marra et at, 2005). Such measures
do not contain any items or health dimensions that are not pertinent to the disease - this serves
to increase their acceptability amongst patients as the instruments have clear relevance to
patients with the presenting problem. However, the very nature of disease-specific measures
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means they are usually only administered to those with the specific health problem, meaning
that the resulting scores cannot be compared with those for the general population, which is a
common approach for assessing the impact of a particular disease on health status. Marra et al.
(2005) argue that this inability to draw comparisons across treatments for different diseases
limits their application in economic evaluation, health policy and resource allocation.
5.2.2 Generic measures
Generic instruments are designed to measure very broad aspects of health across a variety of
medical conditions and therefore may be administered to a wide range of patient and general
population groups to examine the impact of disease and, where appropriate, the impact of
various health care interventions. For example, The Sickness Impact Profile (SIP; Bergner et
al., 1981) has been used across a large number of different populations including RA, angina,
obesity, end stage renal disease, chronic obstructive pulmonary disease, as well as several
healthy populations, and appears to discriminate among them and different degrees of disease
severity (Deyo et al, 1982; VandenBurg, 1988; Sullivan, 1987; Hart & Evans, 1987;
McSweeny et al., 1982; Bergner et al., 1988; 1985).
Generic measures may also be used with healthy populations to generate normative data that
can then be used to compare different patient groups. Their broad scope means they have
potential to capture the influence of co-morbidity on health, in addition to the positive or
negative effects of an intervention. However, such wide applicability may limit the relevance
of generic instruments when applied to a specific patient population, as they may not be
sensitive enough to detect subtle treatment effects.
5.3 Psoriasis and PsA Outcome Measures
Researchers focussing on the impact of psoriasis are generally consistent in their use of
measurement tools, many of which are disease specific, with those typically employed being
the Dermatology Life Quality Index (DLQI; Finlay & Khan, 1994), Psoriasis Disability Index
(PDI; Finlay & Kelly, 1987), Salford Psoriasis Index (SPI; Kirby et al., 2000), Psoriasis Area
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and Severity Index (PASI; Fredricksson & Pettersson, 1978), Self- Administered Psoriasis
Area and Severity Index (SAPASI; Fleisher et al., 1994), Beck Depression Inventory (BDI;
Beck et al., 1961; 1974; 1984) and the Health Assessment Questionnaire (HAQ; Bruce & Fries,
2003).
However, limited research literature concerning the psychosocial impact of psoriatic arthritis
presents a different picture, with studies such as that by Husted and colleagues (2001),
reporting the use of generic instruments or those borrowed from rheumatoid arthritis or
ankylosing spondylitis.
The introduction of new therapies, such as biologics, may be a cause for patient optimism as
they have been shown to improve the debilitating physical symptoms associated with PsA.
Such advancements highlight the need for a consensus regarding the domains to be measured,
along with a core set of standardised and validated instruments, for, as Mease & Menter (2006)
suggest, it is now vital that researchers be able to accurately assess these improvements.
5.4 Available Measures
In the current study, the analysis of the qualitative data revealed five key themes that were
categorised as functionality, pain, emotions, coping and treatment experience and management.
These categories incorporate various smaller themes, some of which warrant further
exploration, in particular, fatigue and depression.
In order to achieve the aim of the second part of the current study, that is to quantitatively
measure the impact of psychosocial factors that were identified by the participants, a brief
review of available measures was undertaken. Given that fatigue and depression were clearly
demonstrated as factors requiring further exploration, the identification of appropriate
measures was required. Similarly, instruments for measuring pain and physical function
needed to be identified, whilst a suitable measure to assess the impact of psoriasis was
required.
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Following the brief review, the measures that had been identified as suitable were included in
the questionnaire booklet that was developed for use in the cross-sectional postal survey that
comprises the second part of the current study.
For each of the searches undertaken for the review of measures, the key search terms are
reported. In an attempt to keep findings current and relevant, a pragmatic decision was taken
by the author, to limit the search to research published from the year 2000 onwards (until date
of search - July 2006).
5.4.1 Function and Disability Measures
The databases, Blackwell Synergy (incorporating 849 journals), Psychinfo and Ovid and
Cinahl were searched for papers between January 2000 and July 2006 using a combination of
key terms - "psoriatic arthritis ", "quality of life ", "functional disability" and "functioning".
A total of 14 matches were returned. The inclusion of the term "psoriasis" returned an
additional 49 matches. The majority of these papers simply mentioned quality of life and did
not necessarily measure the construct. Of those which did, the measures employed included
The Arthritis Impact Measure Scales (Meenan, 1980), Short-Form Health Survey (SF-36;
Ware & Sherbourne, 1992a), Hosptial Anxiety Questionnaire (HAQ; Bruce & Fries, 2003),
European Quality of Life Scale (EQ-5D; EuroQol Group, 1990) and Dermatology Life
Quality Index (DLQI; Finlay & Khan, 1994).
Functional disability and quality of life may be considered key outcome measures for
individuals with psoriatic arthritis, for when considering the impact of any musculoskeletal
disease on an individual, such measures may provide an additional method of assessing the
damage caused by the disease (Kavanaugh & Cassell, 2005).
5.4.1.2 AIMS (Meenan et al., 1980)
The Arthritis Impact Measurement Scales (AIMS Meenan et aI., 1980) is an arthritis-specific
HRQoL instrument consisting of 45 items that are summed into 9 scales: mobility, physical
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activity (walking, bending, lifting), dexterity, household activity (managing money and
medications, housekeeping), social activities, activities of daily living, pain, depression, and
anxiety.
In addition to the original, there is an expanded version, AIMS2, incorporating a further three
scales to evaluate arm function, work, and social support, a short-form of the AIMS2 (AIMS2-
SF), a child version, and a version for the elderly (Geri-AIMS). AIMS have been translated
into many languages including Portuguese, Canadian French, Italian, Spanish, French, Dutch,
Swedish, Turkish, and Norwegian.
AIMS has been used in various other conditions including: psoriatic arthritis, ankylosing
spondylitis, fibromyalgia, carpal tunnel syndrome, colles fracture, hemophilia and in patients
undergoing joint replacement surgery.
Both AIMS & AIMS2 have been validated in patients with PsA and RA, although the
expanded version in not widely used due to its relative length and complexity (Husted et aI.,
1996; Taal et aI., 2004).
5.4.1.3 HAQ (Bruce & Fries, 2003)
Although sometimes viewed as a disease-specific measure because it emanated from the field
of rheumatology, The Health Assessment Questionnaire (HAQ; Bruce & Fries, 2003) is in fact
a generic instrument that is administered across diverse disciplines in many different cultures.
It was originally developed by Fries et aI., (1980) to assess physical function in patients with
RA, however, it has since been found to measure physical disability and pain in patients with
PsA (Wanke et al., 2002).
The HAQ focuses on physical disability and pain, with a modified version available for
spondylarthropathies (HAQ-S), which includes two spinal domains (Daltroy et aI., 1990). In
addition, the HAQ has been modified for psoriasis (HAQ-SK) and includes several items
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relating to the effect of skin disease on health status, however when utilised in study of PsA
patients the HAQ-SK scores did not differ from the original HAQ score suggesting that the
inclusion of skin-related questions did not improve the assessment of health status provided by
the original HAQ instrument (Husted et al., 1995).
The HAQ Disability Index (HAQ-DI) is the disability component of the HAQ that assesses
functional ability. It comprises 20 questions in 8 categories of functioning which represent a
comprehensive set of functional activities - dressing, rising, eating, walking, hygiene, reach,
grip and usual activities.
There is consensus that the HAQ-DI possesses face and content validity, and correlations
between questionnaire or interview scores and task performance have ranged from 0.71 to
0.95, indicating criterion validity. The construct/convergent validity, predictive validity, and
sensitivity to change have also been established in numerous observational studies and clinical
trials (Ramey et al, 1995).
According to Bruce & Fries (2003), the HAQ has been administered by the Stanford Arthritis
Rheumatism and Aging Medical Information System (ARAMIS) in excess of200,000 times to
assess clinical status, evaluate effectiveness in clinical and observational trials, and to define
health outcomes, and it is sanctioned by the American College of Rheumatology for assessing
physical function in RA trials. Available in over 60 languages and supported by more than 500
references, the HAQ is one of the most comprehensive, validated, patient-orientated outcome
assessment measures available.
5.4.1.4 SF-36 (Ware & Sherbourne, 1992a)
The Medical Outcomes Study Short-Form Health Survey (SF-36; Ware & Sherbourne, 1992a)
is one of the most widely used generic HRQL instruments due to it's ability to estimate
disease burden and compare disease-specific benchmarks with general population norms. With
almost four thousand publications to date (Ware, 2006), describing in excess of two hundred
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diseases and conditions, it is of note that arthritis, musculoskeletal conditions and rheumatoid
arthritis have fifty or more SF-36 publications each (Turner-Bowker et al., 2002).
It is a 36-item instrument that measures health across eight dimensions of physical functioning,
social functioning, role limitations due to physical problems, role limitations due to emotional
problems, mental health, vitality, pain, and general health perceptions. Responses to items
within each dimension are summed to produce a health profile of eight scores, whilst the
dimension scores also form physical component (peS) and mental component (MeS)
summary scores.
The SF-36 shows strong internal consistency, with reliability estimates for pes and MeS
usually exceeding 0.90 (Ware et al., 1990).
A major advantage of the SF-36 is its brevity - it can be incorporated into questionnaire packs
whilst leaving space for other more precise general and specific measures to supplement it, a
strategy that has been adopted in numerous studies, for example, Wagner et al., (1995).
The SF-36 has been employed in various PsA therapy trials (Schrader et al., 2002) and has
been found to be a reliable measure, distinguishing PsA patients from the general population
(Husted et al., 1997). Used in various studies, the SF-36 has shown that the impact of psoriasis
is as great as that of other major medical disorders (Rapp et al., 1999)
A further study ofPsA patients by Husted et al. (1998) reported that the SF-36 was equally, or
more, responsive than both the AIMS and the HAQ to short-term changes in perceived health
status and inflammatory disease activity.
5.4.1.5 Psoriatic Arthritis Quality of Life (PsAQoL; McKenna et aI, 2004)
The PsAQoL measure, developed by McKenna, Doward, Whalley, Tennant, Emery & Veale
(2004), is the first patient-derived instrument specific for PsA and was developed for use in
clinical trials. It consists of twenty items, the content of which were derived from qualitative,
unstructured interviews conducted with patients with PsA.
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The researchers reported that the psychometric properties, test-retest reliability (0.89) and
internal consistency (0.91) of the PsAQoL are excellent and that the measure is well accepted
by patients as it takes less than five minutes to complete. McKenna et al. (2004) concluded
that it is a valuable tool for assessing the impact of interventions for PsA in clinical studies
and trials.
5.4.1.6 European Quality of Life Scale (EQ-5D; Euroqol group, 1990)
Established in 1987, the EuroQol Group initially comprised a network of international,
multilingual and multidisciplinary researchers from seven centres in Finland, the Netherlands,
Norway, Sweden and the UK. The process of shared development and local experimentation
resulted in EQ-5D (www.euroqol.org, 1987)
The EQ-5D (EuroQol Group, 1990) provides a generic measure of health status that provides a
simple descriptive profile and a single index value that can be used in the clinical and
economic evaluation of health care and in population health surveys.
It consists of 5 items that measure 5 domains (Mobility, Self-care, Usual Activities,
Pain/Discomfort and Anxiety/Depression) and one Visual Analogue Scale measuring Health
State.
The first of 2 parts records a patient's health state along 5 dimensions (mobility, self-care,
usual activities, pain/discomfort, and anxiety/depression), each having a choice of three
possible levels reflecting no problem, some problem, and extreme problem. This classifies
respondents into 1 of243 distinct health states.
The second part of the EQ-5D is a 20-cm VAS that has the end points: "best imaginable health
state" (100) and "worst imaginable health state"(O). Respondents illustrate how they rate their
own health status by drawing a line that best represents their own health state on that day.
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It is applicable to a wide range of health conditions and treatments and was originally
designed to complement other instruments but is now increasingly used as a 'stand alone'
measure.
EQ-5D is designed for self-completion by respondents and is ideally suited for use in postal
surveys, in clinics and face-to-face interviews. It is cognitively simple, taking only a few
minutes to complete.
On one hand, the brevity of the EQ-5D has been considered a strength (Brooks, Robin & de
Charro, 2003) as it has resulted in better completion rates, even in chronic debilitating diseases
such as stroke (Dorman et al., 1997), but on the other hand, it appears to lack dimensions of
HRQoL such as dexterity, social functioning and vitality that may be impacted by RA, and
other chronic diseases (Johnson & Pickard, 2000). However, in two studies ofRA patients, the
EQ-5D was found to measure both current and changes in health status and demonstrated
index scores that were significantly correlated with other condition-specific measures,
including loss of function, joint pain, tenderness and mood. Such results suggest the EQ-5D
has reliability and cross-sectional and longitudinal construct validity in RA (Hurst et al., 1994;
1997).
The measure has been used in numerous studies to assess quality of life in psoriasis patients
(Weiss et al., 2002).
A summary of these measures is shown in Table 5.1.
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Table 5.1: Summary of function and disability measures
NAME Arthritis Health Medical Outcomes Psoriatic European
Impact Assessment Study Short -Form Arthritis Quality of
Measurement Questionnaire Health survey Quality Life Scale
Scales Disability Index of Life
ABBREVIATION AIMS &AIMS2 HAQ-DI SF-36 PsAOoL EO-5D
OBJECTIVE Measure changes To assess the Generic health Assess To characterize
in global health, difficulty concepts impact of current health
pain, mobility & in performing PsA and it's state
social function activities of treatment
daily living.
DISEASE Rheumatoid & Generic Generic Psoriatic Generic
Osteoarthritis arthritis
No. OF ITEMS AIMS: 45 20 36 20 5 + 1 VAS
AIMS2-SF: 26
COMPLETON AIMS: 20 mins 5 minutes 10 minutes < 5 minutes < 5 minutes
TIME AIMS2-SF: 10 min
POPULATION Adult Adult Adult! Adolescent Adult Adult
ADMINISTRA TIO Self Self/Interviewer SelflInterviewerl Self Self/interviewer/T
N or Telephone Computer elephone
TIME RECALL Past month Last week Std vers: Last 4 wks Present Present
Acute vers: Last wk
ORIGINAL English for the English for the English for the USA English English
LANGUAGE USA USA
AUTHORIS Robert F. Meenan James F. fries John E. Ware jr. & McKenna, EuroQol Group
Cathy D. Sherbourne Doward et al.
5.4.2 Pain
The databases, Blackwell Synergy (incorporating 849 journals), Psychinfo and Ovid and
Cinahl were searched for papers published between January 2000 and July 2006 using a
combination of key terms - "psoriatic arthritis", and "pain". A total of 255 matches were
returned. The inclusion of the term "psoriasis" returned an additional 964 matches. The
majority of these papers mentioned pain but did not necessarily measure it. Of those which
did, the measures employed included Visual Analogue Scales (VAS), Numerical rating Scales
(NRS), AIMSIAIMS2 (Meenan et al., 1980), HAQ VAS Pain Scale (Bruce & Fries, 2003).
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5.4.2.1 Pain Visual Analogue Scales (VAS; Bond & Pilowsky, 1966)
The Pain Visual Analogue Scale (VAS; Bond & Pilowsky, 1996» is a self-report measure
consisting of a ten centimetre (100 millimetres) continuous line, anchored at each end with a
statement representing the extremes of the dimension being measured, usually pain intensity.
The patient is asked to mark their perceived level of pain intensity (for a specified time frame)
on the line. Scoring of the VAS is done by measuring the distance, in millimetres, from the
zero to the patient's mark.
A VAS may be horizontal or vertical and, whilst it can be of any length deemed appropriate by
the researcher, its most common form is a 10 centimetre (100 millimetres) horizontal line.
Indeed, a horizontal VAS has been shown to produce a more uniform distribution of scores
than a vertical VAS (Scott & Huskisson, 1976).
Visual Analogue Scales have been used in clinical and research settings since the 1920's.
Freyd (1923) described the measurement of subjective phenomena using VAS, although at
that time, they were generally referred to as 'graphic rating scales'. VAS were initially used
for the measurement of pain in 1966 (Bond & Pilowsky) since which time, they have
frequently be used to assess both acute and chronic pain (Wewers & Lowe, 1990).
The instrument is quick to complete, as patients are simply required to indicate their present
pain level by marking the line. A widely used outcome measure, VAS are frequently
employed by clinicians assessing the efficacy of drug regimes for psoriatic arthritis as changes
in the VAS score represent a relative change in the magnitude of pain (for example, Cauza et
al.,2006).
The test-retest reliability of the VAS has been evaluated in various studies and has
demonstrated high correlation, for example Seymour (1982), requested participants to rate
current intensity of dental pain and reported correlations ranging from .95 to .99, whilst its
validity and reliability has been reported by Lara-Munoz and colleagues (2004).
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5.4.2.2 Numerical Pain Rating Scales (NPRS; Downie et at, 1978)
Numerical Pain Rating Scales (Downie et al, 1978) are frequently used to assess a patient's
level of pain and consist ofa line with a numerical scale with the range 0 to 10. The words "no
pain" anchor the "0", whilst ''worst pain possible" is found by the "10". The patient is asked to
choose a number from 0 to 10 that best reflects their level of pain and to indicate the point on
the line.
The NPRS are easily administered and simple to score and have demonstrated moderate to
high test-retest reliability, varying from 0.67 to 0.96 (Finch et al, 2002; Good et al., 2001)
5.4.2.3 Arthritis Impact Measurement Scales (AIMS; Meenan et al., 1980)
The AIMS and AIMS2 (Meenan et al, 1980) have been previously described, however they
not only elicit information about physical functioning (six subscales), but also pain (five item
scale).
The pain subscale consists of four items that measure the severity of the arthritis pain, the
frequency of severe arthritis pain, the duration of morning stiffuess and the frequency of pain
in more than one joint.
Both measures have been validated for use with psoriatic arthritis patients (Husted et al, 1996;
Husted et al., 1996), however, Gladman and colleagues (2004) note that clinicians at the
University of Toronto PsA clinic have stopped using these instruments as patients reported
they were tedious to complete.
5.4.2.4 Health Assessment Questionnaire Pain VAS (HAQ Pain VAS; Bruce &
Fries, 2003)
As previously mentioned, the HAQ and HAQ-S (Bruce & Fries, 2003) have been validated for
use with PsA patients (Wanke et al., 2002).
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The HAQ contains the HAQ Visual Analogue pain Scale that, according to Bruce & Fries
(2003) is designed to assess the presence (or absence) of arthritis-related pain and its severity.
The objective is to obtain information from patients on how their pain has usually been over
the past week, even though pain may be reported to vary over the course of a day or from day
to day. The HAQ pain scale consists of a doubly anchored, horizontal VAS, that is scored
from zero (no pain) to three (severe pain), or alternatively from 0 (no pain) to 100 (severe
pain).
The VAS for pain has been used widely in experimental, observational, and clinical settings
(Jansen et at, 2000; Kandziora et al, 1999; Ramey et al, 1995).
A summary of available pain measures is shown in Table 5.2
Table 5.2: Summary of pain measures
NAME Pain Numerical Arthritis Impact Health
Visual Rating Measurement Assessment
Analogue Scale Scales Questionnaire
Scale VAS Pain Scale
ABBREVIATION Pain VAS NRS AIMS&AIMS2 HAQPain VAS
OBJECTIVE To measure ~easurechangesin Assess severity of
severity or global health, pain, Arthritis-related
improvement mobility & social pain
of pain function
DISEASE Generic Generic Rheumatoid & Generic
Osteoarthritis
No. OF ITEMS 1 1 AIMS2: 45 20
AIMS2-SF: 26
COMPLETON < 1 minute < 1 minute AIMS: 20 mins
TIME AIMS2-SF: 10 mins
POPULATION Age7+ Adult Adult
ADMINISTRATION Self Self! Phone Self Self! Phone!
Interviewer Interviewer
TIME RECALL Variable Variable Past month Last week
ORIGINAL English English for the English for the USA
LANGUAGE USA
AUTHORIS Bond& Robert F. Meenan James F. fries
Pilowskv
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5.4.3 Coping
The databases, Blackwell Synergy (incorporating 849 journals), Psychinfo and Ovid and
Cinahl were searched for papers published between January 2000 and July 2006 using a
combination of key terms - "psoriatic arthritis", "coping", "passive coping" and "emotional
coping". A total of 44 matches were returned. The inclusion of the term "psoriasis" returned
an additional 203 matches, most of which concerned coping with stigmatisation regarding the
appearance of skin.
Although matches were returned by the search, none of the psoriatic arthritis studies
specifically utilised instruments to measure coping. However, research with RA patients
(Covic et al., 2002), suggests that useful measures include the Vanderbilt Pain Management
Inventory (VPMI; Brown & Niccassio, 1987), the Arthritis Helplessness Index (AHI;
Niccassio et al., 1985) and the Coping Strategies Questionnaire (CSQ; Rosentiel & Keefe,
1983)
5.4.3.1 Vanderbilt Pain Management Inventory (VPMI; Brown & Nicassio, 1987)
The Vanderbilt Pain Management Inventory (Brown & Nicassio, 1987) is an 18-item measure
that assesses the frequency with which chronic pain patients use coping strategies when their
pain reaches a moderate or greater level of intensity.
The VPMI consists of two internally reliable scales: Active Coping and Passive Coping. When
developing the VPMI, Brown & Nicassio (1987) found that Active Coping was associated
with reports of less pain, less depression, less functional impairment, and higher general self-
efficacy, whilst Passive Coping was correlated with reports of greater depression, greater pain
and flare-up activity, greater functional impairment, and lower general self-efficacy.
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5.4.3.2 Arthritis Helplessness Index (AHI; Niccassio et al., 1985)
The AHI (Niccassio et al., 1985) measures self-perception of ability and inability to control
arthritis. It consists of 15 items designed to assess patients' perceptions of loss of control in
association with their RA. Nine of the items assess perception of ability and six assess
inability. (Nicassio, Wallston, Callahan, Herbert & Pincus (1985).
5.4.3.2 Coping Strategies Questionnaire (CSQ; Rosentiel & Keefe, 1983)
The CSQ (Rosentiel 7 Keefe, 1983) is a 48-item checklist of coping strategies in which
patients are asked to indicate the extent to which they use a given coping strategy on a scale of
1 ('not at all') to 6 ('always').
The measure assesses 6 cognitive coping techniques (Diverting Attention, Reinterpreting Pain
Sensations, Coping Self-Statements, Ignoring Pain Sensations, Praying or Hoping, and
Catastrophising), and 2 behavioural coping techniques (Increasing Activity Level and
Increasing Pain Behaviours). Each domain is composed of 6 items, and participants rate the
frequency of their use of specific coping strategies on a 7-point Likert scale from 0 (''Never do
that") to 6 ("Always do that"). In addition, The CSQ also includes two l-item scales that
assess participants' subjective ability to control or decrease their pain - these two scales are
not thought to measure coping strategies but rather their effectiveness (Rosentiel & Keefe ,
1983)
The CSQ has demonstrated satisfactory internal consistency and test-retest reliability (Main &
Waddell, 1991).
A summary of available measures for coping is shown in Table 5.3.
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Table 5.3: Summary of coping measures
NAME Vanderbilt Pain Pain Coping Arthritis Helplessness
management Strategies Index
Inventory Questionnaire
ABBREVIATION VPMI CSQ AHI
OBJECTIVE Assess 2 general Assess use of coping Measures self-
coping strategies - strategies when pain perception of
Active and passive is experienced ability and inability
to control
arthritis
DISEASE Generic Generic Rheumatoid Arthritis
No. OF ITEMS 18 44 15
COMPLETON 5 minutes 10 minutes 3 minutes
TIME
POPULATION Adult Adult
ADMINISTRATION Self Self Self
ORIGINAL
LANGUAGE
AUTHORIS Brown & Nicassio Rosenstiel & Keefe Nicassio (1985)
5.4.4 Fatigue
The databases, Blackwell Synergy (incorporating 849 journals), Psychinfo and Ovid and
Cinahl were searched using a combination of key terms - "psoriatic arthritis" and "fatigue".
A total of 65 were returned. The inclusion of the term "psoriasis" returned an additional 211
matches. Generally, fatigue was not measured, but referred to as a symptom. However, of
those that did measure fatigue, Visual Analogue Scales, the Fatigue Severity Scale (Krupp et
aI, 1989) and the Functional Assessment of Chronic Fatigue Therapy - Fatigue (Yellen et al.,
1977) were used.
Within the realms of PsA research, fatigue is only just emerging as an important domain in its
own right (Mease et al., 2005). Several multidimensional measures have been developed in
order to capture the emotional and physical aspects of fatigue.
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5.4.4.1 Fatigue Severity Scale (FSS; Krupp et at, 1989)
The FSS (Krupp et al, 1989) is a brief measure comprising nine statements that rate the
severity of fatigue symptoms on a scale of 1 (Disagree) to 7 (Agree).
It has been widely used and validated in patients with systemic lupus erythematosus (SLE;
Krupp et al., 1990) and has been used with PsA patients, successfully distinguishing them
from controls and showing correlation with disease activity (Schentag, Cichon, MacKinnon,
Gladman & Urowitz, 2000).
According to Krupp's et al (1989) the measure has demonstrated high reliability with SLE
patients (a = 0.89), those with Multiple Sclerosis (a = 0.81) and normal healthy adults (a =
0.88). In addition, it has good test-retest reliability (0.84).
5.4.4.2 Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT -f; Yellen et
aI, 1997)
The FACIT-F (Yellen et al, 1997) is a measurement tool that gathers patient feedback about
energy level, listlessness and the ability to start or finish activities, and can be used to assess
various chronic disease states, so enabling comparisons across diseases.
The instrument was originally developed to measure fatigue in patients with cancer (Yellen et
al., 1997) but has since been used in other patient groups and demonstrated good internal
consistency (0.86 to 0.87) when used with RA patients (Cella, et al., 2005).
Although there is, as yet, a paucity of information concerning the use of this measure with PsA
patients, it is currently being used in clinical trials with PsA patients. A press release by global
health care company, Abbott, in which they report their preliminary findings of the
Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT), states that patients' fatigue
levels experienced a mean improvement seven points higher than patients taking the placebo,
however, clinically meaningful improvements in the FACIT-F scale have not been specifically
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defined for psoriatic arthritis, although in rheumatoid arthritis, meaningful improvement is
defined as a four-point change (Abbott, 2005).
A summary of fatigue measures is shown in Table 5.4.
Table 5.4: Summary of fatigue measures
NAME Krupps Fatigue Functional assessment of Chronic Illness Therapy
Severity Scale Fatigue Score
ABBREVIATION FSS FACIT-F
OBJECTIvE To assess fatigue To assess fatigue
DISEASE Generic Cancer
No. OF ITEMS 9 13
SCALE 7-point Lickert 5-point Lickert
COMPLETON TIME Less than 5 minutes Less than 5 minutes
POPULATION Adult Adult
ADMINISTRATION Self-administered Self
ORIGINAL English for the USA English
LANGUAGE
AUTHOR/S Lauren B. Krupps Yellen et al.
5.4.5 Emotions
The databases, Blackwell Synergy (incorporating 849 journals), Psychinfo and Ovid and
Cinahl were searched using a combination of key terms - "psoriatic arthritis", "depression",
"depressive symptoms" and "psychological distress". A total of 106 matches were returned.
The inclusion of the term "psoriasis" returned an additional 646 matches. The most frequently
used measure was undoubtedly the Hospital Anxiety Depression Scale (Zigmond & Snaith,
1983), although the Beck Depression Inventory and CES-D (Center for Epidemiological
Studies Depression Scale; Radloff, 1977) were also featured.
Within the context of the proposed study, the measurement of emotions is primarily concerned
with depression.
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5.4.5.1 Beck Depression Inventory (BDI; Beck, 1961)
The Beck Depression Inventory (Beck, 1961) is a 21-item instrument which aims to measure
presence and degree of depression in adolescents and adults. Each of the twenty-one items
attempts to assess a specific symptom or attitude and includes Mood, Pessimism, Sense of
Failure, Lack of Satisfaction, Guilt Feelings, Sense of Punishment, Suicidal Wishes,
Fatigability and weight Loss.
There are three versions of the BDI-the original BDI, first published in 1961 (Beck et al.,
1961) and later revised in 1978 as the BDI-IA (Beck et al., 1979), and the BDI-II, published
in 1996.
According to Beck and his colleagues (1988), the BDI has become one of the most widely
used instruments not only for assessing the intensity of depression in psychiatrically diagnosed
patients (Piotrowski, Sherry, & Keller, 1985), but also for detecting depression in normal
populations (Steer, Beck, & Garrison, 1986). Numerous studies have addressed the internal
consistency of the Beck Depression Inventory for psychiatric (0.76 to 0.95) and non-
psychiatric populations (0.73 to 0.92).
The Beck Depression Inventory (BDI) has been used with PsA patients (Tyring, 2006).
5.4.5.2 The Hospital and Anxiety Scale (HADS; Zigmond & Snaith, 1983)
The HADS, developed by Zigmond and Snaith (1983), is a brief, self-administered rating scale
of symptoms and functioning that is designed to detect anxiety and depression. It consists of
14 statements divided into two subscales, anxiety and depression, each with 7 items. The
scores for the two components can also be added together to give a composite anxiety-
depression score.
The measure has been used in routine care, multiple types of clinical investigations and is
available in over 33 translations.
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Both subscales demonstrate acceptable reliability (a = 0.80 to 0.93). (Herrmann, 1997).
Indeed, in his review of validation data and clinical results, Herrmann (1997) maintains that
the HADS gives clinically meaningful results as a psychological screening tool both in clinical
group comparisons and in correlational studies with several aspects of disease and QoL.
Research with RA patients (Sharpe et al., 2001) suggests the Hospital Anxiety and Depression
Scale (HADS) is worthy of inclusion as an outcome measure for depression.
5.4.5.3 Center for Epidemiological Studies Depression Scale (CES-D; Radloff,
1977)
The CES-D is a 20-item, self-report scale designed to measure depressive symptomatology in
the general population. It measures frequency of mood and behavioural symptoms that
occurred during the previous week. Items are rated on a 4-point scale ranging from rarely/none
of the time to most or all of the time.
The CES-D has been used extensively in community samples and demonstrates adequate
reliability and validity in the general population (a = .85; Radloff, 1977), RA patients (average
internal consistency = .92; Smith & Wallston, 1992), and a sample of older adults with either
arthritis or no chronic disease (a = .87; Penninx et al., 1997).
A summary of depression measures is shown in Table 5.5.
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Table 5.5: Summary of Emotions Measures
NAME Beck Depression Hospital Anxiety and Center for
Inventory Depression Scale Epidemiological
Studies Depression
Scale
ABBREVIATION BDI HADS CES-D
OBJECTIVE Assess intensity of Assess mood Assess Depressive
depressive symptoms symptoms
DISEASE Generic Generic
No. OF ITEMS 21 14 20
COMPLETION 10 minutes < 5 minutes < 5 minutes
TIME
POPULATION Adult Adult Adult
ADMINISTRATION Self Self Self
ORIGINAL English English English
LANGUAGE
AUTHOR/S Beck, Ward, Zigmond & Snaith Radloff
Mendelson, Mock &
Erbaugh
5.5 Quality of Life Measures for Psoriasis
Assessing QoL in patients with psoriasis may be achieved using a variety of measures that are
either psoriasis-specific, skin specific or generic QoL measures. Whilst the most sensitive
measures are the psoriasis-specific ones, they do not enable comparisons to be made across
diseases, often resulting in studies utilizing more than one measure.
5.5.1 The Psoriasis Index of Quality of Life (PSORIQoL; McKenna et al., 2003)
The PSORIQoL (McKenna et al., 2003) is a dichotomous, 25-item instrument used to
measures the impact of the psoriasis on quality of life, rather than assessing impairment or
disability.
With content derived from qualitative interviews with psoriasis patients, the items cover a
number of areas including, fear of negative reactions from others, self-consciousness and poor
self-confidence, problems with socialisation, physical contact and intimacy, limitations on
personal freedom and impaired relaxation, sleep and emotional stability.
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McKenna and his colleagues (2003) have demonstrated that the measure has high internal
consistency (a = 0.94) and good test - retest reliability (0.90).
5.5.1.2 Psoriasis Life Stress Inventory (PLSI; Gupta & Gupta, 1995)
The PLSI (Gupta & Gupta, 1995) is a 15-item instrument designed to measure psoriasis-
related stress associated with cosmetic disfigurement and social stigma, symptoms of disease
and treatment effects.
The PLSI (Gupta & Gupta, 1995) also permits patients to be classified as a function of their
distribution of score: those patients who react significantly to the stress associated with having
psoriasis (score> 10); and those patients who are not significantly affected by psoriasis-
related stress (score < 10).
The psychometric properties of the PLSI were assessed by Fortune et al. (1997) and they
reported good internal reliability (a = 0.88).
5.5.1.3 Psoriasis Disability Index (PDI; Finlay & Kelly, 1987)
The PDI (Finlay & Kelly, 1987) is a 15-item scale that specifically addresses self-reported
disability in areas of daily activities, employment, personal relationships, leisure, and
treatment effects. The items are concerned with the practical effects of psoriasis in every day
life.
The PDI has been shown to have good concurrent validity with the Sickness Impact Profile
(SIP; Bergner et al., 1981) a widely used generic health status measure (Finlay et al., 1990).
Mease & Menter (2006) maintain that a major limitation of the PDI IS its suboptimal
sensitivity to changes in patients with mild to moderate disease.
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5.5.1.4 Psoriasis Area and Severity Index (PASI; Fredriksson & Pettersson, 1978)
and Simplified PASI (SAPASI)
The PAS! (Fredriksson & Pettersson, 1978) and Simplified PAS! (SAPAS!) are measures used
by clinicians to assess the severity of psoriasis.
Fredriksson and Pettersson created the PAS! as a method to evaluate the clinical efficacy of a
new treatment for psoriasis. It is widely used by clinicians whilst the SAPAS! is a simplified
self-report version (Louden et al., 2004), however, neither measure the impact of psoriasis on
patients' QoL directly, making the use of other QoL scales necessary.
5.5.1.5 Salford Psoriasis Index (SPI; Kirby et al., 2000)
The SP! (Kirby et at, 2000) is derived from combining three figures - a score of current
severity of psoriasis based on the PAS!, a score indicating psychosocial disability, and a score
based on historical information. The first figure reflects the extent of psoriasis, the second
assesses the psychosocial impact of psoriasis on each patient using a 0-10 visual analogue
scale and the third figure reflects historical severity of disease as judged by the need for
systemic treatment, admission to hospital and number of episodes of erythroderma (Kirby et
al.,2000).
Reliability and sensitivity of the SP! was assessed in two separate cohorts and demonstrated
high reproducibility and was highly responsive to changes in health-related quality of life after
treatment for psoriasis (Kirby et al, 2000).
5.5.2 Skin-specific measures
5.5.2.1 The Dermatology Life Quality Index (DLQI; Finlay & Khan, 1994)
Measuring HRQoL over the previous week in patients with skin diseases, the DLQ! was
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developed as a simple and practical instrument for use in dermatology clinical settings to
assess limitations related to the impact of skin disease (Finlay & Khan, 1994).
It is a compact, self-reported questionnaire with ten items based upon the most commonly
identified impacts upon dermatology-specific HRQoL, that were elicited from patients with
skin disease. It contains six subscale scores: symptoms and feelings; daily activities; leisure;
work/school; personal relationships; and treatment.
The DLQI is the most used and validated instrument in psoriasis, and has been used in several
studies of PsA to consistently show discriminant ability (Mease et al., 2004). Reliability
figures ranging between 0.62 - 0.92 have been demonstrated (Shikiar et al, 2003).
Table 5.6: Summary of measures for psoriasis
NAME Psoriasis Index Psoriasis Life Psoriasis Psoriasis Salford
of Quality of Stress Disability Area and Psoriasis
life Inventory Index Severity Index
Index
ABBREVIATION PSORlQoL PLSI POI PASI SPI
OBJECTIVE Measure Assess Assess Measures Assesses
impact of psoriasis- functional severity of current &
psoriasis on related stress disability psoriasis historical
QoL psoriasis
severity &
psychosocial
disabilitv
DISEASE Psoriasis Psoriasis Psoriasis Psoriasis Psoriasis
No. OF ITEMS 25 15 15 3
COMPLETION < 5 mins > 5 mins 5 minutes 5 mins
TIME
POPULATION Adult Adult Adults Adult Adult
ADMINISTRATION Self Self Self Clinician Clinician
TIME RECALL Present Last 4 weeks Last 4 weeks Present
ORIGINAL English English English english English
LANGUAGE
AUTHORIS McKenna et al. Gupta & Gupta Finlay& Fredricksson Kirby et al.
Kelly & Pettersson
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5.6 Outcome Measures in Rheumatology (OMERACT) and the Group for
Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA)
In 1992, an informal, international network of clinicians and investigators in the field of
rheumatology established a group known as OMERACT (Outcome Measures in
Rheumatology Clinical Trials). The group's objective was to achieve consensus on a core set
of measures that should be included in clinical trials in rheumatoid arthritis, however, their
remit has since widened and is now focussed on developing outcome measures for a variety of
disease domains (the group, now called Outcome Measures in Rheumatology, still uses the
acronym, OMERACT).
Since 2003 several consensus exercises have been completed. Taylor (2005) reports that a list
of twenty-six domains was produced following an initial literature review and email
discussions amongst members of the Group for Research and Assessment of Psoriasis and
Psoriatic Arthritis (GRAPPA). Four contexts of measurement were identified:
1) Disease controlling antirheumatic therapy (DC-ART)
2) Symptom modifying antirheumatic drugs (SMARDS)
3) Rehabilitation
4) Clinical record keeping with each context scored separately.
The participants, all rheumatologists and/or members of the Classification of Psoriatic
Arthritis (CASPAR) study, completed a Delphi consensus exercise whereby they were each
asked to determine the relative importance of each domain by distributing one hundred points
amongst as many, or as few, ofthe twenty six domains as they wished.
For DC-ART the highest scoring domains were actively inflamed joint count, radiological
damage score, patient global assessment, pain, physical function, acute phase response and
QOL. For SMARD, the high scorers were pain, patient global assessment, physical function,
QOL and active joint count scores, whilst for clinical record keeping participants rated pain,
patient global assessment and active joint count as important. Finally, six domains were of
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note for rehabilitation - physical function, QOL, pam, patient global assessment, work
limitations and work incapacity.
Taylor (2005) acknowledged that as the participants comprised rheumatologists, not only was
the perspective of the patient excluded, but so too was a domain for psoriasis or skin
assessment. However, this exercise did reduce the number of potential domains from twenty-
six to approximately twelve; although there was insufficient consensus regarding which of the
lower scoring domains should be included in a core set.
Following on from this, GRAPP A undertook a further exercise in order to achieve greater
consensus on the domains and attempt identification of instruments for each domain (Gladman,
2005). In his paper, Gladman notes the advantage of discussing ''these domains in a face to
face meeting of rheumatologists, dermatologists and patients" (pg.113), but it is unclear how
many individuals with PsA, if any, were included in the exercise. However, the resulting
consensus on the domains necessary to evaluate patients with PsA included assessment of
joint inflammation, biomarkers, imaging, other areas of inflammation and patient derived
indicies, including pain, quality of life related to joint and skin disease, itching and function.
Several other domains, including fatigue, were noted as requiring further research and
evaluation.
Although the list was incomplete, the recommended measurement tools included the patient
global VAS for pain, the SF-36 (Ware & Sherbourne, 1992a) and Dermatology Life Quality
Index (DLQI; Finlay & Khan, 1994) for quality oflife measures and the HAQ (Bruce & Fries,
2003) for physical function.
At the seventh meeting of OMERACT in 2004, the focus was on outcome measures for PsA ,
with the workshop based on information obtained from the previous two consensus exercises
carried out through GRAPPA (Gladman et al., 2005). This conference resulted in a list of
proposed domains, that in addition to the requisite clinical response measures, included the
assessment of pain, physical function, quality of life, fatigue and participation (''the capacity to
engage meaningfully and capably in activities of life" (Mease et al., 2005, ii51).
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The HAQ (Bruce & Fries, 2003) is the 'gold standard' accepted by the Outcome Measures in
Rheumatoid Arthritis Clinical Trials (OMERACT) conference committees and the US Food
and Drug administration.
The psychosocial domains highlighted by OMERACT are generally supported by the current
qualitative study, although this has additionally identified emotions, treatment experience and
coping as potential areas for assessment. In this study, fatigue was clearly identified by
patients as a key factor so was included within the domain of functionality, so it is of note that
OMERACT has also identified fatigue and has recommended that further research be
undertaken to establish its impact and identify possible outcome measures.
Identifying appropriate and valid outcome measures for use in studies of PsA is particularly
challenging given that it is a complex, multi-faceted condition that has both rheumatic and
dermatological consequences for patients - indeed, this may account for the paucity of studies
exploring the psychosocial impact of the disease.
5.7 Summary
Research within the field of rheumatology, particularly rheumatoid arthritis, has identified the
important role that psychological and social factors may play in an individual's adaptation and
response to rheumatic disease. It suggests that in future it may be necessary to broaden patient
consultations to encompass more detailed psycho-social information as the use of appropriate
measurement instruments can provide useful information regarding an individual's response to
their illness and facilitate discussions on adaptation.
Estimated to occur in up to thirty percent of people with a diagnosis of psoriasis, psoriatic
arthritis is a complex, multi-faceted condition meaning disease outcome in arthritis is multi-
dimensional and requires assessment across a number of domains including quality of life,
pain, fatigue, functionality and ability to work.
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The introduction of new therapies, such as biologics, may be a cause for patient optimism as
they have been shown to improve the debilitating physical symptoms associated with PsA.
Such advancements highlight the need for a consensus regarding the domains to be measured,
along with a core set of standardised and validated instruments, for, as Mease & Menter (2006)
suggest, it is now vital that researchers be able to accurately assess these improvements.
In the current study, the qualitative results identified, from the patients' perspective, key
constructs of pain, function, fatigue, depression and coping that warrant further exploration.
Following a brief review of the outcome measures that have previously been used with either
psoriasis or PsA patients, it is apparent that a mixture of both generic and disease specific
measures are required to establish the impact of these conditions on a patient's quality oflife.
Whilst the need to obtain meaningful information that is both valid and reliable remains
fundamental to health research, this should not result in patients being burdened with
numerous and lengthy questionnaires.
Guided by these requirements, it seems appropriate that the author's quantitative study
exploring the role and impact of psychosocial issues in psoriasis and PsA, should utilise the
SF-36 (Ware & Sherbourne, 1992a) as this will provide a broad picture of health-related QoL
as this instrument measures not only functional status, but also well-being and general
perceptions of health. Although the SF-36 (Ware & Sherbourne, 1992a) incorporates a
subscale for bodily pain, two numeric rating scales (NRS) will be included to further assess
the impact of pain. The DLQI (Finlay & Khan, 1994) will assess the impact of the skin
element.
Given the strong credentials of the HAQ-DI (Bruce & Fries, 2003) its inclusion in the study is
warranted, not least because it will allow for comparisons across other diseases. It is also of
note that in their 2004 review of measures, Gladman et al. (2004) suggest that, as the HAQ
(Bruce & Fries, 2003) measures physical function and pain, it should be included as an
outcome measure in PsA clinical trials. This choice is particularly pertinent given that the
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HAQ (Bruce & Fries, 2003) has recently become the 'gold standard' accepted by the
OMERACT conference committees and the US Food and Drug administration.
The emergence of fatigue as an important factor for PsA patients necessitates that future
studies consider the role it plays, indeed Mease et al., (2005) note that those patients
prescribed the newer biological agents often report that fatigue is one area that shows
significant improvement. Given that the Fatigue Severity Scale (FSS; Krupps et al, 1999) has
previously been used with this patient group, it was proposed that this nine-item measure be
included in the study.
Unfortunately, no studies exploring psychosocial issues in PsA were identified that had
specified coping as an outcome measure. However, in RA studies research has found that
passive coping is associated with greater pain, disability and depression, and active coping is
associated with less pain, disability and depression (Brown et al., 1987). Furthermore, a study
by Snow-Turek (1996) reported that active coping accounted for a smaller percentage of
variance in relation to pain than passive coping and that passive coping was strongly related to
general psychological distress and depression. Similarly, in a study of RA patients, the
frequent use of passive pain coping strategies in the face of high pain contributed to the most
severe level of depression over time (Brown et al., 1989).
Such findings may imply there is benefit to be gained by focusing attention on reducing
passive coping rather than increasing active coping, but perhaps more importantly they provide
evidence that coping impacts on disability and psychological health and may therefore warrant
exploration and measurement in patients with PsA. However, given the lack of evidence for a
suitable coping measure, the current study will utilise a self-efficacy measure - a factor that
has been implicated in an individual's ability to cope.
As both PsA and psoriasis are considered chronic diseases, a brief 6-item scale, the Self-
Efficacy for Managing Chronic Diseases Scale, will be employed (Lorig et al., 2001).
Following identification of suitable outcome measures, a questionnaire booklet was developed.
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Chapter 6 outlines in detail, the design, methodology, analysis and results of the quantitative
study.
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CHAPTER6
STUDY2
6.1 Introduction
Study 1 employed qualitative methodology to gain an understanding of the lived experience of
people with psoriasis and PsA and identified a number of psychosocial issues that they
perceived impacted on their lives, specifically, pain, fatigue, depression and functionality.
The generalisation of these findings is limited as they were drawn from interviews with a
small sample of patients, meaning there is a need to quantitatively assess these issues in a
larger sample and explore whether the results are consistent.
There are very few studies available which explore and compare health-related quality of life
in patients with both psoriasis and PsA, and indeed none where the choice of quantitative
measures has been initially patient-driven and based on qualitative data collected from patient
interviews. Although none of the previous studies include all the variables that were identified
by the patients in Study 1 as being important, several do include and measure one or more. For
example, a Swedish study that used the DLQI and SF-36 to undertake a comparison between
patients with psoriasis and those with psoriasis and PsA, concluded that individuals with a
diagnosis of both conditions had significantly poorer HRQoL than those with just psoriasis
(Lundberg et al., 2000), whilst a study by Husted et al., (2001) employed the SF-36 and the
HAQ to compare HRQoL between patients with PsA and RA, and found that PsA patients
reported greater role limitations, caused by emotional problems, as well as more bodily pain.
In a subsequent study, Husted et al., (2009) determined that fatigue was associated with pain,
physical functional disability and psychological distress, as measured by the modified Fatigue
Severity Scale, SF-36 and the HAQ.
Given such results, and the findings of the current qualitative study, combined with research
evidence that has emerged from other musculoskeletal diseases such as RA, which suggests,
for example, that fatigue is not only significantly related to depression and anxiety (Lorish et
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at, 1991), but to a large extent can be explained by pain, and self-efficacy (Riemsma et at,
1998) it is clear there is a need to assess the role of psychosocial issues and the burden they
may have in patients with PsA and psoriasis.
Some of the symptoms associated with disease that reflect the impact it has on everyday life,
are only known to the patient, and can therefore only be reported by the patient, consequently,
patient-reported assessments of both the physical and mental burden of a disease are vital
components in monitoring both the progression of disease and the effectiveness of treatments.
With due acknowledgement of this, Study 2 sets out to address the gap in the current research,
by utilising a broad selection of psychosocial measures with these two clinical populations,
this is unlike previous studies which have tended to target a limited selection of variables or
have been concerned only with clinical outcomes.
6.2 Clinical Populations
In order to obtain the clinical populations required for this study, participants were recruited
from two different sources - a hospital rheumatology clinic, that was a recognised Centre of
Excellence and The Psoriasis Association, a self-help group that operates predominantly
online.
The Psoriasis Association was founded in 1968 by Dr Dick Cole, a Consultant Dermatologist
in Northamptonshire, and is the leading national membership organisation for people affected
by psoriasis - patients, families, carers and health professionals. The Association strives to
support people who have psoriasis, raise awareness about the condition and also funds
research into the causes, treatments and care of psoriasis. They achieve this through various
means, including operating a helpline, maintaining social networking sites, providing
information via their website, leaflets, CDs, quarterly journals, conferences and by providing
grants for research (www.psoriasis-association.org.uk).
A consequence of recruiting from the Association is that the sample is drawn from an online
support group. This may result in the participants having very different characteristics to the
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group from secondary care, particularly as self-help groups are designed to develop and
reinforce positive coping styles which are known to be associated with improvements in both
medical and social outcomes (Idriss et al., 2009). Furthermore, there is an expanding body of
research (for example, Shaw & Grant, 2002; van Uden-Kraan, 2008) that has found patients
who have a deeper understanding of their diagnosis, treatment, and recovery, and who have
support from others, are better equipped to cope with the illness, use the health system more
effectively and change their health-related behaviours to influence their course of illness and
reduce psychological distress.
Whilst there are very few studies available that have attempted to determine the demographics
and experiences of online support users amongst dermatology patients, a recent study,
exploring the role of online support to patients with psoriasis, reported that respondents to the
study were primarily middle-aged, white, college educated (84%) with a mean age of 40.1
years (ldriss et al, 2009). Such information may offer a useful comparison when exploring the
data for the psoriasis population in the current study.
The following study aimed to extend the findings of the qualitative study and quantitatively
measure Pain, Fatigue, Self Efficacy, Physical and Social Function and the impact of skin
disease and explore their impact on the participants, and thus explore the roles of the
psychosocial variables that were initially identified through the comprehensive descriptions
provided by the patients and their lived experience of PsA and psoriasis. In the light of
participants being recruited from two different settings, and having a diagnosis of either
psoriasis or psoriasis with PsA, differences in the self-reported levels of psychosocial
variables were explored, as were the relationships that existed between them.
6.3 Design
This study employed a cross-sectional, postal survey and comprised an A4-size questionnaire
booklet that was compiled using seven standard, self-report scales and a demographic data
sheet all of which are detailed in section 6.4.,
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6.4 Participants
The criteria for inclusion into the study was that participants be aged 18+ and have a new or
existing diagnosis of psoriatic arthritis and/or psoriasis.
Participants were recruited from two establishments, The Psoriasis Association and the
Rheumatology Clinic at Aintree Hospital, Liverpoo1. A total of 357 completed questionnaires
were received.
As Table 6.1 shows, an overall response rate of 30% was obtained, although when analysed by
the two different groups, the Psoriasis Association achieved a response rate of 31.6%
compared to 22% recorded by the hospital group.
Table 6.1: Postal Questionnaire Response Rates
Posted Returned Response Useable
Rate % Questionnaires
Psoriasis
Association 1000 316 31.6% 313
Aintree 200 44 22.0%Hospital 44
TOTAL 1200 360 30.0% 357
Following data screening and tests for normality, 5 cases were deleted resulting in the two
groups being represented as shown in Table 6.2:
Table 6.2: Useable Questionnaires following Normality Tests
N % of total
Psoriasis Association 310 88.1
Aintree Hospital 42 11.9
TOTAL 352 100
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6.5 Variables and Measurement Tools
The questionnaire booklets comprised a demographics questionnaire, information sheet,
consent form and standardised measurement instruments as detailed below (see Appendix 4):
6.5.1 Physical and Mental Health (The Medical Outcomes Study Short-Form Health
Survey (SF-36®); Ware & Sherbourne, 1992a)
The SF-36® is a 36-item, self-administered questionnaire designed to assess generic HRQoL
(Ware & Sherbourne, 1992a). It measures health across eight dimensions, including 4 domains
of physical health (physical functioning, bodily pain, role limitations due to physical problems,
and general health perceptions) and 4 domains of mental health (social functioning, role
limitations due to emotional problems, mental health, and vitality-energy/fatigue). The scoring
method for these domains is detailed in the SF-36® manual (Ware & Kosinski, 2002).
Responses to items within each dimension are summed to produce a health profile of eight
scores, these scores are then transformed into standard scores ranging from 0 (worst health
status) to 100 (best health status). The standardised scores are then calculated to form physical
component (SF-36® peS) and mental component (SF-36® MeS) summary scores.
Table 6.3 details the SF-36 population norms for a large, community sample of participants
with no long-standing illness. The norms were reported in a study by Jenkinson et al, (1993)
who used postal survey data gained from the Oxford Healthy Life Survey. The data were also
used to calculate MeS and pes norms in a later study (Jenkinson et al., 1999).
The table also shows the Mean scores achieved on the SF-36 by PsA patients in a study that
compared HRQoL between PsA and RA patients (Husted et al., 2001). Additionally, the Mean
scores obtained by psoriasis patients in a HRQoL study (Lundberg, et al., 2000) are presented.
This measurement tool has strong internal consistency, with reliability estimates for pes and
Mes usually exceeding 0.90 (Ware et al., 1990). In the current study a reliability figure of
0.88 was obtained.
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Table 6.3: SF-36 Norms (and SD where available) for 3 different populations - healthy
(Jenkinson,et al., 1993; 1999), PsA (Husted et al., 2001) & Psoriasis
(Lundberg et al., 2000)
Study SF-36 Measure
Population
MCS PCS PF SF RP V MH RE BP GHP
Healthy 51.28 53.64 92.5 91.3 91.4 64.0 75.4 25.6 86.3 78.8
(9.01) (5.88) (13.4) (15.8) (23.2) (18.2) (16.3) (29.3) (17.9) (15.7)
Psoriasis 50.0 42.1 67.0 80.7 62.6 56.2 72.7 68.5 60.5 58.8
with PsA
Psoriasis 44.7 44.7 77.2 80.8 64.5 54.7 71.1 67.0 62.7 60.7
(11.9) (12.2) (25.3) (25.1) (41.3) (24.1 ) (19.8) (42.6) (29.8) (23.9)
6.5.2 Fatigue (Fatigue Severity Scale (FSS); Krupps et al., 1989)
The FSS (Krupps et al., 1989) is a brief, 9-item, general fatigue scale measurmg the
characteristics and consequences of fatigue during the preceding week. Respondents rate how
strongly they agree or disagree with 9 statements (e.g. 'Exercise brings on my fatigue') on a
scale ranging from 1 ("completely disagree") to 7 ("completely agree"). The 9 scores are
summed and a mean score calculated, with higher scores indicative of more severe fatigue.
Krupp et al., (1989) have reported that the Norm for normal healthy adults is a Mean of2.3
(SD ± 0.7). In the current study, the Mean was 3.83.
It has been shown to be valid in healthy controls and in those with PsA and other various
chronic conditions, including systemic lupus erythematosus (SLE), fibromyalgia, cancer, and
Parkinson's disease (Krupp et al., 1990; Giovannoni et al., 2001; Stone et al., 2000; Shulman
et al., 2000).
The measure has good test-retest reliability and has demonstrated strong internal consistency
across different patient groups, for example 0.89 (SLE patients), 0.81 (multiple sclerosis) and
0.88 in normal healthy adults (Krupp et al., 1989). In the current study, the FSS showed strong
internal consistency (a = 0.95).
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6.5.3 Self-efficacy (Self-efficacy for Managing Chronic Diseases (SEMCD); Lorig
et aI., 2001)
The SEMCD is a 6-item scale that contains questions taken from several self-efficacy
measures that were developed for use in the Chronic Disease Self-management Study (Lorig
et al., 2001). The measure covers several domains that are common across many chronic
diseases - symptom control, role function, emotional functioning and communicating with
physicians.
In response to statements such as, "How confident are you that you can keep the fatigue
caused by your disease from interfering with the things that you want to do?" respondents rate
their current level of confidence on a scale consisting of a series of numbers ranging from 0 to
10. The ends of the scale were anchored with the words "not at all confident" (1) and "totally
confident." (10). The score for the scale is the mean of the six items with a higher number
indicating higher self-efficacy.
Lorig and her colleagues (2001) tested the measure on 605 patients with chronic disease and
reported a mean score of 5.17 (SD = 2.22) and an internal consistency reliability figure of 0.91.
In the current study the Mean score for the total sample was 7.04 and for the PsA-only group
was 5.96, whilst the Chronbach's a ofO.88 demonstrated very good reliability.
6.5.4 Skin Disease and Health-Related QOL (Dermatology Life Quality Index
(DLQI); Finlay & Khan, 1994)
The DLQI, developed by Finlay & Khan (1994), is designed to assess the impact of a wide
rage of skin disease on patient health-related quality of life (HRQoL). It consists of ten items
(e.g. item 1 reads 'over the last week how itchy, sore, painful or stinging has your skin been?')
and covers six domains including symptoms and feelings, daily activities, leisure, work and
school, personal relationships and treatment. The response categories are "not at all", "a little",
"a lot" and "very much", with corresponding scores of 0, 1, 2 and 3 respectively; the response
"not relevant" and any unanswered items are scored as "0". The total score is calculated by
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summing the scores of all items. The DLQI score ranges from 0-30, (with 30 representing the
worst quality of life and 0 the best). Scale scores may be calculated for each domain. Higher
scores indicate poorer HRQoL and therefore more impairment (Finlay & Khan, 1994).
A study assessing the validity of the OLQI in 147 patients diagnosed with moderate to severe
psoriasis reported a Mean score of 12.71 (SO = 7.18). (Shikiar et al, 2006), whilst in a study of
162 PsA patients evaluating the effects of a treatment (Adalimumab) on patient-reported
outcomes of joint-related and skin-related functional impairment, health-related quality of life,
fatigue and pain, a mean score of 10.3 (± 7.5) was reported.
Reliabilty figures ranging between 0.86- 0.92 have been demonstrated (Shikiar et al., 2003). In
the current study the DLQI demonstrated very good reliability (a = 0.87).
6.5.5 Functional Ability (The Health Assessment Questionnaire Disability Index
(HAQ-DI); Bruce & Fries, 2003)
The disability assessment component of the HAQ, the HAQ-DI assesses a patient's level of
functional ability. The HAQ-DI comprises 20 questions in eight categories of functioning,
each of which has at least two component questions. The categories represent a comprehensive
set of functional activities - dressing and grooming, arising, eating, walking, hygiene, reach,
grip and common daily activities (Bruce & Fries, 2003).
The stem of each item asks over the past week, "Are you able to ... " perform a particular task.
For each item there is a four-level difficulty scale - without ANY difficulty (0), SOME
difficulty (1), MUCH difficulty (2) and UNABLE to do (3). The highest component score in
each category determines the score for the category, unless aids or devices are required. When
aids or devices or help are indicated by the patient, the score for the category item is raised
from a 0 or a l, to a 2, but if the patient's highest score for that sub-category is a 3, it stays a 3.
When there are no aids, devices or help indicated for a category, the category score is not
modified. In order to compute the HAQ-DI score (one cannot be calculated unless at least 6 of
the 8 categories have been completed), the categories are summed and divided by the number
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of categories answered (which must be 6, 7 or 8). A complementary scoring method ignores
scores for aids, devices or help when computing the category scores and represents residual
disability after compensatory efforts. In either case, this yields a single disability index score
from 0-3, with 0 indicating no functional disability and 3 indicating severe functional
disability (Bruce & Fries, 2003).
In one study examining the safety, efficacy and effect of treatment in patients with PsA and
psoriasis, the HAQ-DI was used and at baseline, a Mean score of 1.1 was obtained (Mease et
al.,2004).
The HAQ-DI has been validated in numerous studies and disciplines and repeatedly shown
face and content validity via comparison with other instruments in multiple disease conditions.
Construct/convergent and predictive validity have also been established in a plethora of
observational and clinical trials (Bruce & Fries, 2003). Furthermore, it has been validated in
PsA by Husted and colleagues (1995; 1998) for face and content validity, and for
responsiveness to disease state. In the current study the Chronbach's a. obtained was 0.97.
6.5.6 Depression (The Hospital Anxiety and Depression Scales (HADS); Zigmond
& Snaith, 1983)
The HADS, developed by Zigmond & Snaith (1983), is a 14-item scale designed to detect
anxiety and depression, independent of somatic symptoms. The 14 items create two subscales,
with 7 of the statements relevant to generalised anxiety, and 7 to depression, the latter being
largely (but not entirely) composed of reflections of the state of anhedonia (inability to enjoy
oneself or take pleasure in everyday things enjoyed normally).
The patient rates the statements, based on their experience over the past week, using a 4-point
response scale (with 0 representing absence of symptoms, to 3 representing maximum
symptomatology), with possible scores for each subscale ranging from 0-21. Scores of 0-7 on
either subscale are considered 'normal', 8-10 represents 'borderline' or 'possible' case of
depression/anxiety whilst 11 or more indicates probable case psychological morbidity.
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Given the HADS uses cut-off points to establish the possible presence of mood disorders,
population norms are not generally used, however, a Mean score of9.3 (± 4.9) on the Anxiety
subscale and 4.8 (± 3.7) on the Depression subscale was found in one study of psoriasis
patients (N = 115) that assessed the significance of general and psoriasis-specific
psychological variables in predicting psoriasis-related disability (Richards, Fortune, Griffiths
& Main, 2001). Furthermore, a study exploring the long-term outcomes of an arthritis self-
management programme (N = 112) reported Means of 9.37 (± 4.44) and 6.77 (±3.83) on the
Anxiety and Depression subscales respectively (Barlow, Turner & Wright, 1998).
Zigmond & Snaith (1983) have demonstrated item correlation and comparison with
psychiatric ratings and have shown both subscales to be discriminately valid. In the current
study the measure demonstrated very good reliability (a = 0.88).
6.5.7 Pain (Numerical Pain Rating Scales (NPRS); Downie et al., 1978)
The Numerical Pain Rating Scale is a single item scale that uses a 0 (no pain) to 10 (worst
possible pain) rating scale (Hartrick et al., 2003). It is a short, valid, frequently used scale,
which is easy to complete and interpret.
Two NPRS were used:
• 'Please rate the average level of pain you are experiencing TODAY'
• 'Please rate the average level of pain you have experienced during the LAST WEEK'.
Each consisted of a series of numbers ranging from 0 to 10. The ends of the scale were
anchored with the words "no pain" and the "worst pain possible." The patient chooses the
number that best corresponds to the level of pain he or she is experiencing.
In a study of 269 psoriasis patients that explored skin-pain and discomfort, a Mean pain
symptom intensity score of 4.4 was reported (Ljosaa et al., 2010), whilst a score of 6.42 (±
2.60) was found in a population of arthritis patients (Barlow, et at, 1998).
107
The Pain NRS has shown good reliability (0.79 - 0.95) when correlated with the pain Visual
Analogue Scale (VAS) and other pain measurement instruments, such as the McGill Pain
Questionnaire. It has also demonstrated moderate to high (0.67 - 0.96) test-retest reliability
(Kahl & Cleland, 2005).
6.5.8 Demographic Sheet
A demographic data sheet was used to collect information including age, gender, marital status,
employment, education, ethnicity, duration of disease and treatment (see Appendix 4).
6.5.9 Consent Forms
Two copies of a consent form were included in the pack with instructions that the patient
should sign both, retain one for their own records and return the other with the completed
questionnaire, using the Freepost envelope that was also provided, to the researcher. (See
Appendix 4).
6.5.10 Participant Information Sheet
The final inclusion was a Participant Information Sheet detailing the purpose of the study, the
participant's right to withdraw at any time and also the contact details for the researcher. (See
Appendix 5).
6.6 Pilot Study
In order to identify any potential difficulties with the questionnaire booklet, a pilot study was
undertaken.
Opportunity sampling was used to recruit 8 participants from the hospital Rheumatology
Clinic. Having explained the purpose of the study and obtained informed consent, the
researcher requested that they complete the questionnaires. All the participants chose to read
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and undertake the questionnaire whilst sitting in the clinic waiting room and when fmished ,
returned them to the researcher.
No obvious problems were identified.
6.7 Procedure
A total of 1000 paper questionnaire packs were delivered to The Psoriasis Association office
and a member of their staff labelled the envelopes and posted the questionnaires. In order to
recruit participants from across the country, the staff member chose various counties and
mailed out to members of the association within each chosen county.
Participants from Aintree Hospital were all registered as patients with a diagnosis of psoriatic
arthritis (PsA) and were attending the Rheumatology Clinic. Questionnaire packs were posted
to 200 patients.
Response rates are detailed in section 6.3.
6.8 Data Analysis
All data were entered into and managed via SPSS software for Windows version 13.0 (©
SPSS Inc., Chicago, Illnois, 2005).
Whilst coding the data it became apparent that some participants responded to the question
regarding treatment and medications by itemising numerous brands of topical creams,
painkillers etc so a decision was taken to categorise the medications in a hierarchical fashion
that reflected the strength or stages of medication used (moisturisers being the mildest and
biologics being the strongest). A rheumatology clinical specialist assisted in categorising all
the different treatments mentioned by respondents. The following categories and codes were
utilised:
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o = No treatment 3 = Oral steroids
4 =Analgesics
5=DMARD's
6 = Biologics
1 =Moisturisers
2 = Topical steroid creams
In cases where respondents listed multiple treatments that fell into different categories, the
highest category was taken as their answer, for example, if a respondent used a topical steroid
cream, oral steroids and DMARD's then a '5' (DMARD's) was used as their response.
6.S.1 Data screening and normality tests
Box plots for all the study variables were inspected and several outliers were identified,
specifically with the HAQ-DI sub-scales of Arising, Eating, Grip, and Walking and also with
the HAD sub-scales of Anxiety and Depression.
All the variable scores were transformed into Z-scores and any cases with scores >3.25 were
identified and subsequently deleted. This resulted in the loss of 5 cases, reducing the total
sample size to 352.
Prior to conducting descriptive analysis, the data were initially categorised into 2 separate
groups of participants depending on the source of their recruitment, that is, one group of
participants drawn from the hospital, and the other from the Psoriasis Association, in order to
establish if any differences existed. Given that the demographic data suggested these two
groups were similar, the total sample was then split into two 'disease groups' comprising
participants who had psoriasis (Psoriasis Group) and those that had a dual diagnosis of
psoriasis and PsA (Psoriasis with PsA Group), which enabled the impact of the psychosocial
variables on each group to be established.
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6.8.2 Descriptive Analysis
For each questionnaire, the Mean and Standard Deviation (SD) were computed, and where
appropriate, independent t-tests were calculated to explore the differences in the means
between the groups of participants.
One-sample t-tests were also conducted to compare the Means obtained in the current study
with those from other known populations, to determine if any significant differences existed.
As previously stated, because the data were collected from participants drawn from two
distinct sources - The Psoriasis Association and Aintree Hospital, Liverpool - it was initially
examined by categorising participants into these two 'recruitment groups' to establish whether
any differences existed between the two. Following this, descriptive, and subsequent analysis,
were conducted once the participants were categorised into two groups that reflected whether
participants had psoriasis or both psoriasis and PsA ('both conditions').
6.8.3 Correlations
Pearson's correlation matrix was used to establish the bivariate correlations between all the
psychosocial and demographic variables.
The strength of the correlation coefficients were interpreted using Coolican's (2004)
recommendations as a guide: 0 = no relationship, .2 = weak relationship, ~ .4 to .7 = moderate
relationship, ~ .8 = strong relationship, 1 = perfect relationship.
Comparison of the correlation coefficients was undertaken to determine whether any of the
differences were significantly different.
111
6.9 Results
6.9.1 Descriptives
The study population comprised adults with psoriasis, psoriatic arthritis (PsA) or both and
were recruited from two organisations - The Psoriasis Association and Aintree Hospital,
Liverpool. The ethnic origin of the sample was almost entirely white (98.9%) with only 4
participants declaring different ethnicity.
Of the 352 participants, 88.1% (310) were drawn from the Psoriasis Association, with the
remaining 42 recruited from Aintree Hospital.
6.9.2 Descriptives by 'Recruitment Group'
As can be seen from Table 6.4 there is similarity between the two recruitment groups in terms
of gender, age, and marital status. In fact, there was an almost even split in terms of gender
with 178 females (50.6%) and 174 males (49.4%), whose ages ranged from 20 years to 87
years with a mean of 57.10 (SD = 14.30). It is worth noting that the broad range of ages was
largely due to two participants reporting ages of 87 years (Psoriasis Association) and 79 years
(Hospital Group), however, the mean ages in each group were similar at 57.56 (Psoriasis
Association) and 53.67 (Hospital Group).
Table 6.4: Gender. Age and Marital Status displayed by Recruitment Group
Total Sample Psoriasis Association Hospital Group
N=352 Group n =310 n=42
n (% of total n) 352 (100%) 310 (88.1%) 42 (11.9%)
Males (% of group) 174 (49.4%) 152 (49.0%) 22 (52.4%)
Females (% of group) 180 (50.6) 158 (51.0%) 20 (47.6%)
ARe (years)
Mean (SD) 57. ID (14.24) 57.56 (14.64) 53.67 (11.03)
Minimum 20 20 33
Maximum 87 87 79
Range 67 67 46
Marital Status (% ohroup)
Married 222 (63.2%) 194 (62.8%) 28 (66.7%)
Single 59 (16.8%) 52 (16.8%) 7 (16.7%)
Divorced 33 (9.4%) 28 (9.1%) 5 (11.9%)
Cohabiting 24 (6.8%) 23 (7.4%) 1(2.4%)
Widowed 13 (3.7%) 12 (3.9%) 1 (2.4%)
Missing data 1 (0.3%) 1 (0.3%) 0
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The majority of the sample, 63%, was married, and this figure was fairly evenly replicated in
the Psoriasis Association (63%) and Hospital group (67%).
Table 6.5 shows that the Mean disease duration for participants with psoriasis in the Psoriasis
Association Group was 30.72 years (SD = 16.91), whilst for those inthe Hospital Group it was
22.87 years (SD = 16.22). Of those in the Association Group, 91% report using some form of
treatment, with the use of topical steroid creams reported by almost 57% of participants.
Almost 55% of the Hospital Group reported using a treatment, of which 31% used
moisturisers and 19% used topical steroid creams.
For participants with PsA, the Mean disease duration for those in the Association Group was
3.98 years (SD = 9.08), with almost 79% using no treatments. Conversely, for those in the
Hospital Group the Mean disease duration was 11.89 years (SD = 10.97) with 96% reporting
the use of some form of medication.
Table 6.5: Disease Duration and Treatment displayed by Recruitment Group
Total Sample Psoriasis Association Hospital Group
N=352 Group n =310 n-42
PsA Disease Duration (vears)
Mean (SO) 4.88 (9.55) 3.98 (9.08) 11.89(10.97)
Minimum 0 0 1
Maximum 50 50 50
Psoriasis Disease Duration (vears)
Mean (SO) 29.86 (16.99) 30.72 (16.91) 22.87 (16.22)
Minimum 0 0 0
Maximum 80 80 60
Current PsA Treatment
No Treatment 246 (70.1%) 244 (78.7%) 2 (4.9%)
Topical steroid creams 3 (0.9%) 3 (1.0%) 0
Oral steroids 6 (1.7%) 4 (1.3%) 2 (4.9%)
Analgesics 30 (8.5%) 28 (9.0%) 2 (4.9%)
OMARD's 57 (16.2%) 26 (8.4%) 31 (75.6%)
Biologics 9 (2.6%) 5 (1.6%) 4 (9.8%)
Missing data 1 (0.3%) 0 1 (2.3%)
Current Psoriasis Treatment
No treatment 46 (13.1%) 27 (8.7%) 19 (45.2%)
Moisturisers 85 (24.1%) 72 (23.2%) 13 (31%)
Topical steroid creams 184 (52.3%) 176 (56.8%) 8 (19%)
Oral steroids 1 (0.3%) 1 (0.3%) 0
Analgesics 5 (1.6%) 5 (1.6%) 0
OMARD's 25 (7.1%) 25 (8.1%) 0
Biologics 5 (1.4%) 4 (1.3%) 1 (2.4%)
Missing data 1 (0.3%) 0 1 (2.4%)
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As displayed in Table 6.6, full-time employment was reported by almost 40% of the
Association Group and 39% were retired, with 2 participants (0.6%) claiming they were
unable to work due to psoriasis and a further 8 participants (2.6%) unable to work due to PsA.
Within the Hospital Group, 45% were employed full-time whilst 21% were retired. Whilst no
participants stated that they were unable to work due to psoriasis, 11.9% of participants (5)
were unable to work due to PsA.
Of the total sample, 18.2% had no educational qualifications; In the Association Group this
accounted for 17% of participants, whilst in the Hospital Group the figure was 26%. When
combined, Graduate and Postgraduate qualifications were obtained by 15.5% of those in the
Association Group, whilst for those in the Hospital Group the figure was 4.8%.
Table 6.6: Employment and Qualification details displayed by Recruitment Group
Total Sample Psoriasis Hospital Group
N=3S2 Association Group n=42
n=310
Employment status
Full time 141 (40.1%) 122 (39.4%) 19 (45.2%)
Part time 41 (11.6%) 36 (11.6%) 5 (11.9%)
Unemployed 5 (1.4%) 4 (1.3%) 1 (2.4%)
Homemaker 16 (4.5%) 13 (4.2%) 3 (7.1%)
Student 2 (0.6%) 2 (0.6%) 0
Semi-retired 1 (0.3%) 1 (0.3%) 0
Retired 131 (37.2%) 122 (39.4%) 9 (21.4%)
Unable to work due to PsA 13 (3.7%) 8 (2.6%) 5 (11.9%)
Unable to work due to Psoriasis 2 (0.6%) 2 (0.6%) 0
Qualifications
None 64 (18.2%) 53 (17.1%) 11 (26.2%)
CSE/'G' Levell GCSE 86 (24.1%) 70 (22.6%) 16(38.1%)
'A LeveVGNVQJNVQ/City & Guilds 90 (25.6%) 79 (25.5%) 11 (26.2%)
Graduate 58 (16.5%) 58 (18.7%) 0
Postgraduate 50 (14.2%) 48 (15.5%) 2 (4.8%)
Missing data 4 (1.1%) 2 (0.6%) 2 (4.8%)
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For the total sample, Mean and Standard Deviation statistics for all the measures are presented
in the following table (Table 6.7) and include the 'Total' scores for Fatigue and Self-efficacy,
although for these two measures it is the Mean scores (Mean total -;-number of items on the
measure) that are utilised for analysis purposes.
Table 6.7: Means and Standard Deviations (and minimum and maximum scores)
for all measures for total sample
Measure (n = 352) Mean Standard Minimum score Maximum scoreDeviation
Fatigue (Mean of total score) 33.94 15.61 9 63
Fatigue (Mean of Item Scores) 3.77 1.73 9 63
Self Efficacy 42.50 12.49 6 60
Self Efficacy (Mean of Item Scores) 7.08 2.08 6 60
HADS - Anxiety 6.60 4.09 0 18
HADS - Depression 3.77 3.l3 0 14
DLQI total 6.16 5.55 0 24
Current Pain NRS 2.97 2.37 1 10
Pain Last Week NRS 3.23 2.50 1 10
HAQ total score .39 .60 0 2.50
SF- 36 PCS 44.31 13.46 7.33 71.30
SF 36 - MCS 46.47 13.77 6.35 71.30
In Table 6.8 the Mean scores for the measures are shown by Recruitment Group and indicate
that the Hospital Group, all of whom had PsA, fare less well on every measure with the
exception of the Dermatology Quality of Life Index (DLQI). Although the scores for all the
SF36 components (shown in Table 6.9) are lower in the Hospital Group, this is due to the
scoring method, whereby lower scores equate to greater impairment of quality of life.
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Table 6.8: Means and Standard Deviations for measures displayed by Recruitment
Groups
Measure Psoriasis Association Hospital Group
n=310 n=42
Fatigue (Mean of total score) 32.89 (15.18) 41.71(16.70)
Fatiaue (Mean ofltem scores) 3.65 (1.68) 4.63 (1.85)
Self Efficacy (Mean of total score) 43.49 (12.29) 35.16 (11.61)
Self Efficacy (Mean of item scores) 7.25 (2.04) 5.86 (1.94)
HADS - Anxiety 6.49 (4.07) 7.29 (4.23)
BADS - Depression 3.54 (3.03) 5.29 (3.43)
DLQI total 6.42 (5.57) 4.64 (5.30)
Current Pain NRS 2.67 (2.20) 5.19 (2.55)
Pain Last Week NRS 2.89 (2.33) 5.70 (2.37)
HAQ total score .30 (.52) .96 (.73)
SF- 36 PCS 46.05 (12.64) 33.57 (12.38)
SF 36 - MCS 46.81 (13.78) 42.99 (12.81)
Table 6.9: SF-36 Sub-scales Means and Standard Deviations displayed by Recruitment
Groups
SF-36 Subscale (as %) Psoriasis Hospital Group t-test result Pvalue
Association t
n=310 n=42 (df=350)
GH 59.68 (23.76) 39.35 (25.64) 5.15 .000
BP 66.12 (22.41) 36.66 (19.71) 8.10 .000
PF 75.32 (28.29) 47.26 (29.34) 6.00 .000
RP 66.69 (41.53) 31.54 (42.07) 5.13 .000
V 55.66 (21.50) 41.42 (22.69) 3.99 .000
SF 73.40 (25.33) 56.08 (31.42) 3.42 .001
RE 75.91 (37.93) 57.93 (44.20) 2.51 .015
MH 70.06 (19.01) 65.04 (19.59) 1.59 .111
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6.9.2.1 T-tests for Recruitment Group
In order to test whether any of the Mean differences between the Psoriasis Association Group
and the Hospital Group were significant, t-tests were conducted with the following results:
6.9.2.1.1 Fatigue
The fatigue Mean score for the Hospital Group was 4.63 (SD = 1.85) compared with a Mean
of 3.65 (SD = 1.68) for those in the Psoriasis Association, representing a highly significant
difference between the two groups, t (350) = -3.49,p = .001.
6.9.2.1.2 Self-efficacy
Self-efficacy was found to be significantly higher, t (350) = 4.14, p < .001, in the Association
Group (M= 7.25, SD = 2.04) when compared with the Hospital Group (M = 5.86, SD = 1.94).
6.9.2.1.3 Anxiety and Depression
The mean scores for the Hospital Anxiety and Depression Scale (HADS) again demonstrate
the Hospital Group reporting higher scores on both the anxiety and depression sub-scales.
The Hospital Group experienced higher levels of anxiety (M = 7.50, SD = 4.23) than those
from the Association (M = 6.47, SD = 4.07, although the difference was not significant.
However, the difference between the Hospital Group's Mean depression score (5.50, SD =
3.44) and the Association's Mean was highly significant (t (350) = - 3.87, p < .001).
6.9.2.1.4 D~(11
The Psoriasis Association Group achieved a higher Mean score (6.42, SD = 5.57) on the DLQI
than the Hospital Group (4.64, SD = 5.30) which was a significant difference, t (350) = 2.59,p
= .012.
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6.9.2.1.5 Pain
The Hospital Group recorded higher Mean scores for pain. The results for 'Current Pain' show
that the hospital patients' Mean of 5.19 (SD = 2.55) was higher than that of the Association
Group (M = 2.67, SD = 2.20), which was a highly significant difference (t (350) = -6.92, p
< .001.
Similarly, the Hospital Group mean for 'Average Pain Last Week' was 5.76 (SD = 2.29)
compared to the Psoriasis Association mean of 2.89 (SD = 2.33), which was once again, a
highly significant difference, t (350) = -7.49,p < .001.
6.9.2.1.6 1I)l~
The Mean results for the total HAQ scores reflect the poorer function experienced by the
Hospital Group (M = .96, SD = .73) compared to the Association Group (M =.30, SD = .52),
which was a highly significant difference (t (350) = -6.16,p < .001).
Furthermore, the mean scores for all the sub-categories of the HAQ demonstrate that the
Hospital Group reported greater difficulties with all types of function, with t-tests identifying
all these differences as highly significant.
6.9.2.1.7 SF-36
In each of the eight sub-categories of the SF-36, the hospital participants are seen to report
poorer quality of life than those participants drawn from the Psoriasis Association and once
again, the t-tests identify all the differences as significant, with the exception of the Mental
Health (MH) subscale.
When the sub-categories were combined to form the Physical Component Score (PCS) the
difference between the Hospital Group (M = 31.88, SD = 12.76) and the Association Group
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(M= 45.99, SD = 12.66, t (350) = 6.77,p < .001) was highly significant, suggesting that those
in the Hospital Group experience decreased quality of life.
Although not a significant difference, the Mean scores on the MCS suggest that the Hospital
Group endure increased mental health difficulties.
6.9.3 Descriptives by Disease Group (Psoriasis or Psoriasis with PsA)
Regardless of where the participants had been recruited from, the total sample of 352
participants were coded to form two groups - one consisting ofparticipants with psoriasis (n =
225), and a second group consisting of those with both psoriasis and PsA (n = 127).
As can be seen from Table 6.10, the descriptive statistics for gender, age and marital status
reflect those found when the data was explored by Recruitment Groups.
In the Disease Groups, both of which had a Mean age of 57 years, the percentage of males and
females in each was very similar, with males accounting for 48.9% of the Psoriasis Group and
50.4% of the Psoriasis with PsA Group.
Table 6.10: Gender. Age and Marital Status displayed by Disease Group
Total Sample Psoriasis Group Psoriasis with
N=352 n =225
PsAGroup
n = 127
nj% oftotal n) 352 (100%) 225 127
Males (% of group) 174(49.4%) 110 (48.9%) 64 (50.4%)
Females (% of group) 180 (50.6) 115 (51.1%) 63 (49.6%)
Age (years)
Mean (SD) 57.10 (14.24) 57.07 (15.39) 57.15 (12.19)
Minimum 20 20 28
Maximum 87 87 86
Range 67 67 58
Marital Status (% ofJlroup)
Married 222 (63.2%) 140 (62.2%) 82 (64.6%)
Single 59 (16.8%) 40 (17.8%) 19(15.0%)
Divorced 33 (9.4%) 20 (8.9%) 13 (10.2%)
Cohabiting 24 (6.8%) 17 (7.6%) 7 (5.5%)
Widowed 13 (3.7%) 8 (3.6%) 5 (3.9%)
Missing data 1 (0.3%) 0 1 (0.8)
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When examining the employment and qualification data by Disease Group, as shown in Table
6.11, the results are similar to that found in the Recruitment Groups, although it is of interest
that 36% of the Psoriasis Group were either graduates or postgraduates, which is substantially
higher than the 20% found in the group with psoriasis and PsA.
Table 6.11: Employment and Qualification details displayed by Disease Group
Total Sample Psoriasis Psoriasis with
Group PsAGroup
N=352 n=225 n=127
Em~l()l'ment status
Full time 141 (40.1%) 90 (40.0%) 51 (40.2%)
Part time 41 (11.6%) 26 (11.6%) 15 (11.8%)
Unemployed 511.4%) 3 (1.3%) 2 (1.6%)
Homemaker 16 (4.5%) 12 (5.3%) 4 (3.1%)
Student 2 (0.6%) 2 (0.9%) 0
Semi-retired 1 (0.3%) 1 (0.4%) 0
Retired 131 (37.2%) 88 (39.1%) 43 (33.9%)
Unable to work due to PsA 13 (3.7%) 1 (0.4%) 12 (9.4%)
Unable to work due to Psoriasis 2 (0.6%) 2 (0.9%) 0
Qualifications
None 64 (18.2%) 31 (13.8%) 33 (26.0%)
CSE/'O' Level/ GCSE 86 (24.1%) 51 (22.7%) 35 (27.6%)
'A LeveVGNVQINVQ/City & Guilds 90 (25.6o/~ 61 (27.1%) 29 (22.8%)
Graduate 58 (16.5%) 43 (19.1%) 15(11.8)
Postgraduate 50 (14.2%) 39 (17.3%) 11 (8.7O/~
Missing data 4 (1.1%) 0 4 (3.1%)
For each of the disease groups, the disease duration and treatment types are presented in Table
6.12. The zeros recorded by the Psoriasis Group in the PsA Disease Duration and Treatment
columns are to be expected as this group do not have a diagnosis of PsA. Of those in the
Psoriasis and PsA Group, 16.5% reported having no current treatment, whilst 44.9% were
taking DMARD's and a further 7.1% were receiving Biologic therapies. In this same group,
21.3% were having no treatment for psoriasis, whilst of those participants in the Psoriasis
Group only 8.4% reported no current treatment for psoriasis, with almost 58% using topical
steroid creams and 7.1% using DMARD's.
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The Mean figures for psoriasis disease duration were similar for both the Psoriasis Group
(30.69 years) and for the Psoriasis with PsA Group (28.31 years).
Table 6.12: Disease Duration and Treatment displayed by Disease Group
Total Sample Psoriasis Group Psoriasis with
N=352
PsAGroup
n =225 n= 127
PsA Disease Duration (years)
Mean (SO) 4.88 (9.55) 0 13.52 (11.69)
Minimum 0 0 1
Maximum 50 0 50
Psoriasis Disease Duration (years)
Mean (SO) 29.86 (16.99) 30.69 (16.86) 28.31 (17.21)
Minimum 0 1 0
Maximum 80 80 65
Current PsA Treatment
No Treatment 246 (70.1%) 0(100%) 21 (16.5%)
Topical steroid creams 3(0.9%) - 3 (2.4%)
Oral steroids 6 (1.7%) - 6 (4.7%)
Analgesics 30 (8.5%) - 30 (23.6%)
OMARD's 57 (16.2%) - 57 (44.9%)
Biologics 9 (2.6%) - 9(7.1%)
Missing data 1 (0.3%) - 1 (0.8%)
Current Psoriasis Treatment
No treatment 46(13.1%) 19 (8.4%) 27 (21.3%)
Moisturisers 85 (24.1%) 54(24.0%) 31 (24.4%)
Topical steroid creams 184 (52.3%) 130 (57.8%) 54 (42.5%)
Oral steroids 1 (0.3%) 1 (0.4%) 0
Analgesics 5 (1.6%) 4 (1.8%) 1 (0.8)
OMARD's 25 (7.1%) 16(7.1%) 9 (7.1)
Biologics 5 (1.4%) 1 (0.4%) 4(3.1%)
Missing data 1 (0.3%) 0 1 (0.8%)
6.9.3.1 Means and t-tests for Disease Groups
The Means scores for all the measures are displayed by disease group in Table 6.13.
Examination of the Means for these groups reveals that the psoriasis-only group report higher
quality oflife on all scores with the exception of one - the DLQI.
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In order to test whether any of the Mean differences between the group of participants with
psoriasis and the group with both psoriasis and PsA were significant, independent t-tests were
conducted and are presented, with their p values, in Table 6.13 and Table 6.14.
Table 6.13: Means (SD) and t-test results with p values for all measures displayed by
Disease Group
Measure Psoriasis Psoriasis with PsA t-test result p value
Group Group t
n=225 n = 127 (d,{=350)
Fatiaue (Mean of total)
30.83 (14.81) 39.46 (15.51) 5.09 .000
Fatigue Mean Item Score
3.43 (1.65) 4.38 (1.72) 5.09 .000
Self Efficacy(Mean of total)
45.08 (11.84) 37.93 (12.35) -5.28 .000
Self Efficacy Mean Item Score
7.51 (1.97) 6.32 (2.05) -5.29 .000
HADS Anxiety
6.50 (4.15) 6.75 (4.01) 0.55 .581
HADS Depression
3.32 (2.95) 4.55 (3.30) 3.48 .001
DLQI total
6.41 (5.47) 5.72 (5.68) -1.10 .270
Current Pain NRS
2.14 (1.89) 4.45 (2.43) 9.86 .000
Pain Last Week NRS
2.32 (2.03) 4.85 (2.45) 10.39 .000
HAQ total score
.19 (.42) .73 (.70) 8.96 .000
SF- 36 PCS
49.03 (11.54) 35.95 (12.56) 9.65 .000
SF36 MCS
46.50 (14.01) 46.41 (13.38) 0.06 .949
The results of the independent t-tests between these two groups reflect similar differences as
those reported for the Psoriasis Association Group and Hospital group. Indeed, with the
exception of the DLQI, Anxiety and SF-36 MH and MCS scores, significant differences were
found on all measures, with the Mean scores for the group with both conditions suggesting
they experienced impaired quality of life.
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Table 6.14: SF-36 Subscales Means and Standard Deviations displayed by Disease Group
SF-36 Subscale Psoriasis Group Psoriasis with PsA t-test result p value
(As %) Group t
n=225 n= 127 (df=350)
GH 62.61 (22.78) 47.76 (25.58) -5.62 .000
BP 72.17 (20.15) 45.67 (20.92) -11.56 .000
PF 80.48 (26.30) 56.89 (29.77) -7.70 .000
RP 74.22 (38.62) 41.73 (42.85) -7.28 .000
V 57.91 (20.78) 46.97 (22.72) -4.47 .000
SF 74.86 (24.66) 65.09 (28.99) -3.35 .001
RE 74.62 (36.57) 66.93 (42.52) -2.48 .013
MH 69.67 (19.45) 69.10 (18.60) -2.71 .787
6.9.3.2 One Sample t-tests
In order to establish if the Mean scores that were obtained for each group in the current study
differed from norms obtained from known populations (as previously described in sections
6.4.1 through to 6.4.7), one-sample t-tests were conducted, the results of which are presented
in Table 6.15 (Psoriasis with PsA Group) and Table 6.16 (Psoriasis Group).
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Table 6.15 One-Sample t-tests between Psoriasis with PsA Group and a known
population
Measure Norms (SD) from PsA Psoriasis and PsA t-test
with Psoriasis Group Mean
population (unless
otherwise stated) n= 127 df-126
Fatigue 2.3 (0.7) t 4.38 (1.72) 13.62***
Self Efficacy 5.17 (2.22) tt 6.32 (2.05) 6.32***
HADS-Anxiety 9.37 (4.44) ttt 6.75 (4.01) 7.36***
HADS - Depression 6.77 (3.83) ttt 4.55 (3.30) 7.58**
DLQI 10.3 (7.5) 5.72 (5.68) 9.08***
Current Pain NRS 4.4 (2.4) ttt 4.45 (2.43) 0.23 nls
HAQ 1.1 0.73 (.70) 5.95***
SF-36 PCS 42.1 35.95 (12.56) 5.51***
SF-36 MCS 50.0 46.41 (13.38) 3.02*
GH 58.8 47.76 (25.58) 4.86***
BP 60.5 45.67 (20.92) 7.98***
PF 67.0 56.89 (29.77) 3.82*
RP 62.6 41.73 (42.85) 5.48***
V 56.2 46.97 (22.72) 4.57***
SF 80.7 65.09 (28.99) 6.06***
RE 68.5 74.62 (36.57) 1.88 nls
MH 72.7 69.10 (18.60) 2.18*
* t-test significant at the 0.05 level (2-tailed)
** t-test significant at the O.OOllevel (2-tailed)
*** t-test significant at the O.OOOllevel (2-tailed)
t Mean established in a healthy population
tt Mean established in a chronic disease population
ttt Mean established in an arthritis population
The results of the one-sample t-tests concluded that a significant difference existed between
the means of the known population and the Psoriasis with PsA Group, with only two
exceptions - the Current Pain NRS and the SF-36 subscale of RE (Role Limitations -
Emotional). However, the Pain NRS Mean in the current study was marginally higher than the
Mean of the comparison group, suggesting that patients in the current study experienced
marginally worse pain than those in the arthritis group with which it was compared.
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Although a non-significant result, the RE Mean score found in the current group with both
conditions indicated that their role limitations caused by emotional factors were less (M =
74.62) than those reported by a similar group (M = 68.5).
The Mean score for Fatigue (M = 4.38) was higher than that found in a healthy population (M
= 2.3), suggesting the current participants experienced greater levels of fatigue, however, this
group also reported greater levels of Self Efficacy than that found in the arthritis comparison
group, with Means of 6.32 and 5.17 respectively.
The current group fared less well on the DLQI & HAQ measures when compared with a
similar population; however they experienced less Anxiety and Depression when compared
with the levels reported by an arthritis group.
It is of particular interest, given that the comparison was done with a similar group, that the
one sample t-tests and Mean scores for the SF-36 (except RE) suggest that the current group
experienced significant reductions in their quality oflife.
Overall, the results for the HAQ, SF-36 and Fatigue indicate that individuals with a dual
diagnosis (psoriasis with psoriatic arthritis), may experience reductions in their physical and
social functionality, mental health and endure greater levels of fatigue.
Table 6.16 details the results of the one-sample t-tests that were conducted between the
Psoriasis Group and known populations.
The SF-36 produced 5 non-significant results (MCS; GH; PF; RE & MH), of these, according
to the Mean scores, the current Psoriasis Group fared less well, than the similar group they
were compared with, on the GH, RE & MH.
All the other results suggested they fared better than the comparison group, with the exception
of Fatigue and Social Functioning.
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Table 6.16 One-Sample t-tests between Psoriasis Group and known
population
Measure Norms (SD) from Psoriasis Group t-test
psoriasis population Mean
(unless otherwise stated) n=225 df-224
Fatigue 2.3 (0.7) t 3.43 (1.65) 10.18**
Self Efficacy 5.17 (2.22) tt 7.51 (1.97) 17.81 **
HADS - Anxiety 9.3 (4.9) 6.50 (4.15) 10.12**
HADS - Depression 4.8(3.7) 3.32 (2.95) 7.52**
DLQI 12.71 (7.18) 6.41 (5.47) 17.27**
Current Pain NRS 4.4 2.14 17.93**
HAQ 1.1 Ht 0.19 (.42) 32.50**
SF-36 PCS 44.7 (12.2) 49.03 (11.54) 5.62***
SF-36MCS 44.7(11.9) 46.50 (14.01) 1.92 nls
GH 60.7 (23.9) 62.61 (22.78) 1.25 nls
BP 62.7 (29.8) 72.17 (20.15) 7.04***
PF 77.2 (25.3) 80.48 (26.30) 1.87 nls
RP 64.5 (41.3) 74.22 (38.62) 3.77**
V 54.7 (24.1) 57.91 (20.78) 2.31*
SF 80.8 (25.1) 74.86 (24.66) 3.61 **
RE 67.0 (42.6) 66.93 (42.52) 0.02 nls
MH 71.1 (19.8) 69.67 (19.45) 1.10 nls
* t-test significant at the 0.05 level (2-tailed)
** t-test significant at the O.OOllevel (2-tailed)
*** t-test significant at the O.OOOllevel (2-tailed)
t Mean established in a healthy population
tt Mean established in a chronic disease population
ttt Mean established in a population with psoriasis & PsA
6.10 Correlations
Pearson's Correlations were used in order to establish the degree of relationship between the
study variables. These were conducted on the three groups, that is, the total sample (see Table
6.16), the group with both psoriasis and PsA (Table 6.17) and the group with psoriasis (Table
6.18).
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The chance of a Type I error increased due to the number of correlation tests calculated,
however in order to reduce the likelihood of this occurring, a more conservative significance
level was adopted. For each group, this level was calculated by dividing the conventional
probability level of 0.05 by the number of correlation tests performed. Given that 20 variables
were used for the correlations the probability level was calculated as follows: 0.05 -i- 20 =
0.0025, thus a conservative significance level was set at 0.001.
Examination of the three tables shows that the vast majority of the tests produced significant
correlation coefficients that were significant at the .001 level. Although, it is of interest that
'Time with PsA', that is to say, the length oftime an individual had been diagnosed with PsA'
produced only one significant result, (found in the Group with Psoriasis and PsA) which was a
moderately strong relationship (r = .51) with 'Time with Psoriasis'.
6.10.1 Correlations for Group with Psoriasis with PsA
Closer inspection of the correlation matrix for the group with both conditions (Table 6.17)
shows a moderately strong, significant relationship between Fatigue and all the included
variables, with the exception of the DLQI, which shows a weak, albeit significant relationship
(r =.316). Of particular note is the relationship between Fatigue and 'Current Pain' (r = .547),
'Pain Last Week' (r = .519) and Anxiety (r = .423) and Depression (r = .670) and the SF-36
subscale of Vitality (r = -.738).
In the same group, 'Current Pain' was significantly related to all the other measures, with the
strongest relationship found with the HAQ (r = .704) and the SF-36 subscales of Bodily Pain
(r = -.773) and Physical Functioning (r = -.678). The relationship with Depression (r = .607)
was stronger than that found with either Anxiety (r = .304) or the SF-36 MCS (r = -.394).
Although a weak correlation was found with the DLQI (r = .228), it was significant at the .01
alpha level which was outside the .001 level deemed acceptable by the researcher.
Significant relationships were found between Self Efficacy and all the measures, however, the
strongest relationships were observed with Depression (r = -.650), the HAQ (r = -.618) and the
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SF-36 subscales of Bodily Pain (r = .647), Physical Functioning (r = .668) and Social
Functioning (r = .637), whilst the weakest correlation was with the DLQI (r -.330).
All, but one variable (SF-36 MH) was significantly correlated with the HAQ, with moderate
relationships found with SF-36 Bodily Pain (r = -.705) and SF-36 PCS (r = -.761). The
association with Depression was moderate (r = .603) and almost twice the strength of the
relationship found with Anxiety (r = .307).
6.10.2 Correlations for Group with Psoriasis
The correlation matrix for the Psoriasis Group is presented in Table 6.18 and whilst some of
the results are similar to those found in the Group with Psoriasis and PsA, there are some
differences worth noting.
As reported for the Group with Psoriasis and PsA, Fatigue showed significant, moderate
correlations with all the variables, and, whilst the association with the DLQI was only fairly
weak (r = .345) it was slightly stronger than that found in the Psoriasis with PsA group, as was
the relationship with the SF-36 MH (r = -.480). A marginally stronger correlation was also
found with SF-36 Bodily Pain (r = -.532), whilst with the HAQ it was much lower (r =.463).
Interestingly, the association between Fatigue and Depression (r = .645) was weaker than that
found in the Psoriasis with PsA group, whilst with Anxiety it was marginally stronger.
The negative relationship between Current Pain and SF-36 PF was slightly weaker than that
found in the Psoriasis with PsA group (r = -.585).
It is noteworthy that the Psoriasis Group recorded a stronger inverse correlation between the
DLQI and SF-36 Social Functioning subscale (r = -.546), whilst the positive relationship
between Social Functioning and Self Efficacy (r = .636) was almost identical to that found in
the group with Psoriasis and PsA (r = .637).
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6.10.3 Comparison of correlation coefficients
To examine whether the correlations obtained by the Psoriasis Group differed significantly to
those of the Group with Psoriasis and PsA, the correlations coefficients were compared, the
results of which are displayed in Table 6.20.
The results concluded that there was a significant difference (p :S 0.05) between 18 of the
correlations, including those found between Self Efficacy and 5 other variables - the DLQI,
HAQ and SF-36 PCS, PF and MH. Confirmation that the correlations were significantly
different between Social Functioning (SF) and Vitality (V) was also of note, as were the
findings regarding MCS, MH, RE and their correlation with Anxiety.
Of the correlation coefficents that were significantly different, the original Pearson's r
correlations were found to indicate that a stronger relationship existed in the Psoriasis with
PsA Group in 10 of the 18:
Self Efficacy - HAQ
Self Efficacy - PF
Self Efficacy - PCS
Fatigue - HAQ
Fatigue- PF
Current Pain - Vitality
PF - Vitality
PF - MCS
SF - MCS
PF - Depression
For the remaining 8 significant comparisons, the Pearson's r correlations were stronger in the
Psoriasis Group:
Self Efficacy - DLQI
Self Efficacy - MH
MH-RE
Anxiety - MCS
Anxiety-RE
Anxiety- MH
SF - DLQI
SF-MH
These results clearly suggest that significant differences exist between the group with psoriasis
and the group with a dual diagnosis of psoriasis and Psa.
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6.11 Summary of Quantitative Results
The descriptive statistics confirmed that of the total sample, 225 participants had a
diagnosis of psoriasis, whilst 127 participants had psoriasis with an additional diagnosis of
PsA.
Given that participants were originally recruited from two distinct sources, (a hospital and
the Psoriasis Association) the data was initially categorised into these two Recruitment
Groups and explored to establish whether any differences existed between the two.
The demographic data for the two Recruitment Groups indicated that both were fairly
similar in terms of their Mean age, gender split and marital status. It was however
interesting to note that 34% of the Association Group had obtained graduate or post-
graduate qualifications compared to only 5% of those in the Hospital Group. Whilst this
may, in part, be a reflection of the differences in the sample size, it may also reflect
characteristics of individuals who join support groups, perhaps indicating, for example, an
association between higher educational attainment and the ability or preference to seek out
help and information about their disease and therefore actively cope with it.
Examination of the Mean scores for the all the measures, with the exception of the DLQI,
suggest that the participants in the Hospital Group experienced greater difficulties with
their functionality, higher levels of fatigue, pain, anxiety and depression and lower levels
of self efficacy and reduced quality of life, with t-tests confmning that the differences
between the Means were significant, (except for the SF-36 MCS and HADS Anxiety
subscale).
The fmding that the DLQI Mean score was higher for participants in the Psoriasis
Association Group was not unexpected, as this measure is used to assess the impact of skin
disease on patient health-related quality of life. Furthermore, a t-test confmned that this
difference was significant.
Given that PsA affected all of the participants in the Hospital Group, yet only a proportion
of those in the Psoriasis Association Group, it is possible that PsA may provide an added
burden which contributes to reductions in quality of life. In order to explore this further,
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the data was categorised into two groups - one comprising participants with psoriasis
(Psoriasis Group, n = 225), and the other, participants with both psoriasis and PsA
(Psoriasis Group with PsA, n = 127). The data was then analysed according to these two
groups.
Inspection of the Mean scores showed the Group with Psoriasis and PsA fared less well on
all measures with the exception of the DLQI, although an independent t-test revealed that
the difference was not significant.
Further Independent t-tests reflected significant differences on all but the HADS-Anxiety,
SF-36 MCS and MH scores, suggesting that it was the individuals who have both
conditions, that is, a dual diagnosis of psoriasis and PsA who experienced impaired quality
of life.
Furthermore, correlations for this group identified highly significant relationships (p <
0.001) between the majority of the variables. The relationship between Self Efficacy and
the HAQ (an inverse correlation), and SF-36 subscales of Bodily Pain, Physical and Social
Functioning were all fairly strong, whilst it is of note that a stronger (inverse) association
existed with Depression than with Anxiety. Interestingly, these variables displayed similar,
negative associations with Fatigue, whilst Current Pain was, as might be expected, most
strongly related, inversely to SF-36 Bodily Pain and PCS, and positively to the HAQ - all
measures that assess physical functioning, although there was a fairly strong, positive
association with Depression. Interestingly, although the DLQI correlated significantly with
most of the variables, the associations were generally the weakest seen in the matrix,
indeed the strongest was with Anxiety, followed by Depression, both of which were
positive relationships.
The Psoriasis Group also displayed significant relationships between most of the variables,
although generally, the strength of the relationships were lower than those found in the
Psoriasis with PsA Group. Noteworthy exceptions were the DLQI which significantly
correlated with all the other measures, bar the SF-36 Physical Functioning (PF) subscale.
It's positive association with Fatigue was slightly higher and the negative correlations with
the SF-36 were all stronger than those found in the group with 'both conditions', except for
Physical Functioning and PCS, suggesting that psoriasis may be associated with poorer
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psychological health in this group of participants. Although it is of interest that the
association between Self Efficacy and Anxiety was slightly stronger (r = -.547 compared
with -.456), whilst conversely, the correlation with Depression, was weaker.
Comparisons between the correlation coefficients, the results of which are displayed in
Table 6.20, confirmed that significant differences (p = :::;0.05) existed between 18 of the
correlations.
The correlation coefficients for the groups differed significantly when Self Efficacy was
correlated with the DLQI, HAQ, PCS, MH and PF, as did Fatigue with the HAQ and PF.
The correlations also differed between the SF-36 sub scale of PF and Vitality, MCS and
Depression. The difference in the correlations obtained between the DLQI and SF for each
group, were significantly different, as were those for SF with MH and PCS. Other
differences included Anxiety with RE, MH and MCS, RE with MH, whilst finally, the
correlation between Current Pain and Vitality was also significantly different.
The coefficients between both Fatigue and the HAQ, and Fatigue and Physical Functioning
(PF) were signifIcantly different, and for each, the strength of the association was greatest
in the Group with Psoriasis and PsA. These results suggest that fatigue and functional
ability are related, given that the HAQ measures physical disability and pain and the PF
subscale measures limitations in physical activities because of health problems.
Interestingly, the group with both conditions also had the strongest relationship between
the variables of Physical Functioning and Depression, implying that in this group,
reductions in physical ability may be associated with increased levels of depressive
symptoms, a result which this same group also reflects in their association between
Physical Functioning and the Mental Component Score (MCS).
The Pearson's r results showed that the Psoriasis with PsA Group recorded stronger
correlations, which were significantly different to the Psoriasis Group, when Self Efficacy
was correlated with three other variables - HAQ, Physical Functioning and the Physical
Component Score - implying that there is a greater association between levels of self
efficacy and physical and functional ability in the group with both conditions.
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Whilst the results indicate that reductions in both physical and psychological health are
greater in the group with PsA, the psoriasis group appear to experience reductions in
psychological health rather than limitations that impact on their physical functioning.
It is of interest that comparison of the correlation coefficients highlighted a significant
difference between the SF-36 Social Functioning (SF) and the DLQI. When examined, the
Pearson's r coefficient reveals a stronger relationship between these two variables (r = _
.546) than the Group with both conditions (r = -.329), suggesting those with psoriasis
experience greater limitations in social activities due to physical or emotional problems,
than the group with PsA. Similarly, the correlation coefficients for Social Functioning and
Mental Health are significantly different, and again, the strongest relationship between
these two variables is found in the Psoriasis Group, implying that poorer mental health is
associated with decrements in social functioning.
Significantly different from those found in the group with both conditions, the Psoriasis
Group reported stronger associations between Self Efficacy and both the DLQI and MH,
suggesting that levels of self efficacy are associated with limitations related to the impact
of psoriasis and also to levels of psychological distress. It is also noteworthy that it was the
Psoriasis Group that recorded the strongest associations when Anxiety was correlated with
MCS, RE and MH, giving an indication that psoriasis may be associated with
psychological health.
When considering the differences between the correlation coefficients in combination with
the Mean scores and Pearson's r correlations, it appears that in the Psoriasis with PsA
Group, decrements in physical functioning, as measured by the HAQ and SF-36, were
associated with greater fatigue and pain, less vitality, poorer psychological health and
increased depression, whilst physical functioning was also shown to be related to Social
Functioning. However, for the Psoriasis Group, decrements in their health-related quality
of life appear to be less associated with physical functioning and physical disability, and
more with reductions in their psychological health and social functioning.
In the following chapter, these results are discussed in the light of previous research and
their implications for practice considered.
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CHAPTER 7
DISCUSSION
7.1 Introduction
This thesis has attempted to identify, from the patients' perspective, psychosocial issues
that were perceived to be detrimental to their quality of life. Furthermore, through the use
of standardised psychometric instruments, the impact of these factors has been investigated
and their role assessed.
This chapter contains a discussion of the results from both the qualitative and quantitative
aspects of this study. The principal findings will be presented and discussed with due
consideration also given to the merits of the author having utilised not only mixed
methodology, but also postal surveys that were largely dependent on a membership
organisation. Then follows the implications of this research for practice, the limitations of
this study, possible directions for future research, followed by the author's concluding
comments.
7.2 Discussion of Qualitative Results
The qualitative study in the first part of this thesis clearly illustrates the complexities and
multi-faceted nature of living with PsA, for whilst five major themes were identified and
described as conceptually distinct, it was almost impossible to separate them from one and
other (Aitken et al., 2006).
Although many smaller themes supported the development of five superordinate themes _
Pain, Functionality, Emotions, Coping and Treatment Experience/ Management - the lived
reality, as conveyed by the patients, suggests that these are not necessarily contained
within one major category, but overlap and are entwined.
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The first major theme to emerge, Pain, clearly permeated every aspect of the participants'
lives and had a major impact on daily activities, mood, social functioning, employment,
relationships, fatigue and mobility.
The participants identified pain as a symptom that was ever-present in varying degrees and
considered it an integral part of living with an arthritic condition. It was clear that pain
impacted on their ability to engage in physical activities, a finding which may be expected,
however, it was also clear that pain greatly affected their ability and intention to attempt
even the most minor of normal activities of daily living, such as opening a box of
cornflakes. This finding reflects the results of a study by Husted at al. (2001), who found
that PsA patients reported greater role limitations as a result of both bodily pain and
emotional problems, whilst those with PsA have also been found to report significantly
worse pain and physical mobility levels, as indicated by the Nottingham Health Profile,
when compared with a healthy population (Borman et al., 2007).
Although participants in the qualitative study generally acknowledged that the presence of
psoriasis was a minor issue compared to PsA, it was of interest that they all discussed pain
and discomfort as symptoms associated with their psoriatic arthritis, not their psoriasis.
This is noteworthy in the light of a survey of skin disease in general practice which found
that 25% of patients with psoriasis reported pain (Verhoeven et al., 2007). Furthermore,
previous studies have found that patients with psoriasis frequently experience pain and skin
discomfort (Sampogna et al., 2004; Unaeze et al., 2006). It is possible that in this study, the
level of pain that occurs as a result ofPsA outweighs the impact of any pain or discomfort
that is generally associated with psoriasis.
Pain not only had consequences for everyday capacities, but also resulted in participants
evaluating themselves in relation to former capabilities and achievements, and comparing
this with their present expectations. This in tum fuelled the sense of loss and grieving
experienced by sufferers, as pain was viewed as an obstacle to activities that formerly had
been a source of pleasure, such as working, playing football, going to the gym or simply
being able to get down on the floor and play with young children.
Similar feelings of grief and loss were reported in Dildy's (1996) qualitative study, which
used Grounded Theory to identify the nature of suffering in fourteen people with
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rheumatoid arthritis. The participants acknowledged what would have been different in
their lives, especially in relation to careers, hobbies, leisure activities, and plans for
retirement, had they not been diagnosed with RA, whilst managing to identify that it was
the loss ofpersonal dreams and the need to restructure a future orientation that was implicit
in their experiences of suffering and grief. Explaining these fmdings, Dildy (1996)
suggests that many aspects of suffering may relate to the issue of control, and that loss,
particularly of independence and personal control, has been found to have serious
implications to the overall health of individuals as it may impede an individual's ability to
exert control and successfully manage their disease.
In the current study there was consensus that living with PsA imposed a series of losses,
which, in turn contributed to the sense of ongoing grief experienced by the participants,
themes which have been identified in studies of people with RA (Stephens & Yoshida,
1999).
Interestingly, fatigue has been implicated in feelings of loss, grief and sorrow following
research with Multiple Sclerosis (MS) patients. The researchers found that when MS
patients became fatigued and were unable to manage what they intended (shopping trips,
housework etc.) they experienced a sense of grief and sorrow for what they had lost. Each
time they failed to manage their tasks, the same feelings were aroused, leading the
researchers to suggest that when the grief feelings are recurrently experienced, fatigue may
act as the triggering event as it reminds the individuals' of the loss of energy or ability
(Flensner et al., 2003). In order to protect oneself from such feelings, Lazare (1992)
suggested that a strategy of 'hiding' may be adopted, so that instead of showing their loss
of ability in the presence of others, people may choose isolation. Although this research
related to MS patients it is possible that it has application for those with PsA and may offer
a starting point from which patients can re- frame their lives, alter their goals and accept
their limitations, so reducing their experiences of loss and grief Altering one's goals in
life, in order to feel well, may be seen as being in harmony with Nordenfelt's theory of the
nature of health (1995) and could be used as a framework for exploring and enlarging our
understanding of loss and grief, and determining whether fatigue is a causal factor.
The feelings of loss expressed by the participants were generally linked to the functional
disability caused by PsA and also their deliberate decisions to withdraw from social events,
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however, it was unclear whether, in this study, the presence of psoriasis was implicated in
any of their feelings of loss or isolation. This warrants consideration, given that previous
research has found that psoriasis patients experience increased levels of isolation and
rejection. Indeed, Ginsburg and Link (1993) reported that in their study of 100 psoriasis
patients, 19% reported 50 episodes of gross rejection, most often from a gym, swimming
pool, hairdresser or job, as a direct result of their skin condition. The authors posit that
those patients, who experience such feelings of rejection and isolation, may feel
stigmatized and suffer further adverse effects on their emotional and occupational life. In
view of this, it is interesting that a later study found that, in individuals with psoriasis,
perceptions of stigmatisation were significantly related to both psychological distress and
degree of disability (Richards et al., 2000).
A variety of studies exploring the incidence of psychological distress consistently report
that patients with psoriasis are at an increased risk of experiencing depression. Most
recently, a large, population-based cohort study using data collected as part of patient's
electronic medical record from 1987 to 2002, was conducted in order to determine the
incidence of depression, anxiety, and suicidality in patients with psoriasis compared with
the general population. The data included 146,042 patients with mild psoriasis, 3,956
patients with severe psoriasis, and 766 950 patients without psoriasis. The researchers
concluded that patients with psoriasis had an increased risk of depression, anxiety, and
suicidality and they estimated that in the United Kingdom, in excess of 10,400 diagnoses of
depression, 7,100 diagnoses of anxiety, and 350 diagnoses ofsuicidality are attributable to
psoriasis annually (Kurd et al., 2010).
The negative emotions experienced by individuals with PsA extended beyond feelings of
loss and grief Indeed, all of the participants referred to feelings of depression, anger,
frustration and fear at various times. The unpredictable and flaring nature of PsA may
contribute to the emergence of such feelings, and would support previous findings from
studies with RA patients, such as those of Ryan (1996) who found participants associated
their frustration with increased physical disability.
Although there are few studies exploring the impact of depression in PsA patients, the
current qualitative study confrrmed that episodes of low mood and depressive symptoms
were an issue for all ten participants. Evidence from the RA literature has found that
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depressive symptoms and depression are more common in individuals with RA (Dickens et
al., 2002), and indeed other chronic illnesses (Chapman, 2005) when compared with
healthy controls. Whilst depression in RA is frequently considered to be a consequence of
chronic pain, the causal nature of the association often remains unclear given the multitude
of other variables that could be implicated. Although several cross-sectional studies of
patients with RA, such as Hurwicz & Berkanovic (1993), have examined the degree of
association and concluded that depression varies in proportion to the level of pain being
experienced, others have found that once the effects of other variables, such as
demographics and disability, are controlled for, the magnitude of the association weakens
and can become non-significant (Newman et al., 1989).
For the participants in the current study, symptoms of depression were detrimental to their
confidence and assertiveness, and seemed to contribute to problems in accessing help and
support, from both social networks and their GP's and other healthcare providers. Indeed,
from some participants there was a sense that their condition did not entitle them to GP
time and resources and so deterred them from raising concerns about their emotional
distress and depressive symptoms. Similar findings have been reported by others (Rogers
et al, 2001; Lester et al., 2005), yet results from a study by Pollock (2007) simply found
that patients actually suppressed the expression of emotional distress during medical
consultations because they were trying to 'maintain face' and conform to "the socially
sanctioned role of the stoic, good and uncomplaining patient in order to retain the social
esteem and good will of others" (page 175).
Within the RA literature, the relationship between symptoms and depression has been
explored from a variety ofperspectives, including whether pain is a predictor of depression
(for example, Nicassio & Wallston, 1992) or whether depression influences pain (for
example, Parker et aI., 1992) whilst other studies have sought to identify factors that may
mediate the pain-depression relationship (for example, Schiaffino et aI., 1991). However, a
somewhat unique study conducted by Fifield and her colleagues (1998) departed from the
predominately exclusive focus on the connection between current emotional distress and
current illness, to consider whether a patient's affective history may influence their future
illness experience. The researchers endeavoured to determine whether a previous episode
of major depression leaves a 'scar' that places previously depressed patients with RA at
risk for experiencing high levels of pain, fatigue and disability. They concluded that an
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episode of major depression, even if it occurs prior to the onset of RA, leaves patients at
risk for higher levels of pain when depressive symptoms persist, even years after the
depressive episode.
Although Fifield et al (1998) could only speculate as to the possible mechanisms that
operate with respect to major depression and future symptom reports, their study and the
'scar' hypothesis does offer some evidence of the long-term risk associated with a past
episode of major depression and suggests that a patient's affective history warrants
consideration in future studies.
In the current study, there was a sense that a broad array of negative feelings prevailed at
various times. Whether in the guise of depression, frustration, fear or anger, often these
feelings seemed linked to flare-up's of the disease and were a response to forced
limitations and role changes caused by reduced physical abilities and severe episodes of
pain.
Similar emotional responses have been reported in qualitative studies about RA, such as
that by Barlow et al. (1999) who used focus groups to explore the realities of parenting
from the perspectives of mothers, fathers and grandparents with arthritis. The researchers
found that there was consensus among the participants that pain, fatigue and restricted
physical functioning combined to interfere with the parenting role, with the key themes
concerning physical limitations, practical and caring issues, social factors, emotional
response, hereditary risks and safety issues. The perceived inability to fulfil parenting
roles resulted in feelings of anger, depression, frustration and guilt, leading Barlow et al
(1999) to conclude that the presence of a painful, disabling, chronic disease, such as
arthritis, may have implications for perceived ability to fulfil a parenting role.
In the current study, reduced physical abilities not only compromised domestic tasks, but
also impacted on participant's employment capabilities. Half of the group were unable to
work due to their disease, whilst two had changed their work roles in an attempt to stay
working and earning a wage.
For most adults, participation in paid employment is a major life role and is central to
many peoples' life goals however, for those of working age, having arthritis can affect the
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ability to remain employed. In their recent report, 'Differences in the Workforce
Experiences of Women and Men with Arthritis Disability', Kaptein et al. (2009) have
suggested that, when compared with individuals with other types of chronic disease or
disabilities, arthritis appears to have a more profound impact on the ability to work and
participate in other life activities - a view supported by various studies that have found
approximately 50% of people with arthritis or arthritis-related disability were out of the
workforce (Badley & Wang, 2001; Backman, 2004). Given that individuals with severe
psoriasis report missing work frequently, and experience increased levels of
unemployment as a result of their psoriasis (Linden & Weinstein, 1999), it is possible that
a dual diagnosis of psoriasis and psoriatic arthritis has a greater impact on occupational
employment than if an individual just has one of the conditions.
According to Ryan (1996), the enforced physical disability and role changes that occur as a
result of RA lead to negative self-esteem, whilst the significant association between loss of
valued activities and poor health outcomes, such as depression, has been observed as a
consequence of RA (Neugebauer, Katz & Pasch, 2003). Indeed, in the current qualitative
study, decreased functional ability pervaded every aspect of the participants' lives resulting
in the need to be adaptive and develop various coping strategies in order to manage their
condition.
The participants used numerous strategies in an attempt to remain independent and be able
to carry out everyday activities. These included using a wheelchair when out shopping,
sitting down to prepare food and installing a seat in the shower - all positive adaptations
designed to help the individual cope with the disease.
Conversely, in an attempt to deal with their pain and fatigue, several participants described
the excess use ofalcohol as a way of helping them induce sleep - clearly a negative coping
strategy that may have deleterious implications for their health.
The finding that self-medication with alcohol is a coping strategy in this patient group
aligns itself with other research such as that of Riley & King (2009) who examined the use
of alcohol to manage pain, including arthritis pain, in a sample of community-dwelling
adults and concluded that self-medication of pain with alcohol was associated with pain
frequency, depression and use of pain medications, whilst interestingly, among patients
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with chronic back and neck pain there is some evidence to suggest that weekly alcohol
consumption predicts the development of widespread chronic pain (Sjolander & Johansson,
2004).
Such findings suggest there may be a need to address adverse self-medication behaviours
as they may be implicated in longer-term health problems that not only add to the burden
of living with a chronic pain condition, but also contribute to the development of
maladaptive coping strategies.
Alcohol use may be considered a transparent strategy, however, what was less clear, were
the strategies employed when social interaction was pending, for an element of
contradiction existed. On the one hand, most participants reported feeling lonely and
isolated, yet on the other, they reported frequently rejecting offers of help from friends and
family, deliberately shunning social contact, reducing communication with friends and
avoiding social events - the common reasons being that they felt a burden, or, perceived
that other people didn't understand the disease, or people would try and help.
This was an interesting fmding, particularly in the light of much research that suggests
social support, whether negative or positive, is an important coping resource in managing
illness and is thought to act as a buffer between the individual and the source of stress or
demands of a chronic illness, as well as providing tangible assistance in meeting needs
(Miller,2000). Indeed, according to Silver, Wortman and Crofton (1990), one of the most
challenging aspects in managing illness, is to maintain social support and preserve
interpersonal relationships as valued coping resources.
Within the RA literature, there is increasing evidence that social support is predictive of
long-term functional disability and pain, with both the qualitative aspects of perceived
social support and the quantitative aspects of the size of the social network believed to play
a role. In their study, Smith & Wallston, (1992), found that lower levels of perceived
support were prospectively related to more interference in the daily activities of RA
patients after one year, whilst another study reported increased pain after one year (Waltz
et al., 1998). Similarly, Evers et al. (1998) found that smaller social networks predicted
functional disability after one year.
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Furthermore, a study conducted in Ireland tasked with identifying the prevalence of
depression and anxiety in RA patients attending hospitals, which also explored the role
played by psychosocial, illness and disability variables, reported 65% of patients had
evidence of depression (37.5% moderate or severe) whilst 44% had evidence of anxiety
(17.8% moderate or severe). After controlling for age, gender, marital status and duration
of disease, perceived social support was a highly significant, independent predictor of both
depression and anxiety, suggesting that that increasing social support may be particularly
important in the management of depression and anxiety in RA. (Zyrianova et aI., 2006).
Social support has also been shown to playa role in the levels of psychological distress
experienced by individuals with psoriasis. For example, Evers et al. (2005) explored
contributors to psychological distress in 248 adults with either psoriasis or atopic
dermatitis, and found that less social support was one of the best predictors of
psychological distress in both groups of patients. Given that participants in the current
study admitted they had times when they specifically avoided engaging social support, this
finding suggests that the issue of actual or perceived social support may be a complex one.
In the current study, participants were reluctant to mobilise social support ("if family don't
help, that's it, you either do without or do it yourself'), partly because it required them to
engage and interact with other people, an act they claimed, that was often exhausting and
contributed to feelings of fatigue. It was clear that the participants experienced varying
intensities of fatigue on most days and perceived it as having a significant impact on their
lives, affecting their mental health and physical functioning and causing them to limit or
give up activities - "I used to walk miles, I was outgoing... now I spend most of my time
sitting".
All those interviewed seemed to experience problems resulting from the incapacity that
was induced by the extreme tiredness and fatigue. The fatigue was generally viewed as two
types - one being the sheer and complete exhaustion that arose after activities of some sort,
such as shopping, whilst the other was a physical and mental lethargy that left participants
feeling fragile, without energy and often needing to lie down.
Emerging from the qualitative data is the shared experience of fatigue as a distressing,
disruptive, unpredictable, extreme, frequent and multidimensional symptom that impacts
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on every aspect of life. The participants clearly perceived fatigue as a threat to their
traditional roles as they struggled to complete housework, care for children, attend and
enjoy social engagements and maintain both social and close relationships.
Although little has been written about the impact of fatigue on patients with psoriasis, the
results of the 1998 National Psoriasis Foundation Patient-Membership Survey found that
among the 17,425 who responded to the question regarding symptoms, 19% reported that
fatigue was a frequent symptom (Krueger et al., 2001), which serves to highlight the far-
reaching impact that psoriasis can have.
Examination of the available literature revealed a paucity of qualitative studies that
explored the impact of fatigue on those people with conditions that fall under the umbrella
of Rheumatology, let alone PsA. However, of the handful of studies identified, all reported
similar experiences and offer some evidence for the nature, consequences and management
of fatigue (Hewlett et al., 2005; Power et al., 2008; Repping-Wuts et al., 2008).
The descriptions given to fatigue in this study are similar to those used by participants in
other studies - its unresolving and unpredictable nature being key themes. Hewlett and her
colleagues explored the concept of fatigue as experienced by RA patients and found it to
be a severe and dramatic symptom that was intrusive and overwhelming (2005), whilst
comparable descriptions were noted by Power et al. (2008) in their study of fatigue in
Osteoarthritis patients.
The commonality of themes that emerge from these studies extends to the consequences of
fatigue, as participants comment on the far-reaching effects on their traditional roles,
physical function, employment, everyday tasks, relationships and social functioning, m
addition to their mental and emotional health.
Repping-Wuts and his colleagues (2008) undertook a qualitative study with the aim of
exploring fatigue as experienced by patients with RA and clearly demonstrated that RA-
related fatigue was viewed as being different from "normal" fatigue. It was seen as an
unpredictable, almost daily experience that had a great impact on quality of life. Half the
respondents described fatigue as more bothersome than pain and felt it required everyday
adaptation and although it had consequences for roles, relationships and leisure time,
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respondents rarely mentioned it to their health professionals assuming it was an untreatable
symptom that they must manage alone. Despite the disease focus being RA, the fmdings of
this study certainly align themselves with those of the current qualitative study exploring
PsA.
The lack of research examining fatigue communication in rheumatology out-patient clinics
certainly results in a gap in the current knowledge that needs addressing, however, it is also
of note, particularly in the light of the fmding that fatigue is a key theme, that to date, no
studies were found exploring health professionals knowledge, attitude, and current care for
fatigue in PsA patients. Even a search of the RA literature produced only a couple of
studies exploring these areas - both published in 2008 by Repping-Wuts, van Riel and
Achterberg.
Describing rheumatologists' knowledge and management of fatigue, Repping-Wuts et al
(2008) found that these health professionals underestimated the prevalence of RA-related
fatigue, although they were willing to assess and manage it. Although there was
acknowledgement of poor communication about fatigue, there was awareness that if a
patient is asked about fatigue, they rarely denied the symptom.
Fatigue communication at the outpatient clinic of rheumatology was the focus of a further
study by Repping-Wuts et al (2008). They concluded that fatigue, although a common and
severe symptom for RA patients, was only communicated in 6% of the total encounter
time, and that, mostly, it was the patients who initiated the communication on fatigue in the
consultations. Interestingly, the researchers noted that patients used implicit cues more
than explicit concerns in their communication on fatigue, and whilst there were no
suggestions as to why this occurs, this finding supports other health literature that reports
patients more often use cues to express their worries instead of communicating their
concerns (1996).
Whilst the qualitative data is limited, quantitative studies have sought to explore the role
and impact of fatigue in various rheumatological diseases. For example, Pollard et al.
(2006) sought to determine the relative contribution of RA disease activity to fatigue, in
comparison with factors such as pain and depression in established RA. They found that
fatigue was the dominant symptom and, that the patients' scores on the Health Assessment
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Questionnaire (Zigmond & Snaith, 1983) were positively associated with high levels of
fatigue, indicating they experienced greater disability, whilst the association with disease
activity was secondary. In this case, disease activity was established using both clinical
(Erythrocyte Sedimentation Rate - ESR, tender and swollen joint counts) and patient
measures (Patient Global Assessment), however many musculoskeletal conditions may
utilise different routine measures of disease activity and severity, therefore it is not always
possible to generalise results across conditions.
The interviews clearly demonstrated the detrimental effect that PsA has on many aspects of
life, much of it resulting from having to cope with intense pain and fatigue. Pain has long
been recognised as a major symptom of many musculoskeletal conditions whereas fatigue
has only recently begun to emerge as a core symptom - possibly because it has previously
been viewed as a subjective functional sign of other factors, such as co-morbid diseases,
medication side-effects or depression.
Fatigue, it seems, warrants further investigation. Indeed, writing an Editorial in
Rheumatology (2009), Repping-Wuts and his colleagues note their disappointment that,
despite fatigue being a common symptom in RA patients, few studies have focussed on the
treatment of fatigue and undertaken trials to establish the efficacy of interventions.
Unfortunately, the same is true of fatigue in patients with PsA.
The interviews in the first study gave the participants a voice and facilitated the
identification of common themes. In order to explore these themes further, the fmdings
were used to drive the choice of measures adopted in the quantitative study - as described
in Chapter 5 of this thesis.
7.3 Discussion of Quantitative Results
The qualitative results suggested that, in those with PsA, pain, fatigue and depression were
perceived as key issues that impacted on quality of life. Pain was viewed as always being
present in some form and in varying degrees, whilst fatigue was difficult to manage
because of its unpredictable nature, both of which impacted on the participants physical
functioning. Meanwhile depressive symptoms and low mood were universal features
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discussed by all the participants, as were reductions in social functioning, all of which
combine and seemingly contribute to decrements in health-related quality of life.
The lack of existing published studies that have explored the health-related quality of life
in PsA patients means a comparison of this sample to others is exceptionally difficult,
however a Canadian study by Husted et aI., (2003) did examine and compare health-related
quality of life in patients with RA and PsA, using a study sample comprising of 107 PsA
patients (and 43 RA patients). Of the 107 participants, 38% were female (62% male) which
compares favourably with the 48% (52% male) of females found in the hospital group of
patients. Similarly, in Husted et al.'s study the mean age for those with PsA was 50.2 (±
12.6), whilst in the current study it was 53.67 (± 11.03). The average duration of disease
was slightly higher in the Canadian study (14.2 years, ± 8.18) when compared with the
current one (11.89, ± 10.97).
It is of note, that Husted and her colleagues found that both the RA and PsA patients in the
study experienced lower physical health compared with that of a general population
sample, but when compared to the RA group, the PsA patients reported more role
limitations due to emotional problems and more bodily pain.
The very nature of PsA is such that it is very rare for those affected by the disease not to
have had, or continue to have, psoriasis. Indeed, of the respondents in the present sample
only eleven participants had PsA without simultaneously experiencing psoriasis. The
quantitative data in the current study was therefore split into two groups and explored by
'participants with psoriasis' and 'participants with psoriasis and PsA'
Examination of the quantitative results for the group of participants with both psoriasis and
PsA revealed significant correlations between the study variables, although of particular
note were the moderately strong correlations between fatigue, pain, depression and vitality
_ all of which were positive relationships, except for vitality which was negative due to the
scoring method. Further exploration of the correlation coefficients determined that strong
associations, which were significantly different to those found in the Psoriasis Group,
existed between physical functioning and several other variables - fatigue, self efficacy
and mental health, whilst social functioning was related to mental health. Furthermore, an
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interesting finding in this group was that the mean scores on all the measures signified
poorer physical and mental health when compared to the norms of known populations.
Conversely, in the Psoriasis Group, key associations were identified between psychological
health, anxiety and social functioning, whilst the DLQI was related to social functioning. It
is also interesting to note, that this group, as indicated by the mean scores, reported more
anxiety, depression, current pain, and reductions in physical function (as measured by the
HAQ) and greater role limitations due to emotional health problems, when compared with
the norms of a known population.
Levels of fatigue were higher in the group with PsA, with a mean score that was
significantly different to that found in a healthy population.
In the current study, the relationships between fatigue and the other variables supports
various studies of RA patients that have stressed the importance of psychosocial factors in
relation to fatigue. For example, Lorish et a1 (1991) found that fatigue was significantly
related to depression, anxiety and helplessness, whilst Wolfe et al (1996) concluded that
depression, together with pain and sleep disturbance, are the strongest independent
predictors 0 f fatigue.
The association between depression and fatigue would appear to be a complex one as
fatigue has been found to be higher among RA patients who have a lifetime history of
current or previous clinical depression or generalised anxiety. Consequently their fatigue
trajectories are usually stable, but elevated over time when compared to those RA patients
without mood disorders, whose fatigue trajectories commence at a lower level, but increase
over time (Fifield et at, 2001). Although it was not known whether respondents in the
current survey had a previous history of depressive episodes, given the incidence in the
general population and other pain populations, it is possible, and may therefore be
implicated in the levels of fatigue they experience.
A study by Pollard et al. (2006) explored the association between RA fatigue and pain and
concluded that high fatigue levels are common in RA and are mainly linked to pain and
depression. The researchers assessed fatigue by means of a 100mm VAS and the vitality
subscale of the SF-36 questionnaire (the lower the score the more severe the fatigue, with a
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range ofO - 100). In their cohort, the VAS scores indicated 80% of patients had clinically
relevant fatigue and over 50% had high fatigue scores, whilst the mean SF-36 Vitality
score was 51 - a figure that is substantially less than the 61 - 65 usually reported in the
normal UK population. Interestingly, in the current study, the mean SF-36 Vitality score
for the group of participants with both psoriasis and PsA was 47, whilst for those with
psoriasis alone it was 58. As was the case in the study by Pollard et al (2006), the SF-36
Vitality scores moderately correlated with the HAQ scores suggesting that those
individuals with lower energy levels, which may reflect fatigue, experience greater
physical disability.
Although the Psoriasis Group reported lower levels of fatigue and had weaker correlations
with the other variables, than the group with both conditions, a significant difference was
found when the mean was compared to that of a healthy population. In the current study it
appears that fatigue was experienced by individuals with psoriasis, but not to the same
extent as the group with PsA, although previous research suggests that fatigue is of
concern to those with psoriasis. For example, the results from a study of 492 patients with
skin disease found that 50% of the respondents reported fatigue as a frequent symptom
(Verhoeven et al., 2007), whilst Evers et al. (2005) concluded that higher levels of fatigue,
perceived helplessness and less social support best predicted psychological distress m
patients with psoriasis.
According to Swain (2000), fatigue is being recognised as the least well-managed
symptom in many chronic illnesses and is largely responsible for a loss of health-related
quality of life. Various studies have demonstrated the wide-ranging impact, such as social
isolation and unemployment that fatigue can have on the lives of those individuals
suffering with a chronic illness (Schreurs et al, 2002; Dittner et aI, 2004).
A recent study by Salaffi et al. (2009) lends further weight to these findings as the
researchers utilised, amongst other measures, the SF-36 as they sought to compare the
health-related quality of life in RA, AS and PsA with a selected sample of healthy people.
Their fmdings indicate that adults with inflammatory rheumatic disease have poorer self-
reported health status than those without arthritis in all domains of living, but notably with
respect to those scales measuring physical functioning, mobility, role limitation due to
physical health and bodily pain. Although RA emerged as the disease with the worst
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health-related quality of life for physical dimensions of the SF-36, their mean PCS score
was 32.5 which is comparable to 35.95 found in the current study in the group of
participants with PsA and psoriasis - as Pollard et al note, based on the PCS scores alone ,
the physical functioning of these patients is comparable to patients with congestive heart
failure (Ware, 2000). The impact of PsA on physical functioning is further emphasised
when the mean scores are compared with the 49.03 recorded by the psoriasis-only group-
a substantial difference that serves to highlight the decreased physical functioning
associated with PsA.
Furthermore, Pollard et al. (2009) also found that patients with PsA reported more
psychosocial problems than patients with RA and AS, and that the SF-36 MCS dimensions
typically affected by PsA were mental health, limitations due to emotional health, and
social functioning. In the current study those participants with both PsA and psoriasis
seemingly endured poorer mental health than those with just psoriasis, as was confirmed
by a t-test which found a highly significant difference between the groups on the
depression scale of the HADS. It is also of note that although the Mean score for the
Mental Component Score was marginally higher in the Psoriasis Group, the difference was
non-significant.
Given that PsA usually only presents in people who have, or previously had, psoriasis, it is
possible that this finding reflects the additional burden of the joint disease, although it must
be acknowledged that generally there is widespread ambiguity regarding the relative
contributions of skin and joint disease to overall health-related quality of life among
patients with psoriasis. Assessing quality of life in this patient group is challenging and
often confounded by the simultaneous presence of joint and skin disease.
Lesion severity was not assessed in the present study so it is not possible to ascertain the
additional impact that this may have had on psychological distress and functionality.
However, the burden of living with psoriasis has already been established in various
studies, such as that by Schmitt & Ford (2007) who found that of their sample of 285
psoriasis patients, 32% screened positive for depression. Furthermore, they concluded that
specific disease-related problems in everyday life seemed to cause depression in a
significant proportion ofpatients.
153
A finding to emerge from the current data for the Psoriasis Group was that social
functioning was related to psychological health. This result certainly supports previous
research with psoriasis patients that consistently report that that individuals with psoriasis
experience reductions in their social functioning. For example, one study that explored the
psychological effects of psoriasis amongst 104 Irish patients found that a large percentage
of patients avoided common social activities, for example swimming and sports; 50% felt
that psoriasis had inhibited their sexual relationships and 11% of patients said they would
avoid having children in case their offspring should develop the condition (Ramsay &
O'Reagan, 1988). Further support for the impact that psoriasis can have on social
functioning is provided by Weiss et al. (2002) who evaluated the health effects of skin
disease by comparing psoriasis to other primary medical disorders. Using 3 different scales
of health-related quality of life, the researchers concluded that individuals with psoriasis
are significantly affected in their social functioning when compared with individuals
without chronic disease and those with certain primary medical conditions.
In the group with both conditions, social functioning was also found to be associated with
psychological health, as measured by the SF-36 Mental Component Score. Given that the
initial qualitative study revealed that participants would regularly avoid social events, this
fmding was perhaps to be expected. However, in the light of a similar finding in the
Psoriasis Group, further research may be useful to disentangle whether the impact on social
functioning in PsA patients is due to psoriasis or the presence of the arthritic condition.
Unfortunately, few studies are available that compare the health-related quality of life of
patients with psoriasis with those patients who have both psoriasis and PsA. One such
study undertook a comparison among three groups of Swedish patients - one group had
psoriasis, another had atopic dermatitis whilst the third had psoriasis and PsA. Using the
DLQI and the SF-36 the researchers concluded that those people with the dual conditions
of psoriasis and PsA had significantly poorer health-related quality of life than those
patients with psoriasis only. However, as no objective measures of severity or skin disease
area were used, there is a possibility that this result could have been related to greater
psoriasis severity among those with PsA (Lundberg et al., 2000).
Furthermore, a study conducted by Zachariae and his colleagues (2002) employed the
Psoriasis Disability Index (PDI) and the Psoriasis Life Stress Inventory (PLSI) in order to
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compare health-related quality of life between patients with PsA and patients with psoriasis
only. Their findings supported those of Lundberg et al. (2000) as the patients with both
PsA and psoriasis exhibited significantly decreased health-related quality of life.
Interestingly, this group also reported more cutaneous lesion severity than the group with
just psoriasis, which raises the possibility that their diminished heath-related quality of life
could still have been associated with a greater burden of skin disease.
In the current study, the impact of skin disease on HRQoL, as measured by the DLQI, was
found to be greater in the Psoriasis Group, furthermore, examination of the correlation
coefficients indicated that there was a moderately strong, inverse association with social
functioning. However, similar to the study by Lundberg et al.(2000), no objective measure
of skin disease was used.
The findings of the current study clearly demonstrate that poor mental health, low mood
and depressive symptoms impact on those individuals with PsA, yet within the literature
the research once again is focussed on the experiences of RA patients. Nevertheless,
examination of this literature is useful as it underlines that depression is RA'S most
common co-morbidity and that it is a complex multitude of interactions between clinical,
psychological and demographic factors (Covic et al., 2006).
Indeed, a meta-analysis of twelve studies found that depression was significantly more
common among RA patients than healthy individuals and was influenced by levels of pain
but not demographic factors (Dickens et al., 2003). Although pain is largely viewed as a
sensory experience, there is increasing evidence that it is strongly linked to depression,
with various studies reporting that pain leads to depression (for example, Sharpe et al.,
2001) whilst others suggest it is depression that leads to pain (for example, Zautra &
Smith, 2001). However, Covic et al. (2003), in a series of cross-sectional and longitudinal
studies, found depression to be mostly independent of pain and predicted by physical
disability - a relationship which it has been suggested, is further influenced by the level of
importance attached to leisure and social activities at risk or lost due to RA (Katz & Yelin,
2001). Furthermore, Smith & Zautra (2008), in a study that explored the effects of anxiety
and depression on weekly pain in women with OA and RA, suggested that the absence of
pleasure (activities, etc) may have played a role in the greater vulnerability experienced by
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depressed persons in time of stress. They also found that in the RA group, those low in
depression reported less pain in times of stress.
It is interesting that in the present qualitative study, one of the fmdings concerned people's
reluctance to discuss pain levels and the management of their pain with health
professionals, yet the quantitative study clearly identifies pain as a key issue that is
associated with reduced quality of life and appeared to seriously interfere with the
continued involvement with valued activities and interests.
In the present study pain was shown, in the group of respondents with both PsA and
psoriasis, to have a positive, moderately strong, significant relationship with fatigue,
depression, HAQ and self-efficacy. The same association existed with all sub-scales of the
SF36 and the two component scores (PCS and MCS), although due to the scoring method
the correlation was negative.
The correlation between HAQ and Fatigue was stronger in the group with both conditions
and was also significantly different from that found in the Psoriasis Group. This result not
only suggests that greater reductions in functional ability are found in the group with PsA,
but also that it is associated with levels of fatigue.
The HAQ has been found to have good predictive value in various studies of RA patients,
for example, Cohen et al. (2006) examined the utility of HAQ as the best predictor of 5-
year quality of life in early rheumatoid arthritis. Using the Arthritis Impact Measurement
Scales 2 (AlMS2) as the outcome measure for quality of life, the researchers found that the
baseline HAQ score was the best predictive factor for the physical, symptom,
psychological, social interaction, and work scores of the AIMS2.
The relationship between pain and physical disability is far-reaching and has been shown
to lead to diminished health-related quality of life and life satisfaction amongst RA patients
(Borman, 2007), whilst Katz (1998) found that patients with RA report pain, fatigue,
functional impairment and unpredictability of symptoms as having a significant impact on
their lives (Katz, 1998). Furthermore, Covic et al. (2000) studied 111 RA patients and
examined the association between pain and coping and the impacts of psychological
variables on the relationship. In order of strongest correlations with pain, the strongest link
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was passive coping, followed by physical disability, depression and helplessness, whilst
the only significant predictors of pain were physical disability and passive coping.
Such studies suggest that physical disability is an outcome of the underlying disease and is
closely linked to pain. However, differences in the disease itself may playa role given the
unpredictable and chronic nature of RA, meaning the importance of key factors may
change. For example, physical disability may dominate during a disease 'flare-up', whilst
psychological factors may have a greater impact over time due to the perceived and real
loss of quality of life caused by the disease.
Despite the variety of studies investigating the relationship between pain and depression,
causal effect remains difficult to determine. However, what such studies do indicate is that
a multimodal assessment ofa broad set of physical, psychological, and social stressors and
resources are needed for the understanding and prognosis of psychological distress.
When considering the current study, in which levels of depression and anxiety were
assessed using the Hospital Anxiety and Depression Scale (HADS), it is important to
acknowledge that many of the participants had the additional burden of skin disease to
contend with, which could potentially be a causal factor for any symptoms of depression or
psychological distress. The results identified 13 people (3.7%) with probable depression
and a further 39 (11%) as being border-line for depression. These figures not only support
those reported in the RA literature that used research interviews - the gold standard of
psychiatric assessment - to conservatively estimate the prevalence of depression to be in
the region of 13 -20% (Creed, 1990) but also clearly demonstrate the heightened levels of
psychological distress experienced by those with PsA and psoriasis.
Whilst the focus of this study is PsA, it is impossible to ignore the role of psoriasis, and the
profound impact it can have on some patients. Psoriasis-related decrements in health-
related quality of life have been shown to result in significant stress for the patient, as they
have to manage and cope with, what can be a disfiguring disease. Significantly higher
degrees of depression have been noted in psoriasis patients when compared with controls,
with Beck Depression Inventory (BDI) scores shown to be strongly correlated with the
severity of the psoriasis symptoms (Devrimci-Ozguven et aI., 2000). In their study of 127
psoriasis patients, Gupta et al (1993) found a 9.7% prevalence ofa death wish and a 5.5%
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prevalence 0 f acute suicidal ideation at the time of the study, furthermore at least 20% had
contemplated suicide.
Studies of psoriasis patients consistently report elevated levels of depression and
depressive symptoms. Indeed in a large questionnaire-based study of Italian psoriasis
patients (n = 2391), 62% returned scores indicating the presence of depressive
symptomatology, as determined by the Centres for Epidemiologic Studies Depression
Scale (Esposito et al., 2006), whilst another study used the General Health Questionnaire to
assess the psychiatric morbidity of patients with psoriasis and vitiligo and concluded that
53% of psoriasis patients versus 17% of vitiligo patients had scores suggesting the
presence of psychiatric illnesses, such as depression, anxiety, and sleep disturbance
(Sharma et al., 2001).
In the current study, the Psoriasis Group reported lower levels of depression and anxiety
that a similar reference group, and it is particularly interesting that in the current study,
although the difference between the groups was not significant, the Psoriasis Group
experienced greater levels of anxiety, than depression, as measured by the HADS, than
those with PsA. However, when the three variables of MCS, RE and MH were correlated
with Anxiety, the resulting coefficients were not only stronger than the group with PsA,
but they were also significantly different. Whilst acknowledging that the MCS takes into
account the correlations among the RE and MH subscales, it may be argued that the result
for the MCS may be expected in this case, but it is possible, according to Ware et al.
(1994) to just use the component scores to clearly reflect the impact of the disease without
substantial loss of information. The source of the anxiety in this group is unknown and
warrants further investigation, particularly in the light of the various psychosocial issues
perceived to have an impact on quality of life, and cited by respondents in the 1998
National Psoriasis Foundation Patient-Membership Survey, as being workplace difficulties,
socialisation with family members and friends, exclusion from public facilities and
contemplation of suicide (Krueger et al., 2001).
These studies not only illustrate the severe and deleterious effect that psoriasis can have on
an individual's well-being but serve to show that clinical measures of disease status alone
are insufficient to describe the burden of illness.
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Mease & Menter (2006) have suggested that health-related quality of life is a relatively
new area of research focus in psoriasis as there is a growing awareness among health
professionals that the physical manifestations of psoriasis such as redness, scaling and
pruritus represent only part of the burden of the disease, as these physical problems
inevitably impact on psychosocial domains.
The results of the present study clearly show that the group of participants with both
psoriasis and PsA experience decreased quality of life, measured using the SF36, when
compared with the group who have psoriasis only, and that living with PsA and psoriasis is
clearly a challenge as patients contend with the varying influences of pain, fatigue and
depression and their inevitable impact on daily activities.
An individual's ability to manage such symptoms varies, but one concept that may help in
understanding the variation in adjustment and the perceived ability to self-manage is that
of self-efficacy. Developed within the framework of social-cognitive theory by Bandura
(1977), self-efficacy refers to the belief that one is capable of performing in a certain
manner to attain certain goals, and once formed, self-efficacy beliefs influence not only the
course of action pursued, but also the effort expended, level of perseverance and the
amount of stress experienced in demanding situations. It is not concerned with the skills
one has, but with the judgement ofwhat one can do with whatever skills one possesses.
Researchers have suggested that self-efficacy is one of the key cognitive factors that
influence pain tolerance, negative affect (e.g. stress and anxiety) and choice of coping
strategies (Arntz & Schmidt, 1989; Haerkaepaeae et al., 1996; Schermelleh-Engel et at,
1997) and that it is possibly the most important factor in predicating long-term change for
those dealing with pain disorders (Schermelleh-Engel et al., 1997).
To date, there has been little exploration of the role of self-efficacy in individuals with
PsA, although various studies of patients with rheumatoid arthritis, osteoarthritis and
ankylosing spondylitis have included various self-efficacy measures.
Measurement of self-efficacy in the current study was undertaken using the Self-efficacy
for Managing Chronic Disease measure (Lorig et al., 2001). The mean score recorded for
the group with psoriasis (M = 7.51) was higher than the mean of 6.32 for the other group -
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a figure similar to the mean of 5.17 reported in the validation study by Lorig et al. (2001).
It is possible that self-efficacy measurement needs to be more in context - that is, specific
to either psoriasis or psoriatic arthritis or possibly arthritis- related pain. It may be the case
that the instrument needs to incorporate not just the expectation that a person could
perform a particular behaviour or task, but also their confidence in being able to do it
despite their pain.
Nonetheless, the results confirm the existence of associations between self-efficacy and
physical and psychological health, as low self-efficacy was associated with more pain,
more fatigue, greater depression and anxiety and greater physical impairment.
The group with both conditions recorded lower levels of self efficacy than the psoriasis
group. However, of particular interest were the correlations found between self efficacy
and the HAQ, PF and PCS, as all three were significantly different to those found in the
psoriasis group. They are results which clearly suggest an important association between
physical and functional ability and self efficacy.
These findings are similar to those of Barlow et al. (2002) who examined the psychosocial
well-being, self-efficacy and preferences for psycho-educational interventions among a
group of fifteen RA patients. The researchers concluded that low self-efficacy was related
to greater physical impairment, more fatigue, more depressed and anxious mood and less
acceptance of their condition. Furthermore, Higher self-efficacy scores have been
associated with lower pain intensity (Brekke et al., 2001; Cross et al., 2005), less
functional impairment (Turner et a12005; James et al, 2005) and better adherence to non-
analgesic medication (Brus et al., 1999).
Cross-sectional studies have generally been used by the handful of researchers who have
studied the effect of self-efficacy on certain aspects ofRA. For example, Taal et al. (1993)
found that the higher the level of self-efficacy, the better the patients judged their health
status, independently of disease activity. Self-efficacy has also been found to correlate with
the level of fatigue (Riemsma et al., 1998) and with daily pain and mood (Lefebvre et al.,
1999).
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In the psoriasis group, stronger correlations, that were significantly different to those in the
other group, were found between self efficacy and the both the DLQI and SF-36 subscale
of MH, implying that for those individuals with psoriasis self efficacy is more clearly
associated with psychological health rather than physical health. It is of interest that this
fmding is somewhat opposite to that found in the group with both psoriasis and PsA and
may reflect a subtle difference in the burden of the different conditions. It certainly
warrants further investigation as it may just reflect the need to measure self efficacy with a
disease specific measure rather than a generic one.
The concept of self-efficacy is widely accepted and acknowledged to be important in the
study of pain and there is evidence to suggest that patients with higher perceived self-
efficacy report less pain (Keefe et al., 2005) Cross-sectional measurements of self-efficacy
are believed to be a meaningful indicator of daily pain and coping, with greater self-
efficacy often leading to more effective pain coping mechanisms (Gustafsson, 1999).
Indeed, people with high levels of self-efficacy (for pain) have reported less pain then
those with low self-efficacy when subjected to painful stimuli in a laboratory (Keefe, 2005).
Given the evidence that higher self-efficacy is associated with better health behaviours,
researchers have explored ways of enhancing self-efficacy. Interventions such as exercise
and stress management programmes have been utilised with patients and their impact
assessed. For example, in one UK. study, Buszewicz and her colleagues (2006) randomised
812 patients with osteoarthritis to six sessions of self-management of arthritis and an
education booklet (intervention group) or the education booklet alone (control group) and
found that the two groups showed significant differences at twelve months on the Anxiety
sub-score of the HADS, Arthritis Self-efficacy Scale for Pain and self-efficacy for other
aspects of management. They concluded that the self-management of arthritis programme
reduced anxiety and improved participants' perceived self-efficacy to manage symptoms.
These results provide further evidence that self-efficacy is a modifiable factor that is
associated with current and future health behaviours.
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7.4 Summary of Results
The results of both the qualitative and quantitative studies have clearly shown that
reductions in health-related quality of life occurred, and were perceived, by the
participants, to be as a result ofhaving either psoriasis or psoriasis with PsA.
The Group with Psoriasis and PsA experienced greater reductions across all the
psychosocial variables that were measured, with the exception of the DLQI, than the
Psoriasis Group. However, those individuals in the Psoriasis Group undoubtedly
experienced decrements to their quality of life and what is more, the decrements appear to
be different in nature to those experienced by the group with both conditions.
Fatigue emerged as a key issue for those with PsA, impacting on physical functioning and
pain, whilst levels of self efficacy and depression were also associated with the ability to
function well.
By comparison, in the Psoriasis Group, anxiety levels were highlighted as an issue and
were associated with other measures of psychological functioning, as was social
functioning and self efficacy.
When encompassing all the findings of the current study in which higher levels of fatigue,
depression and pain, and decreased self-efficacy have been found to be detrimental to
health-related quality of life, impacting on both physical and social functioning, the
implication is that the traditional medical model of care needs expanding to incorporate
psychological and social support into the assessment and management of patients with PsA
and psoriasis. The use of a multi-disciplinary team could support and facilitate coping
strategies for pain management and fatigue, assess and monitor actual and potential
psychological distress whilst physiotherapy and occupational therapy could be used to
maintain and enhance physical functioning to improve activities of daily living.
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7.5 Discussion of Mixed Methodology
Mixed methods investigations involve integrating more than one type of research method
and may be a mix of both qualitative and quantitative methods, or a mix of just qualitative
methods or just quantitative methods in a single study.
The use of mixed methodology remains the focus of much debate amongst researchers,
with the advocates of quantitative and qualitative research paradigms seemingly engaged
in ardent dispute for more than a century, with purists emerging on both sides claiming that
their paradigm is the superior (Johnson & Onwuegbuzie, 2004) thereby positing that
qualitative and quantitative research paradigms cannot and should not be mixed.
Clarke and Yaros (1988) have argued that combining research methods is useful in some
areas of research, such as nursing, because the complexity of phenomena requires data
from a large number of perspectives, whilst Haase & Myers (1988) have strongly
advocated that the two approaches can be combined because they share the goal of
understanding the world in which we live. Moreover, Reichardt & Rallis (1994) maintain
that the use of mixed methods is acceptable because they are united by a shared
commitment to understanding and improving the human condition, a common goal of
disseminating knowledge for practical use, and a shared commitment for rigor,
conscientiousness, and critique in the research process.
Whilst it is outside the scope of this thesis to engage at length about the intrinsic worth of
each type of research, the author fully appreciates the differences in the paradigms, and
suggests that by utilising quantitative and qualitative techniques within the same
framework, mixed method research can incorporate the strengths of both methodologies.
Indeed almost fifteen years ago, Sechrest & Sidana (1995) argued that a growth in the
mixed methods movement would have the potential to reduce some of the problems
associated with singular methods. In the context of the current study this is certainly the
case, for it is the author'S position that neither qualitative nor quantitative methodology
alone would have answered the research question, whereas a combination of the two would
be more productive. The approach was viewed as being complimentary as it offered the
potential to provide insights that may not be achievable through the use of a singular
method.
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Within this research, the justification for employing both a qualitative and a quantitative
study was driven by the distinct lack of published literature. This highlighted the need for
an initial exploration of the phenomena as a first step to understanding the key issues that
impacted on patients with PsA. A qualitative study would achieve this objective whilst at
the same time it would allow the research to be patient-driven and patient-centred and
would ground the research in the lived experiences and real world of the sufferers, so
infact, the qualitative study became an essential preliminary to the quantitative research.
A phenomenological approach was chosen as it arms to describe or elucidate such
experiences of a phenomenon as the individual lives it. It was deemed appropriate because
complex phenomena such as feelings and experiences of illness and disease cannot always
be explained and accounted for in terms of things or objects as in the natural sciences
(Karlsson, 1995).
As PsA research has rarely explored, either qualitatively or quantitatively, the psycho-
social consequences of the disease, the author believed that the fmdings of the initial
qualitative study could be used to inform the selection of measures which could then be
employed in a quantitative study. Therefore, the merits of combining both quantitative and
qualitative methodology to adequately elucidate patients' perspectives were advocated.
7.5.1 Integration of Results
There is certainly no guarantee when a mixed method approach is adopted, that the final
results will support each other, however in this study the quantitative study certainly
supported the findings of the qualitative study, and vice versa.
It is of note that the health-related quality of life of participants in the small qualitative
group was just as affected as that of the much larger sample used in the quantitative study.
This not only adds to the reliability of this research, but also provides general further
support for the argument that mixed methodology has a role to play in health research.
In this instance, the rich, descriptive data of the qualitative study enabled an appropriate
selection of measures to be identified in order to quantify the issues that had been
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highlighted by the participants. Regardless of the methodology used, the key issues found
were the same.
7.6 The Use of Postal Surveys and Self-Report Measures
Postal surveys are widely used to collect data in health research and are a useful tool for
examining the attitudes and behaviours of both patients and health professionals. Indeed,
often they are the only fmancially viable option when collecting information from large,
geographically dispersed populations.
In the current study, the postal survey achieved an overall response rate of30%, although it
is of note that of the questionnaires sent out to members of the Psoriasis Association,
31.6% were returned, whilst of those mailed to hospital patients only obtained a 22%
return.
When considering why a higher response rate was not obtained, it is important to
acknowledge the impact of several factors. Firstly, the questionnaires were mailed during
the summer period so there was a possibility that people may have been away on holiday
so when returning to their mail they may have simply viewed the survey as low priority
and categorised it as 'junk' mail. Secondly, given that staff at the Psoriasis Association and
not the researcher, mailed out 1000 of the 1200 surveys, it is not known how many were
undeliverable because of incorrect addresses and lastly, due to financial and time
constraints, the study design did not include any type of follow-up procedure, such as
sending a written reminder or using a telephone call, to contact non-responders.
According to Asch et al. (1997) postal surveys need high response rates to be successful.
They suggested that a high response rate typically lowers the cost per response and the cost
necessary to achieve a sufficient sample, and that it reduces the extent or possibility of
non-responder bias.
Furthermore, Cook et al. (2009) maintain that low response rates increase the potential for
bias and threaten study validity. However, in their study of response rates in postal surveys
of health care professionals between 1996 and 2005, the researchers found that only 17% of
350 studies attempted assessment of possible non-response bias, leading them to suggest
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that researchers should at least recognise the influence of non-responders and consider
whether they undermine the generalisability of findings to a wider population.
Whilst the author acknowledges there is an ever-growing body of research examining
possible methods for increasing response rates and reducing non-response bias in postal
surveys, such as using multiple mailings to make frequent contact and the use of financial
incentives (Van Geest et al., 2007), as previously noted, these were not feasible within the
current study.
Similarly, it has not been possible to perform any non-responder analysis given the
anonymity of the sample. However, there is some evidence suggesting that demographic
characteristics of responders and non-responders to health surveys may be similar. In an
American study, Filip et al. (2004) conducted a postal survey of a dermatology patient
population, all of whom had a diagnosis either of non-melanoma skin cancer, acne rosacea,
dermatophytosis, eborrheic keratosis or warts, and a response rate of69.8% (3203 patients)
was achieved. The researchers analysed the non-responders and found that their
characteristics did not generally differ from those of the responders, indicating that non-
response bias may be of less concern than in some studies, and that their respondents were
probably representative of their target population.
Given that the design of the current study excluded the use of follow-up or reminder
mailings, it could be argued that a good response rate of 30% was achieved, however in
order to improve the informativeness of postal survey fmdings in future studies,
researchers should routinely consider the use of follow-up reminders and assess the
potential for non-response bias, as this would undoubtedly increase response rates. This is
supported by research that found the use of reminders, either telephone or written,
increased response rates by approximately 13% (Asch et al., 1997).
Postal surveys may be a less accurate method of collecting data due to the self-report style
of the questionnaires, which highlights not only the issue of using postal surveys, but also
the issue of using of self-report measures.
Firstly, it is important to recognise that information such as functional disability,
depression and pain describe the progressive disability and suffering endured by these
patients and as such, is information that cannot be easily obtained except through patient
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self-report instruments and interviews, however, the latter undoubtedly require greater
resources in terms of time and expertise. Secondly, such data is perhaps best viewed as
adding value to the usual clinical data. It is not that one type of data is superior, but simply
that the combination of both sets can be used to better inform clinicians' judgements
regarding potential treatments, and also assists in the early identification of comorbid
conditions such as depression. Indeed, Wolfe & Pincus (1999) in their commentary paper
entitled 'Listening to the Patient', argue that self-report questionnaires are probably more
informative than clinical measures such as tender joint counts. They do however, recognise
that self-report data are not perfect as it is impossible to determine whether the patient
responses are truthful and they suggest that, whilst there is general agreement that the
patient is the best source of data regarding pain, function and global severity, it is the
combination of clinical and patient data that facilitates the best estimate of disease status.
7.7 Membership Groups
The majority of the returned questionnaires were from members of the Psoriasis
association - therefore it could be argued that the responses are representative of a group
of individuals who are willing to take the time to participate in the survey and may be more
involved and knowledgeable about their condition.
It was interesting to note that a higher proportion of the participants from the Psoriasis
Association had attained either graduate or post graduate qualifications - the implications
of this are unclear and the author can only speculate that members of the Association may
be more likely to engage in seeking out information about their health condition or be more
comfortable engaging in a self-help group.
Previous research with AS patients, that focussed on the possible differences between
members and non-members of self-help groups for people with this form of chronic
disease, analysed health locus of control beliefs along 3 dimensions: internality, powerful
others and chance. The results showed that members of National Ankylosing Spondylitis
Society self-help groups placed significantly less reliance on "powerful others" for control
of health, than did non-members. The researchers posited that such patterns of beliefs may
be related to the nature of AS, which is incurable, progressive, unpredictable and difficult
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to diagnose - infact, very similar to PsA. Itmay be from the patient perspective that health
care professionals have little to offer them and that people who join a self-help group feel
less reliant on medical professionals to control their health. The group members not only
displayed a tendency to seek out information about their disease, but also differed from
non-members in terms of belief in the value and frequency of exercise for AS and
interestingly, received a valuable source of social support from fellow members (Barlow et
al., 1992).
These fmdings mirrored those of an earlier study by Volle et al., (1990) who had
investigated psychological correlates of membership in self-help groups for rheumatic
diseases among 138 patients with either RA, AS or arthrosis. Volle et al. found that self-
help group members display specific control beliefs that differ from the non-self-help
group members, with group members viewing the disease as more controllable by
themselves and as less dependent on health personnel. They too searched out more
information and demonstrated better disease and treatment knowledge.
This evidence suggests that members of self-help groups may speak more frequently about
their disease and the available treatments and 'tap in' to the knowledge shared by other
sufferers, which in turn empowers them to take greater control over their symptoms. Such
empowerment could be argued to have a beneficial effect on an individual's level of self-
efficacy, which as a consequence facilitates their management of symptoms such as fatigue
and pain.
Self-help groups may be considered as a therapeutic extension to health services as they
appear to offer important benefits to their members. They provide a structure for mutual
aid and support, and offer a forum for knowledge exchange and social action, which then
has the potential to empower people to deal with a chronic disease.
Again, the author can only speculate as to the degree these results were affected by the
majority of the respondents being members of the Psoriasis Association. However as
evidence of group membership is associated with improved locus of control when dealing
with a chronic disease, it is likely that health-related quality of life would have shown even
greater decrements, had the sample consisted of non-members.
168
7.S Limitations/Future studies
The current study did not address the presence of comorbidity and therefore did not
account for any additional impact they may have on quality of life. Research into PsA
could certainly be enhanced by incorporating an assessment of comorbidity into future
studies of PsA involving health-related quality of life outcomes, as coexisting conditions
may impact on outcomes of interest such as depression, physical functioning and global
health status. Measures of comorbidity are often sourced from health records that may be
difficult to obtain, however research suggests patients can accurately assess current and
past medical conditions including comorbidities by means of a questionnaire (Katz et al.,
1996). This suggests future studies may overcome this limitation by including a patient
self-report, such as the Self-Administered Comorbidity Questionnaire that has been found
to be an efficient method to assess comorbid conditions in clinical and health services
research (Sangha, Stucki et al, 2003).
Health-related quality of life is a relatively new area of research focus in patients with PsA
and, to a lesser extent psoriasis, although there is a growing awareness amongst health
professionals that the physical manifestations ofPsA and psoriasis represent only a part of
the total impairment and disability that may result from living with these diseases.
There are a limited number of validated, disease-specific tools that are currently available
to measure health-related quality of life in this patient group. The findings of this study
underline the need to strive towards the development of suitable measuring instruments
that are patient driven. The incorporation of patients' perspectives into outcome measures
is essential as it respects the uniqueness and individuality of patients' experiences and
ultimately reflects a more accurate assessment of the health and psychosocial concerns
associated with the disease.
In this study, fatigue, depression and pain were found to overlap and entwine and may
produce additive impairments in many areas of an individual's life, including daily
functioning, social functioning and, unemployment. Although significant rates of work
disability in PsA patients have been reported (Mau et al., 2005), most researchers largely
ignore employment and work disability. Employment was one of the issues identified in
the qualitative study, but was not the focus in the quantitative study, thus leaving a gap that
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future research should aim to bridge, particularly as work disability associated with
inflammatory arthritis accounts for the majority of the costs associated with diseases such
as RA and ankylosing spondylitis. (Shanahan & Ahern, 2008). Furthermore, Shanahan &
Ahern (2008) suggest that it may be feasible for simple workplace changes to reduce work
disability from arthritis, and posit adjustments such as start time, shift work and ergonomic
adjustments to work stations as possible solutions.
Future research should investigate the possibility of self-efficacy as a mechanism or an
intervention to effect positive change in fatigue and health-related quality of life.
Measurement of self-efficacy is useful for planning patient education programmes because
the identification of areas with low self-efficacy helps in the targetting of self-management
to individual patients. For example, Barlow et al (2002) established that RA patients
preferred education about the disease, it's treatment and emotional issues to be dealt with
on a one-to-one basis by health professionals, a group intervention format for self-
management and exercise and relationship issues, but preferred videos for the
demonstration of aids and coping. Such information would enhance the design and
development of appropriate interventions and ensure their delivery was accurately targeted
to achieve maximum impact.
The effect of belonging to a self-help group for both psoriatic arthritis and psoriasis needs
further investigation as this may have implications for the self-management of disease.
Through such groups it may be possible to facilitate empowerment and knowledge about
PsA and treatment and enable patients to take greater control over their condition, thereby
making more efficient use of the primary and secondary care services that are available to
support them.
It must be acknowledged that small study numbers can limit the generalisation and
significance of findings, particularly those from the qualitative study. Nonetheless, this
methodology has highlighted fatigue, depression and pain as the predominant health status
impairment and provides a good springboard from which to launch further research.
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7.9 Practical Implications for Treatment
The results of the two studies presented in this thesis have implications for the treatment of
patients with psoriasis and PsA, or indeed, psoriasis.
Key issues identified in the current research concerned pain, fatigue, self efficacy, physical
and social functioning, all of which may benefit from a range of interventions.
Although the development of new 'biologic' treatments for both PsA and psoriasis
continues, their use is in their infancy, they remain expensive and are currently not
available to a large percentage of patients. Whilst health professionals continue to rely
heavily on treatments primarily based on the traditional medical model, there are a variety
of psychosocial interventions that have been shown to improve the quality of life of
patients with established disease, are generally inexpensive to administer, and which may
be used alongside traditional medical treatments.
For many people with PsA and psoriasis, managing their chronic disease is an ongoing
process, where the day-to-day care responsibilities fall most heavily on patients and their
families, and where medical interventions are focussed on minimising symptoms, such as
pain, rather than being curative.
Interactions with close family members have consequences for the emotional and physical
well-being of individuals who are dealing with chronic physical illness, which may suggest
that a logical treatment approach would be to consider the inclusion of a close family
member in psychosocial interventions that have the potential to boost the effects of
intervention on the patient, and also benefit the family member.
In the current study, patients with PsA experienced levels of pain that were detrimental to
their physical functioning and restricted their participation in other roles, including those
integral to family life, such as being a parent, managing a household, and maintaining
relationships. Although many were prescribed regular pain medication, the participants
referred to a constant awareness ofa background level of pain.
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This finding suggests there is a need for other interventions that may alleviate the
experience of pain. Indeed, evidence from the results of an education and support
intervention for osteoarthritis patients and their spouse, found that patients in the family
intervention experienced a greater gain in their efficacy for managing arthritis than patients
who received information and support with other patients, although there is contradictory
evidence from a study that utilised a family intervention where the partners (88% spouses)
attended arthritis self-management sessions with patients. Unexpectedly, the educational
program attended by patients was found to enhance self-efficacy and reduce fatigue
significantly better than the program attended by patients and partners. In fact, patients
receiving the family intervention experienced decreased self-efficacy and increased fatigue.
(Martire et al., 2003).
Whilst such studies may produce mixed results, a meta-analytic review that focused on
multiple chronic illnesses, showed that psychosocial interventions incorporating a family
member had small effects on patient depression and mortality and small to medium effects
on burden, depression, and anxiety in the family member (Martire, et al., 2004), suggesting
that family interventions have a valuable role to play.
There is undoubtedly a need to keep evaluating the efficacy of family caregiver
interventions as this will illuminate specific programmes that support and benefit the
patients and, in turn, may inform conceptual models of the impact of family interactions on
health.
As previously stated, patients living with PsA and psoriasis make day-to-day decisions
about the self management of their illness, which suggests there is a need for self-
management education which goes beyond the traditional patient-education offerings of
information leaflets. Self-management education teaches problem-solving skills and
complements traditional patient education in supporting patients to live the best possible
quality of life with their chronic condition.
A central concept in self-management is self-efficacy which is defmed as having the
confidence to carry out behaviour necessary to reach a desired goal. In the current study
self efficacy was found to be associated with physical functioning in PsA patients, whilst
in those with psoriasis it was associated with psychological functioning
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Research suggests that self efficacy is enhanced when patients succeed in solving patient-
identified problems and that this can be achieved through the use of self management
education. Moreover, there is evidence from controlled clinical trials that found
programmes teaching self-management skills are more effective than information-only
patient education in improving clinical outcomes and, that in some circumstances self-
management education improves outcomes and can reduce costs for arthritis patients
(Bodenheimer et al., 2002).
The routine measurement of self-efficacy in rheumatology and dermatology clinics may be
beneficial as it may be used to detect individual differences between patients and identify
those with low levels of self efficacy. This information may be used as an indicator to
predict important health outcomes such as health-related quality of life and even hospital
admissions, so highlighting those patients most at need of an intervention to improve their
levels of self efficacy. Changes in self-efficacy over time can be easily measured and this
facilitates the evaluation of the impact of patient education programmes.
An association was found in the current study between self efficacy and psychological
health, although anxiety and depression were also associated with decrements in both
physical and social functioning in the participants. It is possible that early screening for
such conditions may result in prescribing therapies and drugs to improve emotional
functioning and potentially impact on the levels of pain and fatigue.
It would be beneficial to highlight the importance of identifying anxiety and depression in
this clinical group with health professionals, in order that timely, appropriate treatment be
given. This is one area, where the use of an education programme with practice nurses and
'nurse prescribers' in Primary Care may be useful, as they are well placed to provide
interventions to patients with chronic conditions.
For many healthcare providers, pharmaceutical treatments may be the first choice to
manage depression and anxiety however, there is much evidence to support the use of
psychosocial interventions as an effective treatment. A systematic review of psychological
interventions was completed by Astin et al. (2002) and included a review of studies that
examined the efficacy of interventions such as relaxation, biofeedback, cognitive-
behavioral therapy and stress management. Their conclusions were based on data from 25
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randomised controlled trials that compared these interventions to non-intervention control
groups (usual medical care or waiting list). Overall, the researchers reported small, but
statistically significant, average effect sizes for pain, functional disability, depression,
coping, and self efficacy post-treatment. Additionally, after follow-up (an average interval
of 8.5 months) the effect sizes for coping, psychological status, and tender joints were
significant, whereas those for pain, disability, and self efficacy became non-significant.
It is clear that such interventions are a useful treatment and as such, their use in psoriasis
and PsA patients warrants exploration as they may provide an effective adjunct to
conventional medical management.
Similarly, cognitive-behavioural therapy (CBT) may have a role to play in improving the
psychological health of PsA and psoriasis patients. CBT addresses the links between
thoughts or beliefs, feelings and behaviours, and uses individualised goal-setting and
cognitive restructuring to help patients make desired changes in behaviour. In RA patients,
such changes have been shown to have a positive impact on psychological health, which in
turn, resulted in significant improvement in fatigue post-intervention, and at follow-up six
months later (Evers et al., 2002).
An understanding of the different contributions of depression, fatigue, and pain to health-
related quality of life may inform future interventions and advice provided to those with
PsA with a possible beneficial effect.
Social functioning emerged in the current study as an issue for the participants, and was
shown in the quantitative study to be associated with self efficacy and psychological
health. Furthermore, the participants would actively avoid social events, yet they didn't
enjoy being isolated. This finding requires further exploration as several participants
mentioned that they would feel more comfortable in a group of similar patients as they
would be sympathetic and understanding. This suggests that interventions that employ a
group format may be an appropriate strategy for this clinical group.
Psychosocial and psychological interventions have been delivered in individual as well as
group formats, with each offering the potential of providing different benefits. A group
format may provide a context to normalise patient experiences and to benefit not only from
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interaction with a designated group leader, but also from the experience of other patients,
whilst also gaining the social support provided by the group members. This contrasts with
the benefits associated with individual interventions which offer the opportunity to
specifically tailor interventions to the needs of the individual patient and to intervene
intensively with that patient (Bracke & Thoresen 1996).
It is clear from this research that negative emotions and loss impact greatly on the patients
and their families, yet it seems that during clinic visits, there is little offered in the way of
support, particularly emotional support. The specialist rheumatology nurses that are usually
present in clinic are ideally placed to provide support through empathic listening, yet the
results of this study suggest that patients are reluctant to discuss issues, firstly because they
feel it is not appropriate to seek support, and secondly because they fear they are wasting
the nurses' time. In order to overcome these barriers nurses need to develop a trusting
relationship with the patient and to this end may benefit from the acquisition of counselling
skills. Once the dialogue is open, nurses should be able to assist in identifying suitable pain
management strategies, the development of healthy coping skills and the management of
negative outcomes of the disease process, such as increasing disability and deformity.
The participants in the current study have emphasised the need in Secondary Care for more
clinical time to be made available for multidisciplinary care that optimises patient
outcomes. What is more, undergraduate and postgraduate medical education needs to
reflect the prevalence and importance of psoriasis and PsA in the population so that, in
future, they can identify and manage these conditions, whilst consultants and specialists
need to embrace the new concepts and array of possible interventions that may be used in
effectively managing these diseases.
In a world that is constrained by health economics, easy access to a multi-disciplinary team
of health professionals may be a distant vision, yet may prove to be the best answer to
improving the health-related quality of life for people with PsA and psoriasis; consultants,
nurses, physiotherapists, occupational therapists and counsellors all have a role to play.
PsA and psoriasis are complex, multi-faceted diseases which require multi-faceted answers
and therapeutic decisions should be based on thorough assessments that include health-
related quality of life.
175
7.10 ConcludingComments
Whilst recognising that there is no one best method of research, the inference from this
study is that it is the combined data from rheumatologists, dermatologists, clinical
measures, health-care professionals and patients that should be utilised to impact positively
on health status and prognosis in patients with PsA and psoriasis.
Through the use of mixed methodology this PhD research has firstly, by means of a
qualitative study, identified, from the perspective of those patients with PsA and psoriasis,
psychosocial issues that were perceived to be detrimental to their quality of life. A
quantitative study then proceeded to employ standardised psychometric instruments m
order to investigate the impact of these variables and assess their role.
While acknowledging that qualitative research findings should not be generalised, the areas
of concern highlighted are noteworthy. In addition to fatigue, pain and depression and self
efficacy, concerns emerged that related to the uncertainty imposed by the disease due to
limitations in both the treatment and understanding of disease aetiology. Also, disease
unpredictability was viewed as impacting on fatigue and pain levels that in tum were
reported to affect numerous daily activities, role competencies, dependency levels and
relationships.
The impact of living with psoriasis and PsA has been highlighted in the current study and
furthermore, the burden of disease has been shown to be different, depending on whether
patients have psoriasis and PsA or just psoriasis.
The results of this study contribute to the current understanding that pain is a complex
phenomenon that is capable of pervading every aspect ofa person's life. Whilst it was not
unexpected that pain emerged as a major symptom in patients with PsA and psoriasis, the
qualitative study certainly revealed the far-reaching impact that pain can have. There is
little doubt that in this patient group, it cannot be viewed as a stand-alone symptom as it is
implicated in, and affected by, a variety of other factors such as mood and fatigue.
Fatigue continues to defy efforts to conceptualise or define it and typically remains ignored
or excluded from the assessment of symptom severity or outcome in many disease
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processes including PsA and, given that it is consistently neglected as a target for
treatment, it is not surprising that little is known about the phenomenology of fatigue.
This study has found that patients with PsA perceive fatigue to be an untreatable symptom,
and that they generally fail to express their concerns about it to their health carers. It is a
subjective symptom, meaning the only way that health professionals can understand the
patient's experience of fatigue, is by listening to their patient and exploring their concerns.
It is therefore of paramount importance that health professionals are aware of fatigue and
the impact and consequences it can have on the daily lives of those it affects.
These fmdings have highlighted the need to elucidate the symptom of fatigue in PsA and
position it as an appropriate target not only for clinical management, but also psychological
management. By advocating fatigue as a legitimate concern this may offer patients the
chance to discuss fatigue explicitly and obtain appropriate health advice.
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Appendix 1
Audio & questionnaire consent Forms
SUPPLEMENTARY CONSENT FORM FOR AUDIO TAPING
Title of project: Quality of life in people with psoriasis and psoriatic arthritis
Narne of researcher: Cathy Aitken
Please initial box
1. I confirm that I have completed the consent form to participate in the above
had the opportunity to ask questions
study and
2. I understand that interviews and focus groups will be audio taped and that
the tapes have been transcribed they will be destroyed.
3. I agree to the audio taping of my focus group.
as soon as
4. I understand that my participation is voluntary and that I am free to
withdraw at any time, without giving any reason, without my medical
care or legal rights being affected.
5. I agree to take part in the above study
Name of Patient Date Signature
Name ofperson taking consent
(if different from researcher)
Date Signature
Researcher Date Signature
1 copy for patient, 1copy for researcher, 1copy to consultant
Audio tape consent form, Version 1 (06/06/05)
Appendix 2
Participant invitation letter & questionnaire consent form
Aintree University Hospitals '~l:kj
NHS Foundation Trust
Dear Psoriasis Association Member,
The Psoriasis Association has sent the enclosed questionnaire to you, as they are assisting me,
Mrs Cathy Aitken, with PhD research entitled 'Psoriasis and Psoriatic Arthritis: The role and
impact of psychosocial factors'.
It is anticipated that this research will enhance our understanding of the ways in which these
conditions may impact on quality of life.
I have enclosed a full participant information sheet for you to read, however, if you have any
questions please do not hesitate to contact me.
May I take this opportunity to thank you in advance for assisting with this valuable research.
Yours faithfully,
Mrs Cathy Aitken
PhD Student
Liverpool John Moores University
Room 303b Henry Cotton Bldg
15-21 Webster Street
Liverpool
L32ET
Aintree University Hospitals '~/:bj
NHS Foundation Trust
CONSENT FORM
Title of Project: Quality of life in people with psoriasis and psoriatic arthritis
Name of Researcher: Cathy Aitken, Liverpool John Moores University.
Please tick box
1. I confirm that I have read and understand the information sheet dated 08/12/06
(Version 1) for the above study and that full details of the projecUprocedure have been
described in writing.
D
3.
I understand that my participation is voluntary and that I am free to withdraw at any time, D
without giving any reason, without my medical care or legal rights being affected.
I understand that any information I may provide to the researcher will be kept confidential D
and secure in accordance with ethical guidelines of the British Psychological Society, and
furthermore that my name will not be linked to any data used in publications or research
reports arising from this study.
2.
~ 4. I agree to take part in the above study. D
Date SignatureName of Participant
Witness (an independent third party) Date Signature
1 copy for participant, 1 to be returned to researcher with questionnaire pack
Psoriasis Association Participant consent form Phase 2, Version 1 (08/12/06)
Appendix 3
Participant information Sheet
Aintree University Hospitals '~l:~j
NHS Foundation Trust
Participant Information Sheet
Quality of Life in people with psoriasis and psoriatic arthritis
You are being invited to take part in a research study looking at quality of life in people with
psoriasis and psoriatic arthritis. Before you decide, it is important for you to understand why
the research is being done and what it will involve. Please take time to read the following
information carefully and discuss it with friends, relatives and your doctor if you wish. Ask us
ifthere is anything that is not clear of if you would like more information. Take time to decide
whether or not you wish to take part.
Why have I been chosen? This study is intended for people who have been diagnosed with
psoriasis or psoriatic arthritis (or both).
Who is doing this research? The study is being carried out by researchers from Liverpool
John Moores University and Aintree Hospital. If after reading this information you have any
questions at all about the study, please contact Cathy Aitken (0151 231 411 0) who will be
pleased to discuss any aspect of the study with you.
What is it about? As health professionals we understand that psoriasis and psoriatic arthritis
can sometimes affect the quality of many aspects of your daily life (such as work life, social
life, leisure activities etc). As we routinely measure the impact of these conditions it is
important that we continue to measure the aspects that affect you most. In order to do this we
are looking for patients to complete a questionnaire booklet.
What will I have to do if I take part? If you decide that you would like to take part in this
research all that you will have to do is complete the enclosed questionnaire that will take
approximately twenty minutes.
Who will see the information I give? The research team will use any information you give
for the purposes of the project only; it will not be passed on to any other agencies. All
information given will remain strictly confidential. All data will be destroyed once the
research is complete.
Will my decision affect the treatment I am getting already? No. Participation in this
research is entirely voluntary and you are free to withdraw at any time. Your decision to take
part or not will have no effect whatsoever on the care you receive from your consultant or the
NHS.
What do I have to do next? If you have decided that you would like to take part, all that you
have to do is sign the two consent forms (retain one copy for you own records), complete the
questionnaire booklet and return them to the research team at the university in the FREEPOST
envelope enclosed (No stamp needed).
How can I get further information? If you have any questions or would like to discuss any
aspect of this research, please contact Cathy Aitken on 0151 231 4110 or by email at
cathyaitken@hotmail.com or at the following address: Room 303b, Henry Cotton Building,
15-21 Webster Street, Liverpool, L3 2ET.
Indemnity: If you are harmed by taking part in this research project, there are no special
compensation arrangements. If you are harmed due to someone's negligence, then you may
have grounds for legal action but you may have to pay for it. Regardless of this, if you wish to
complain about any aspect of the way you have been approached or treated during the course
of this study, the normal National Health Service complaints mechanisms may be available to
you.
Consumers for Ethics in Research (CERES) publish a leaflet entitled 'Medical Research and
You'. This leaflet gives more information about medical research and looks at some questions
you may want to ask. A copy can be viewed online at www.ceres.org.uk.
Thank you for taking the time to read this information.
Psoriasis Association Participant information sheet, Phase Il, Version 1 (08/12/06)
Appendix 4
Questionnaire Booklet
Aintree University Hospitals h'l:kj
NHS Foundation Trust
Please complete the following questions in order to
provide us with some background information:
Study No: _
Age: _
Gender: Male 0 Female 0
Marital Status: Married 0 cohabiting 0 Divorced 0 Single 0
Employment Status (please tick appropriate box):
Full Time 0 Part Time 0 Unemployed 0 Homemaker 0 Student 0
Retired 0 Unable to work due to either psoriatic arthritis 0 and/or psoriasis 0
If employed, what is your job? _
If previously employed, what was your job? _
What educational/professional qualifications do you have? (Tick all boxes that apply to
you)
None 0 CSE/ '0' Levell GCSE 0
'A' Levell GNVQ/ NVQ/City & Guilds 0 Graduate 0 Postgraduate 0
How would you best describe your ethnic origin? (Tick box)
White 0 Black 0
Asian
0African Indian
Caribbean 0 Pakistani 0
Black Other Bangladeshi 0
(please state) Chinese 0
Asian Other
(please state)
If none of the above accurately describe your ethnic origin please
provide your own description:. _
Phase II Demographic data sheet, Version 1 (08/12/06)
9. Please state how many years/months you have had a diagnosis of:
(If you can't remember exactly, state approximately how many years/months)
Psoriatic Arthritis: _ Psoriasis: ----
10. Please state below all the treatment you currently use for
your psoriatic arthritis e.g, medicines prescribed by your
consultant or doctor (include doses if possible), over the
counter medicines, TENS machine, acupuncture,
physiotherapy etc...
11. Please state below all the treatment you currently use for your
psoriasis e.g. medicines prescribed by your consultant or doctor
(include doses if possible), over the counter medicines etc.
12. Have you ever visited any other type of therapist for your pain?
e.g. physiotherapist, osteopath, acupuncturist, masseur?
Yes D No D
If yes, please give brief details (e.g. type of therapist, number of visits,
did the therapy help reduce your pain etc•.)
Phase II Demographic data sheet, Version 1 (08/12/06)
SEMen
We would like to know how confident you are in doing certain activities. For each of the
following questions, please circle the number that corresponds to your confidence that
you can do the tasks regularly at the present time.
1. How confident are you that you can
keep the fatigue caused by your disease
from interfering with the things you want
to do?
2. How confident are you that you can
keep the physical discomfort or pain of
your disease from interfering with the
things you want to do?
3. How confident are you that you can
keep the emotional distress caused by
your disease from interfering with the
things you want to do?
4. How confident are you that you can
keep any other symptoms or health
problems you have from interfering with
the things you want to do?
5. How confident are you that you can do
the different tasks and activities needed to
manage your health condition so as to
reduce you need to see a doctor?
6. How confident are you that you can do
things other than just taking medication
to reduce how much you illness affects
your everyday life?
not at all I I I I I I I I I I totally
confident 1 2345 67 8910 confident
not at all I I I I I I I I I I totally
confident 1 2 3 4 5 6 7 8 9 10 confident
not at all I I I I I I I I I I totally
confident 12345678910 confident
not at all I I I I I I I I I I totally
confident 1 2 3 4 5 6 7 8 9 10 confident
not at all I I I I I I I I I I totally
confident 12345678910 confident
not at all I I I I I I I I I I I totally
confident 12345678910 confident
The following questions ask for your views about your health, how you feel and how well you are able to do your
usual activities. If you are unsure about how to answer any questions please give the best answer you can and
make any of your own comments if you like. Do not spend too much time in answering, as your immediate
response is likely to be the most accurate.
1. In general, would you say your health is:
Excellent Very Good Good Fair Poor
2. Compared to one year ago, how would you rate your health in general now?
(mark one box)
Much better now than 1 year ago
Somewhat better now than 1 year ago
About the same
Somewhat worse now than 1year ago
Much worse now than 1 year ago
3. The following questions are about activities you might do during a typical
day. Does your health now limit you in these activities? If so, how much?
(Mark one box on each line.)
a) Vigorous activities, such as running, lifting heavy
objects, participating in strenuous sports
b) Moderate activities, such as moving a table, pushing a
vacuum cleaner, bowling, or playing golf.
c) Lifting or carrying groceries
d) Climbing several flights of stairs
e) Climbing one flight of stairs
f) Bending, kneeling, or stooping
g) Walking more than a mile
h) Walking half a mile
i) Walking 100 yards
j) Bathing and dressing yourself
Yes, Yes, No, not
limited limited limited
a lot a little at all
c=J C:=J C:=J
c=J C:=J C:=J
C:=J C:=J CJ
c=J c=J CJ
c=J CJ c=J
c=J c=J c=J
c=J c=J c=J
c=J c=J CJ
c=J c=J c=J
CJ CJ c=J
4. During the past 4 weeks, have you had any of the following problems with your
work other regular daily activities as a result of your physical health? (Mark one
box on each line.)
Yes No
a) Cut down the amount of time you spent on work or c=:J
other activities c=:J
b) Accomplished less than you would like
c) Were limited in the kind of work or other activities c=:J c=:J
d) Had difficulty performing the work or other activities
(for example, it took extra effort) c=:J c=:J
5. During the past 4 weeks, have you had any of the following problems with
your work or other regular daily activities as a result of any emotional problems
(such as feeling depressed or anxious)? (Mark one box on each line)
Yes No
a) Cut down the amount of time you spent on work
or other activities c=:J c=:J
b) Accomplished less than you would like
c) Didn't do work or other activities as carefully as c=:J c=:J
usual
6. During the past 4 weeks, to what extent has your physical health or
emotional problems interfered with your normal social activities with
family, friends, neighbours, or groups? (Mark one box)
Not at all0 Slightly 0 Moderately 0 Quite a bit 0 Extremely 0
7. How much bodily pain have you had during the past 4 weeks? (Mark one
box.)
None 0 Very Mild 0 Mild 0 Moderate 0 Severe D Very Severe 0
8. During the past 4 weeks, how much did pain interfere with your normal
work (including both work outside the home and housework)? (Mark one box.)
Not at all 0 Slightly 0 Moderately 0 Quite a bit 0 Extremely 0
9. These questions are about how you feel and how things have been with you
during the past month. (For each question, please give the one answer that
comes closest to the way you have been feeling)
(Please mark one box on each line)
How much time during
the last month:
All Most A good Some A little None
of the of the bit of of the of the of the
time time the time time
a) Did you feel full of life?
b) Have you been a very nervous
person?
Cl
Cl
Cl
Cl
c) Did you feel so down in the
dumps that nothing could cheer
you up?
d) Have you felt calm and peaceful?C1 Cl
Cl Cl
e) Did you have a lot of energy? Cl Cl
t) Have you felt downhearted and
blue?
Cl Cl
g) Did you feel worn out? Cl Cl
h) Have you been a happy person? Cl Cl
i) Did you feel tired? Cl Cl
Cl
Cl
Cl
Cl
Cl
Cl
Cl
Cl
Cl
Cl
Cl
Cl
Cl
Cl
Cl
Cl
Cl
Cl
time time
Cl
Cl
Cl
Cl
Cl Cl
Cl Cl
Cl Cl
Cl Cl
Cl Cl
Cl Cl
Cl Cl
10. During the past 4 weeks, how much of the time has your physical health or
emotional problems interfered with your social activities (like visiting friends,
relatives, etc.)?
All of the time
Most of the
Some of the
A little of the
None of the
time
time
time
time
11. How TRUE or FALSE is each of the following statements for you?
Definitely Mostly Don't Mostly Definitely
True True Know False False
a) I seem to get sick a little easier than D D D D D
other people know D D D D Db) I am as healthy as anybody I know
c) I expect my health to get worse D D D D D
d) My health is excellent D D D D D
The aim ofthese questions is to measure how much your skin problem (psoriasis) has affected
your life OVER THE LAST WEEK. Please tick one box for each question.
1. Over the last week how itchy, sore, painful, or stinging has your skin been?
Very much
A lot
A little
Not at all
2. Over the last week, how embarrassed or self-conscious have you been because of
your skin?
3. Over the last week how much has your skin interfered with you going shopping or
looking after your home or garden?
~ Not relevant
Very much
A lot
A little
Not at all
Very much
A lot
A little
Not at all D
4. Over the last week how much has your skin influenced the clothes that you wear?
i~:;;much ~
A little
Not at all Not relevant D
5. Over the last week how much has your skin affected any social or leisure
activities?
Very much
A lot
A little
Not at all ~ Not relevant D
6. Over the last week, how much has your skin made it difficult for you to do any
sport?
~el:;much ~
A little D
Not at all Not relevant
7. Over the last week has your skin prevented you from working or studying?
Yes
No B Not relevant D
If"NO" - over the past week how much has your skin been a problem at work or
studying?
A lot
A little
Not at all
8. Over the last week, how much has your skin created problems with your partner
or any of your close friends or relatives?
Very much
A lot
A little
Not at all ~ Not relevant D
9. Over the last week, how much has your skin caused any sexual difficulties?
~~:;much ~
A little
Not at all Not relevant D
10. Over the last week, how much of a problem has the treatment for your skin
been, for example, by making your home messy, or by taking up time?
Very much
A lot
A little
Not at all Not relevant D
FSS-SD
The Fatigue Severity Scale (FSS) is a method of evaluating the impact of fatigue on you.
The FSS is a short questionnaire that requires you to rate your level of fatigue.
The questionnaire contains nine statements that rate the severity of your fatigue
symptoms. Read each statement and circle a number from 1 to 7. based on how
accurately it reflects your condition during the past week and the extent to which you
agree or disagree that the statement applies to you .
• A low value (e.g., 1) indicates strong disagreement with the statement, whereas a high value
(e.g., 7) indicates strong agreement .
• It is important that you circle a number (1 to 7)for every question.
During the past week, I have found that: disagree <--------> Agree
My motivation is lower when Iam fatigued. 1 2 3 4 5 6 7
Exercise brings on my fatigue. 1 2 3 4 5 6 7
Iam easily fatigued. 1 2 3 4 5 6 7
Fatigue interferes with my physical functioning. 1 2 3 4 5 6 7
Fatigue causes frequent problems for me. 1 2 3 4 5 6 7
My fatigue prevents sustained physical functioning. 1 2 3 4 5 6 7
Fatigue interferes with carrying out certain duties
1 2 3 4 5 6 7
and responsibilities.
Fatigue is among my three most disabling
1 2 3 4 5 6 7
symptoms.
Fatigue interferes with my work, family, or social
1 2 3 4 5 6 7
life.
Total Score (office use only): _
HAQ-DI
In this section we are interested in learning how your illness affects your ability to function in
daily life.
For each statement, please tick one box that best describes your usual abilities over the
past week.
Without ANY With SOME With MUCH UNABLE
difficulty difficulty difficulty to do
Dressing & Grooming
Are you able to:
-Dress yourself, including
r==Jtying shoelaces & doing c=:::J c=:::J c=:::J
buttons?
- Shampoo your hair? r=J c=:::J c=:::J c=:::J
Arising
Are you able to:
- Standup from a straight r=J c=:::J c=:::J c::=Jchair?
- Get in & out of bed? r=J c=:::J c=:::J c=:::J
Eating
Are you able to:
- Cut your meat? r=J c=:::J c=:::J c=:::J- Lift a full cup or glass to r=J c=:::J c=:::J c=:::Jyour mouth?
- Open a new milk carton? r=J c::=J c=:::J c::=J
Walking
Are you able to:
-Walk outdoors on flat ground? r=J c::=J c=:::J c::=J
- Climb up five steps? r=J c::=J c::=J c=:::J
Hygiene
Are you able to:
r=J r=J c=:::J-Wash & dry your body? c=:::J
- Take a bath? c=:::J r=J c=:::J c=:::J
- Get on & off the toilet? c=:::J r==J c=:::J c=:::J
(Contd ... For each statement, please tick one box that best describes you usual abilities
over the past week)
Without ANY With SOME With MUCH UNABLE
difficulty difficulty difficulty to do
Reach
Are you able to:
- Reach & get down a 5 lb
object from just above your
head?
- Bend down to pick up
clothing off the floor?
Grip
Are you able to:
- Open car doors?
- Open jars that have been
previously opened?
- Turn taps on & off?
Activities
Are you able to: c:=J c:=J c:=J c:=J- Run errands & shop?
- Get in & out of a car? c:=J c:=J c:=J c:=J
- Do chores such as vacuuming, c:=J c:=J c:=J c:=Jhousework or light gardening?
Please tick any aids or devices that you usually use for any of these activities:
Cane D Walking frame D
Built-up or special utensils D
Crutches D Wheelchair D
Special or built-up chair 0 Raised toilet seat D Bath seat D Bath rail 0
Long-handled appliances for bathroom D Jar opener (for jars previously opened) 0
Long-handled appliances for reach D Devices used for dressing (button-hook, zipper-pull,
Shoehorn) 0
Other aid/device (please specify) _
Please tick any categories for which you usually need help from another person:
Dressing & Grooming D Eating D Rising 0 Walking D
Gripping & opening things D Errands & housework D
Hygiene D Reach 0
The scales below are for you to let us know how much pain you are experiencing.
Please place an 'X' through the number that best describes how much pain you are
experiencing. (1- no pain, 10 - worst possible pain):
Please rate the average level of pain you are experiencing TODAY
No pain at all Worst possible
pain
Please rate the average level of pain you have experienced during the
LAST WEEK
No pain Worst possible
pam
Pain NRS, Version 1 (08/12106)
HADS
This questionnaire is designed to help us understand how you feel. Read each item and
place a tick in the box opposite the reply that comes closest to how you have been feeling
in the past week. Don't take too long over your replies: your immediate reaction to each
item will probably be more accurate than a long thought-out response.
Tick only one box in each section
I feel tense or wound up:
3 Most of the time
2 A lot of the time
1Time to time
o Not at all
I still enjoy the things I used to enjoy:
o Definitely as much ~
INot quite so much
2 Only a little
3 Hardly at all
I get a sort of frightened feeling as if something
awful is about to happen:
3 Very definitely and quite badly ~
2 Yes, but not too badly
1A little, but it doesn't worry me
, 0 Not at all
I feel as if I am slowed down:
3 Nearly all the time ~
2 Very often
1 Sometimes
o Not at all
I get a sort of frightened feeling like butterflies in
the stomach:
o Not at all
1Occasionally
2 Quite often
3 Very often
I have lost interest in my appearance:
3 Definitely
2 I don't take so much care as I should
1 I may not take quite as much care
o Itake just as much care as ever
I can laugh and see the funny side of things:
o As much as Ialways could ~
INot quite as much now
2 Definitely not so much now
3 Not at all
Worrying thoughts go through my mind:
3 A great deal of the time
2 A lot of the time
1From time to time but not too often
o Only occasionally
i I feel cheerful:
3 Not at all
2 Not often
1Sometimes
o Most of the time
I can sit at ease and feel r~d:
o Definitely
I Usually
2 Not often
3 Not at all
·I feel restless as if I have to be on the move:
I 3 Very much indeed ~
2 Quite a lot
1Not very much
· 0 Not at all
I look forward with enjoyment to things:
o As much as ever Idid EJ
1 Rather less than I used to
· 2 Definitely less than I used to
I 3 Hardly at all
I get sudden feelings of panic:
3 Very often indeed
2 Quite often
INot very often
o Not at all
-
-
I can enjoy a good book or radio or TV
programme:
o Often
1 Sometimes
2 Not often
3 Very seldom
Appendix 5
Interview Schedule
Interview Schedule
1) Can you recall how you felt about a diagnosis of psoriatic arthritis?
2) Were you aware of the condition before you were diagnosed?
3) What sort of symptoms do you experience?
4) How have these impacted on aspects of your life?
5) Have you found your own way of coping with the symptoms?
6) What was/has the reaction been from your friends and family?
7) Do you feel supported by friends and family?
8) What sort of treatments do you use?
9) How have your daily activities and social life been affected?
10)How do you feel about the future?
Appendix 6
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Appendix 7
Example of Interview Transcript
;1
1 INTERVIEW 1
2
3 I: When you think back, 11years is quite a long time isn't it, but can you recall
4 howyou felt at the time about a diagnosisof psoriatic arthritis?
5 P: It was a surprise because it was just a pain in the knee, that's all, and I thought I
6 had just damaged my knee but the doctor said "oh, you've got arthritis" but he
7 wasn't really sure, you know, what type it was atfirst, when I went to the hospital
8 then they found out once they'd done the blood tests and that
9 I: Andwere you aware of the condition at all?
10 P: No
11 I: Did you have the psoriasis first?
12 P: Yeah. since [was 15
13 I: Right, but you didn't ••youweren't aware that you could get arthritis with it?
14 P: No, they don't tell you
15 I: So it was quite a surprise then?
16 P: Yeah
17 I: And did you feel it had been quite well explainedonce they had diagnosed it
18 and sort of told you how the condition affected people?
19 P: Yeah, but they said to me it wouldn't spread, they said it would probably stay in my
20 knee ... it wouldn't spread but it's in virtually every joint now
21 I: Is it?
22 P: Yeah
23 I: Soyou're feelingquite immobolised?
24 P: Yeah, it's ruined my lifo..that's it now ..that is my life..really quick
25 I: Really, it's altered you that much?
26 P: Yeah. (Cries)
27 I: Don'tworry .•.OK.. and that's in the space ofll years•.and did that begin
28 fairly quickly?
29 P: urmm.. not at first, first it was my knee .. it was fine, but the last few years (cries)
30 I: It's ok..it's to be expected••ifyou're happy to keep going that's fine, but if you
31 want me to stop just shout, no worries
32 P: ljust feel stupid!
33 I: So to beginwith, the first fewyears, you felt youwere okwith it and that you
34 were copingwith it and then did it..did you get a sudden flare-up or..
35 P: Thefirst few years it was just like my knee, that was the first to go, after that it
36 Started gradually going to other joints like my ankles
37 I: Andwhat about the impact of that on your ...on your sort of day-to-day life,
38 your daily routine if you like?
39 P: Well sometimes [ get up in the morning and I can't move ..it takes me hours to get
40 Moving, I panic about going out now, urmm, I'm tired all the time
41 I: Are you tired becauseyou don't sleep, has it affectedyour sleeppattern?
42 P: It's both ... think all the medication ..I'm on quite a lot of medication and that makes
43 me sleepy, I can't sleep, as soon as you get to sleep and you turn over you're
44 waking up again
45 I: So it's the pain that actually disturbs your sleep?
46 P: Yeah
47 I: OK, so that's obviouslymaking you feelvery tired, so in terms of your day-to-
48 day life,were youworkingwhen youwere diagnosed?
49 P: No, I'd been with the children, one is now 17and one is 11.
1
50 I: Right, so you'd had the youngest when you were diagnosed?
51 P: Yeah
52 I: So have you not worked since?
53 P: No
54 I: And do you feel that you'll be able to work at aU?
55 P: Not at the moment, 'cos I can't stand for long periods oftime ...I'm not too bad
56 sitting down ... it's in my wrists and my hands so ...mean I'd love to, it's the one
57 thing I'd love to do, I'd give up everything, if I could
58 I: How does it make you feel, the prospect of not perhaps being able to work
59 Again?
60 P: Scared
61 I: Scared? In what sense?
62 P: Useless
63 I: So it makes you feel useless and scared?
64 P: Yeah ... (Cries)
65 I: Are you OK, sure, do you want me to stop?
66 P: No
67 I: Umm, so it's had quite a major impact do you feel on your lifestyle?
. 68 P: Yes
69 I: And how about aside from work, in your d~iIy activities that you might do
70 with kids or whatever?
71 P: You can't, you know, they want to gofor days out or that, you can't 'cos you can't
72 walk
73 I: So you wouldn't be able to go out and walk with them for any great distance
74 or •••
75 P: No, no
76 I: Is that because of the pain or the tiredness?
77 P: It's the pain
78 I: So how about the treatments for pain, do you try and take something to lessen
79 it?
80 P: I'm on painkillers, strong painkillers, I'm supposed to take eight a day, but I take
81 More
82 I: Eight a day? And do they help, I mean do you get relief?
83 P: They take the edge of it, but it's like taking smarties, once you get used to them
84 I: .So you're learning to live with the pain?
85 P: I have days when I know what to do and what not to do
86 P: Have you got any examples of that, of the different ways you've adapted?
87 P: If it's bad, then going up the stairs I go up on my bum, you find ways, of like,
88 coming down the stairs, I can't come down forwards, I have to come down
89 sideways, I can't run, I can't get on the floor, I can't get on the floor and play with
90 the kids and that
91 I: Is that because your joints won't bend?
92 P: It's too painful, can't get yourself back up, sometimes when I can't get myself out
93 of bed, 'cos you just, it's like you sieze up, you know ifyou're in one position too
94 long
95 I: Have you found any way of coping with that, maybe anything alternative?
96 P: I've got a TENS machine
97 I: And how's that, does that give you any sort of relief? .
98 P: Sometimes, it depends on the pain, sometimes it will work but other times, you just
99 have to learn how to move your body. I think the worst of it is the way people think
2
100 about it..they think your age, you can't have arthritis it's an old people's disease,
101 like sometimes when I take my daughter to school they think I've been drinking, you
102 know because of my balance?
103 I: Yeah, how did that make you feel?
104 P: Annoyed
105 I: That they could actually think that?
106 P: Yeah I wouldn't mind if I could drink, I can't drink (laughs)
107 I: Have you felt you've had quite a lot of negative reaction from other people?
108 P: I find that when you first tell them they don't think it's that bad because of your
109 age and all that, but then when you explain to them they sort of, they just get used
110 to it and they forget about it then, it's awful, everyone wants to help at first, then
III nothing
112 I: So is that a sense ofwhen you initially get told what the diagnosis is, you have
113 that 'honeymoon' period when people are helping and coming around and
114 then that stopped, and has that left you feeling isolated or.•
115 P: Yeah 'cos people can't understand that you are limited inwhat you can do and
116 they'll phone up and say we're having a night out, do you want to come out, but
117 you can't, you can't do it
118 I: So in terms of your sociallife that's ...
119 P: I haven't got one
120 I: Not at all?
121 P: No
122 I: And did you before?
123 P: Yeah, yeah
124 I: I know it's difficultwhen you've got young kids, but you did have a social
125 life?Have you still got the motivation, I mean would you like to go out and
126 have a social life?
127 P: Oh yes, yes, but you feel like you're spoiling it for everyone else, you know because
128 you can't last
129 I: Haveyou not found a way to think about maybe going out for a coupleof
130 Hours or..
131 P: Yeah, but everyone seems to make a night of it don't they? Then you've got to
132 say" I've got to go home", or like everyone's drinking but like you can't or they're
133 - up dancing and you're just left, you know what I mean? (cries). I sound like a sad
134 case don't I?
135 I: Not at alJ.So from your point of view,you would say the impact has been
136 total, both on your social life and certainly on your prospect of employment at
137 the moment?
138 P: No employer will touch you when you've got arthritis, who wants you when you've
l39 got to go to the hospital, get your bloods done, you're going to take bad one day,
140 they're not going to give you ajob
141 I: Is that sort of a regular occurrence, you having to goweekly to the hospital
142 for blood tests or injections or something?
143 P: Erm..every 4 or every 2 weeksfor blood tests depending on how high my levels
144 are,for Dr Tompson it's usually every next available appointment every 3 or 4
145 months. I have to do the injections myself
146 I: Howdo you copewith that, is it quite difficult to do?
147 P: It's more nerve-racking than anything
148 I: Had you ever done anything like that before?
149 P: No
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I: So have they taught you how to do it?
P: You get a nurse a nurse outfor one day, I've only been on them two months
I: Are you coping with that alright?
P: Gotto
I: Is that how you feel, you've just got to get on with it?
P: Got to, I'll try anything. I've tried virtually all the medications and they workfor
the first three months and then stop
I: So the injections that you're on, do you have the option of going into the
hospital to have them, or have they said you take control of it and you do
them?
P: I can get a nurse to come out and give me them, but that means I have to sit and
wait, you know, incase something did come up and I did have to go out, it would
mean I'd be tied in
I: So this way you feel you're at least slightly in control of your own medication?
P: Yeah
I: And do you feel immediate benefit from the injection or is there a time delay
P: They said it could take up to three months
I: To get any benefit?
P: Yeah
I: And how often do you have to inject your~elf?
P: At the moment it's only once every three weeks but it could go to once every week
I: Right, and how about any sort of physical therapy, do you have anything like
massage or anything like that?
P: No, I couldn't bear people touching me
I: You couldn't?
P: No. it's too sore
I: So you're solely reliant on your injections and your painkilling tablets
P: Well, how about, in terms of your children it's obviously had quite an impact, how
about with your husband, how's that sort of affected .. is he still able to go out and
socialise?
P: Yeah, I make sure he does. I find I'm making excuses 'though now, you
know, like if I know there's a family party coming up I try my hardest to get
out of it, or if I know I've got to go out say to the shops the next day or go &
do something the next day, it's like I want to go out, but I'm trying to make
excuses not to go out, if I can find some way of not going out ...
I: What, you do what you can to avoid it?
P: Yeah.
I: You mention there about going out to the shops••is that like you'd avoid going
out to a party or something because you're trying to make sure you're fit
enough to be able to go& do shopping or something the day after ••if you did
both would you not be able to do anything?
P: I don't like people seeing me like this ..you know, like struggling to walk or "oh Sue
why aren't you drinking" or "Sue have a drink" all of the time ..it's like it's not
Sue anymore, it's Sue with arthritis. They don't say "Hiya Sue ",it's "Hiya Sue,
how's your arthritis" or "what tablets are you taking now" or ...you know, that's
not just Sue.
I: So you feel it's not you that they're looking at? I'm getting a sense that you
feel your identity has gone?
P: Totally (cries)
I: I can see that this is obviously very upsetting for you and wonder if you've
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spoken to your friends, good friends maybe, about ••
P: You can't explain it to them
I: People don't understand?
P: I think it's hard to explain how difficult it is to someone because they haven't been
through it
I: So there is a feeling of isolation & being away from your friends
P: Ohyeah
I: Well how about your husband, do you feel the same way.,
P: He does understand about it, because his family, some have arthritis .., he's lived
with it 'cos his cousin had psoriasis so it's not unusual
I: So he's a bit more tuned in to it & the impact it can have
P: Yeah
I: How about everyday activities like cooking, you know sort of things we aD
take for granted, everyday activities?
P: I can do like light stuff, can't lift any heavy pans & that, it's dangerous
I: What, because you haven't got the strength to ••
P: l've got no strength in my wrists, not to lift heavy pans, I can do a sandwich or that
I: So if you're cooking a family meal can you cope to do ••
P: I will ask my daughter or my husband, I try to do as much as I can, but I will ask
them, say will you move this for me, I can't do it or
I: How does that make you feel as, sort of,"'as a mum?
P: Useless ...useless, you feel like you're constantly asking people to help, like a child
I: And is that quite a difficult thing to do, ask for help?
P: I've just got used to it no, but I won't ask anyone outside the house
I: So it's just your family?
P: Just my husband & daughter, I couldn 't lower myself to ask anyone
I: Why would you feel it was lowering yourself to ask for help?
P: Because I shouldn't need to ask, 38, you shouldn't be asking for help should you?
I: Is that how you feel? Is it because you're 38, do you think ifyou were 68 you'd
think it was part & parcel of life?
P: Yeah
I: So it's kind of linked in to being a young woman?
P: I think, even when I go to the hospital I think it's mostly old people, but they look at
you as if to say " what are you doing here, you shouldn't be here, there's nothing
wrong with you ", it's just the way everyone views it, I think it's drummed in to you
that it's an old person's disease.
I: And yet you know it isn't. Is there a sense that people should know more, do
you think we're lacking in perhaps making it more, sort of creating awareness
that these conditions can affect younger people?
P: Yes, 'cos everyone I've told, no-one, no-one knew it could affect someone so
young.
I: Do you feel that they're not believing you?
P: Oh, they believe me now, but I think at the beginning it was just "oh, you've got
something wrong with your knee" so it was nothing drastic, It's like my doctor,
my GP, when I went to see him I said "I've got a pain in my knee, I can't kneel
down or anything" he said, "what do you want to kneel down for, get on with it,
it's not the be all & end all "
I: So did you feel you were a bit dismissed by him? ,
P: It's ../'m not important. But how are you supposed to do your cleaning & that if
you can't kneel down? You don't realise how important being able to get on the
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floor & that is, bending your knees & that, you seem to start understanding then,
you know how important your joints are & that, like getting in & out of the bath is
simple for anyone else, but it's a nightmare
I• So have you had to adapt things like that, do you walk in to a shower now as• ?opposed to getting a bath.
P: No, I've got a bath seat
I: So you've had to adapt th~t side of!our lifestyl~?
P: Mmm ..extra rails on the statrs, stuff like that. Can t wear proper shoes anymore,
can't walk around without anything on my feet
I: Is that because of pain?
P: Yeah
I: So is it that constant, the pain?
P: Yeah, I can 'tremember not having it now, it IS been that much now that I can't
remember not being inpain, I can 't remember my life without it, this, this is it now
I: Do you feel that, sort of your life stopped with your diagnosis, is that what
your saying?
P: No. I never, I never thought 0/... about the diagnosis. It didn't bother me <cosI
was told it was just in my knee I thought I'd still get around, but the more it's gone
through my joints, the more difficult it's got.
I: Do you feel that your life has kind of gone 'before arthritis' and 'now' because
it's altered so much )
P: Yeah, I can't remember my life before, remember what it felt like to be pain-free
I: And do you think it's the pain that has affected the biggest aspect of how you
feel, about sort of feeling isolated & affecting your social life, do you feel that
pain is one of the major reasons why?
P: I'd say pain, tiredness &feeling nauseous all the time
I: Nausea is related to taking the drugs?
P: Yeah, medication & the pain-relief tablets
I: And you can't livewithout the medication because of the pain? And you have
to control the pain because it affects your sleep? So is there a sense that you're
kind of in a hamster wheel almost?
P: Yeah, it's like 'Groundhog Day', it's the same thing everyday, no difference, no
difference, it's like you think what's the point 0fit, if it wasn't for the kids there's
no point, you know, just to do this every day
I: I sense that you are, kind of, at the end of your tether with it?
P: Mmm ... (cries) ...Mmm, just hope they find a cure, just want to be normal, want to
be me.
I: Do you view yourself as 'not normal' because of the condition?
P: It's just a life no more (cries), but then you feel guilty, you know with my husband
& the kids, because you feel like you're dragging them down. Gets to the point were
you turn into a liar because you're saying to them "I'm fine, I'mfine"
I: And really you'd like to be honest about it & tell them?
P: I don't want people knowing
I: Why, do you think they'll view you as something completely different?
P: They already do, like I said before it's "Sue with arthritis" not just Sue, It's like
the more I tell them the worse it's going to get
I: Do you have a special friend, like a best friend or anything?
P: I've got a few, but they've all got their own lives haven't they? Jobs, kids. I still see
them all, they still come down & I get lifts up to theirs, but it's not the same is it?
I: Is there a sense that you're missing out on something?
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300 P: I'm missing out on loads,just like I'm missing out on life isn't it?
301 I: You feel like life is passing you by?
302 P: Mmm.feellike I've done nothing
303 I: So has it affected, kind of,what were, before you had your diagnosis, has it
304 affectedwhat maybeyour life goalswere & what youwanted to achieve in
305 your life.Bas all that been affected?
306 P: Yes, they'vejust gone now
307 I: So have you got a senseof, I don't know, lossaround that, grieving almost?
308 P: Yeah, I've just got to try not to think about it now, the way Ifeel, even now if there
309 is a cure, it's going to takeyears, you're still going to be on all the medications &
310 to go & get ajob it's going to be a bigproblem, like I started off doing
311 hairdressing & that ..can't do all that now
312 I: Is there something that you'd like to do, that you feel that you're never going
313 to be able to do?
314 P: No, 'cos I gave up on everything
315 I: But it doesn't stop you dreaming
316 P: It's not worth it is it? Ifyou knowyou're not going to be able to do it, it's going to
317 makeyou worse dreaming about it isn't it? All I can see now, as long as I get my
318 youngest to 18, that's it
319 I: And then what?
320 P: I'm not bothered
321 I: Not bothered about anything?
322 P: No, my worry is looking after the kids now, as long as I can look after the kids
323 that's it, I don't care
324 I: And is that the Sue that used to be?
325 P: No, I used to play sport and everything, walk everywhere, always out shopping,
326 even used to go out with my mum, but I don't anymore
327 I: What do you feelyou've lost from this past life?
328 P: It's two totally differentpeople
329 I: Are you angry about it?
330 P: Yeah, butyou don't know who to blame, there's no-one to blame is there?My
331 mum's blaming herself & that makes me angry 'cos she keeps buying me stuff you
332 know, like she's trying 10 compensatefor everything, any new gadget or cream or
333- anything, she comes down "I bought you this, oh it's myfault ", I've got enough to
334 deal with. It's just gettingpeople to, err, even the doctors don't understand
335 I: You say they don't understand?
336 P: You go in & it's "Blah, blah, blah, how are you feeling?" It's like what really
337 makes me angry, honestly Ifeel like hitting them sometimes, they've got this, like
338 a ruler thing. "put the arrow on that to tell me where your pain is over thepast
339 week", that really, really makes me angry that, it's stupid, how canyou describe
340 howyour pain is on a ruler when it's differentfrom day to day & they sayjust over
341 the last week? Or,you get aform tofill out whenyou go in "what canyou do,
342 what can't you do?"
343 I: So they're trying to measure what kind of,what your pain levelhas been & is
344 that quite a difficult thing for you to explain?
345 P: Yeah because it's differen: day to day, it's different morning, different to night, you
346 can't do it.
347 I: So can you think of anyway,you know, you're livingwith the condition, can
348 you think of a better way to do that, have you got any ideas of bow..
349 P: All they'd have to do is say, to ask you, in the mornings ...theyjust shove this thing
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at you & say "on the level, that being the highest, that being the lowest, put the
arrow to where the pain is"
I: So they're trying to get an average for the week? So do you feel that is not the
right way to do it, you want to be able to say to them " I was screaming with
pain one day?"
P: Yeah, I want to be able to say like, in the morning it was this way or in the night,
on Tuesday I couldn't move 'cos you can't put an average on..,.how can you put an
average on pain? That means you'd have to sit & think about it constantly so ...
(cries)
I: And you don't want to?
P:No
I: You don't want to be reminded of it? Have you told the doctors how you feel
about that?
P: No, No, 'cos you don't get enough time do you? Youfeel like Umm ... they're
always saying "Oh, there's loads of people, we're so many hours behind". It's like
you go to see your rheumatology nurse, I go once every four weeks at the moment,
& you go in & she says "what's wrong? ", but you don't want to tell her.
I: Wbat stops you wanting to teDher?
P: You feel like you're wasting ...wasting her time, you know she's got loads of people
sitting outside & she must hear it all the time, so what's so different about you?
Why would they want to hear about you?
I: Do you not think ifyou're having intense pain, or whatever, they're the
people that need to know so they can try & help?
P: Yeah, but you know it's going to be the same thing every time you go to hospital
I: So is there a sense that it's almost a waste of time for you, that even though
you go, keep your appointments & you speak to your consultant, you feel that
you're actually not going to be any better off!
P: Ifoellike a guinea pig, even my doctors say they're banging their heads against a
wall at the moment
I: Is that because the drugs aren't working as they should be?
P: Yeah, that's why they started me with these ...he really pushed to get me ...he
is..he 's a good doctor, but there's only so much they can do, he really pushed to
get me on these injections hoping these would work, then if these work I'm on these
for the rest of my life
I: And does that bother you, does the treatment programme itself, is that
actuaDy a source of concern because it's long term?
P: It just gets to the point where it does your head in & I don't want to take the tablets
no more, I'm fed up taking them, it's like, ifyou do go out anywhere, you've got to
take all these tablets with you, excuse yourself when you go & take the tablets,
otherwise ifyou don't take the tablets you're in that much pain tou 're going to
have to come home anyway, can't win, might as well just stay in.
I: So the actual treatment is, kind of, part of the issue as well is it, that the
treatment itself is enough to stop you wanting to go out? Let alone the pain?
P: Yeah, 'cos you've got to think when is my tablet due?Got to make sure I take these
tablets at that time & then when you've took your tablets you're feeling sick,
you're just exhausted all day. I'll get up, get myself sorted, it's half eight I want to
go back to bed, just want to sleep.
I: Do you, do you try & have a rest during the day & catch up?
P: I could/all asleep in two minutes, but it's notfair, you know like when the kids are
off school & that, & you think, oh, it gets to the point where I panic about having
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the kids in the house all day, 'cos you know you've still got to look after them, one's
only eleven, the other one can look after herself but it's still not fair is it? You still
realise you've got to do things for them even 'though they understand, but you've
got to.
I: They understand the situation that you're in?
P: Yeah, the little one's lived with it all her life, hasn't she? the older one, she was
only about six. When it first started it wasn't too bad, I could still do things, I was
only like sort of limited slightly, but now ...
I: So how about your concerns for the future then? Your kids are growing up &
presumably will go off & do whatever & how about you?
P: I can't see one
I~ You can't see one?
P: Same as it is now, unless all of a sudden there's some cure, if that's the case I'll
just be done some shopping won't I? (Laughing)
I: Making up for lost time?! Is there no sense of any satisfaction with your life?
P:No
I: ~ot in any aspect of it?
P: I'm glad I had the kids, I'm glad I had them young or I wouldn't have had any. It
takes over your life, people don't realise the pain, or how much it limits you
I: So do you feel that you're constantly preoccupied with your own illness?,"
P: Everything you do now you've got to think how it's going affect you, you can't just
think "oh, I'll go out, Oh, I'll do this", it's "I can do this, but ... ". I tidy the
bedroom & want to tidy under the bed, I can get on the floor but I'll be stuck there,
I have to get someone to lift me up. Everything you want to do you've got to think
Out.
I: So you have to pre-plan do you?
P: Yeah
I: So has your spontaneity gone completely?
P: Well, I can't say I'll go out tomorrow 'cos I don't know what it's going to be like
until I get up, so I can't just plan ahead
I: So is your situation that you wait to see each morning how you are before you
decide what you're going to do with the day?
P: Yeah, it's the only way you can do it, it's so difforent everyday, one day you can
feel "Oh great, I'll go & do this today" & then the next day you'll pay for it, if
you've overstretched what you normally do, you will pay for. it the next day 'cos
you're totally seized up
I: Is it worth it? Do you feel that •••there's always a cost in everything we do isn't
there? But do you feel that ifyou can go out &have a good day it's worth the
pain & the discomfort the following day or the following week?
P: You get used to it, you get used to accepting it so..I'd do anything to get out &just
live a normal life. I've told the doctors that, I'd give up every penny I had,
everything I had just to be back the way I was.
I: Is that a sense of desperation?
P: I suppose it's just the way you get to thinking, I mean, you heard the word, I
remember when before I had arthritis, arthritis meant nothing to me, I just thought
you got a pain like people get in some of your joints, that was it, it was nothing,
you don't realise how ...how much it changes someone's lifo
I: And apart from their lives, you've quite clearly put across that it changes the
Person
P: Yeah, it takes you over, it's got to the point now I've started to think of myself as
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450 'Sue with arthritis', it's not me no more. I actually feel angry with everyone, don't
451 know why, it's like you're not getting heard, you feel like shouting. I lose my
452 temper very quickly, not with the kids or anything, just angry all the time
453 I: And do you think that's because of the condition that you're living with?
454 P: Yeah
455 I: You didn't used to be angry?
456 P: No, No I was always shy & quiet. People come up to me & they moan about stupid
457 Things 7you feel like saying, you know, "get a grip, I wish that's all I had to moan
458 over ", but they don't get it. Ifyou went up to someone in the street who hasn't g(Jt
459 arthritis ...it's nothing, it's just another condition
460 I: And that's what makes you angry, the fact that there isn't the recognition?
461 P: Yeah, people don 't.i.they don't get it. They can't understand it until it happens to
462 You, I don't think there's any way to explain, they ..I think people need to know
463 that's it's not just an old persons disease
464 I: Have you considered making, as some of your goals in life you feel got taken
465 Away, have you considered making that a goal..to try & make the condition
466 more high prof"de& educate the person in the street?
467 P: I don't see the point, people don't want to 'cos it reminds you too much, it makes
468 you realise that you've sort of pushed it to the back of your mind & you've just got
469 to get on with it
470 I: so you'd quite like to forget that you're living with the disease?
471 P: I think everything is a constant reminder but you just want to ...youjust want to be
472 normal (cosyou feel you're not normal
473 I: What was being 'normal' before?
474 P: Stupid things. Walking down the street without having to walk next to a wall, you
475 know, so you've got something to hold on grab on to , being able to carry shopping
476 bags without worrying "Oh, I can't buy that because it's too heavy, I won't be able
477 to carry it"
478 I: Pretty much everyday tasks?
479 P: Opening a tin, turning over in bed without waking up in pain, stupid things.
480 I: It's very much things that probably we all take for granted when we're in
481 good health?
482 P: Yeah, it's like going on holiday, we go to America but everyone goes around th e
483 theme parks, where I'll just sort of sit, I can't go on any of the rides or anything,
·484 I've just got to sort of sit, ill say "Oh, just leave me here, you go off & do what
485 you've got to do ", It's daft because you become a person-watcher, like a people-
486 watcher, makes you more aware of what's going around
487 I: Has the condition done that to you? Do you find that you think more about
488 maybe other people with other conditions & how they must be feeling & what
489 they're thinking?
490 P: I think constantly. I find my mind, it doesn't sleep ...something is going on all th e
491 time. It's like stupid problems, you can't let them rest because you're thinking
492 about them, you're thinking the worst of everything ... like you can 't help ..you feel
493 like nothing good happens anymore. It's like in the summer, some mums, you know
494 they get out in the street &play rounders with the kids & you've just got tio sit up 7
495 watch, wish I could, I'd get out there with them, but you feel like they don't
496 understand, they're like "Oh, come on" &you say "oh, I can't I'm doing
497 something or.. "
498 I: so you're aware of making lots of excuses?
499 P: Yeah, got an excuse for everything me. I don't need changing into a liar, because
10
500 you don't want ...you want to say cc I can't cope with that, I've got arthritis", it's
501 not whatyou want to do so you make an excuse.
502 I: Don't you think it's OK to say "I can't do it because I've got arthritis"? Is
503 that Dot OK to be able to say that to them?
504 P: Iwouldn'twant to...ljuat feel ashamed,probably because I'm young, because it's
505 an oldpersons disease & you don't hear other people in the street "I've gotthis
506 wrong with me, I can't do that"
507 I: Do you think maybe other people are sitting at home as well & they've got
508 something wrong & they want to come out & say "I can't do it because ••"?
509 P: Probably, but you don't see it, do you? Like you hear of children with arthritis, but
510 how many of them doyou see in the street? Can't say I've ever seen them.
511 I: Do you think there would be any benefit in something like a support group?
512 You know, where a group of people with the same condition, like psoriatic
513 arthritis, get together & relate their own experiences & things, do you think
514 something like that would be useful?
515 P: I think a lot of people would I'm shy, I'd find it difficult myself, but I suppose once
516 I'd got into it...it's somethingyou just don't hear of it. If there is something it's got
517 to be close
518 I: Yes, because presumably mobility is an issue, if getting to hospitals or places
519 where they could hold a group?
520 P; Yeah
521 I: You've mentioned a couple of times that you wouldn't do something because
522 you're shy, do you just feel that you're shy now or ...
523 P: I've always been shy, I've always had, sort of the back seat
524 I: So it's not something that's happened as a result of your condition?
525 P: No, it's like if there's an argument in the/amity, they all say" We'll go to Sue, 'cos
526 Sue doesn't drink, Sue's the shy one, she'll sort everythying out"
527 I: So your condition hasn't made you shy particularly, even though you feel like
528 you've withdrawn a bit from life ••. the shyness isn't a result?
529 P: No, the shyness has always been there. Thenyou wonder if it's going topass on
530 to the kids or not...every little twinge...
531 I: Is that a worry for you, about their future health? Is that something you've
532 discussed with the consultant?
533 _P:They reckon it won't butyou can't be sure about some things, I didn't think I
534 Wouldend up with it. I think that scares me because I can't do anything to control
535 It, there's no cure, onceyou've got it,you've got it.
536 I: WeD how about the focus on your psoriasis, is that just an added burden to
537 the whole thing?
538 P: Sometimes it clears up totally, but thenjust as you're getting used to not having it,
539 itjust reallyflares up again & then you need help with the creams becauseyou
540 can't twist around toput your creams on. I'm always saying to the kids, because I
541 got it through exams worrying, IIdon't worry, don't get stressed out"
542 I: That's when it first started, was it?
543 P: Yeah,when [was doing my last lot of exams at senior school. I'm one of those
544 people who worry about anything, a knock on the door, I worry who it is, it's just
545 the way it goes, itjust gets worse & worse, you know becauseyou're not really
546 getting out & that, you just think it's got to be something bad
547 I: Do you never expect anything good to happen or anything good to knock at
548 your door?
549 P: No. what is there? What is there that's going to be good?
11
550 I: What would you like there to be good?
551 P: You just do don't you? if someone came knocking on my door to say, "Sue, we've
552 got a trip organised or we've got this organised" ...what's the point?
553 I: So even if somebody made the effort to organise something it wouldn't
554 particularly motivate you to want to go & take part?
555 P: I'd try, but all you're thinking of is at the end of it, you know, what's going to be at
556 the end or halfway through it or, you know, it's just going to be the pain, or you're
557 too tired &just think "oh, I can't be bothered"
558 I: So is you expectation that you go & do something, ifyou go & do something,
559 you know it's going to end up in a lot of pain?
560 P: Yeah, ifyou know it's there, you know it's going to be that way, you know whatever
561 you do you're going to suffer for it
562 I: So that would prevent you, I assume, from enjoying anything, whether it be
563 from saying "let's go to the pictures or..?"
564 P: Especially the pictures, you're stuck in those little seats for ages & you fidget &
565 people don't understand why you're moving around
566 I: Do you think there is something to be said for your condition being more
567 Visible, as it were, for example if you are in a wheelchair were there is an
568 obvious disability?
569 P: Yeah because when people can't see it, they don't understand it
570 I: So do you feel you would get a better reaction if you were on crutches or in a
571 wheelchair?
572 P: People would sort of know to..like when you've got kids around yo~, you're
573 constantly standing back incase they knock you or anything ... it's really painful,
574 but whereas ifyou're on crutches or anything, they know to be careful
575 I: Do you feel that people would react more positively to you?
576 P: Yeah, but ... it's hard to say because I wouldn't want to be on crutches or in a
577 wheelchair, I wouldn't wish that on anyone. It's just so hard because they can't
578 see it, they don't know what it's about, so they don't know, you can't until you've
579 got it, until it's happened to you, even someone who lives with you, they can't fully
580 understand it, that's the point. This is going to sound stupid (laughs), I started
581 getting tattooes because I could control the pain
582 I: because you could?
583 P: It's like ... this sounds really weird, you're getting pain but you know it's going to
584 stop, it's like harming yourself but not going that far because you know that pain is
585 there, but that pain is going to stop. It sounds stupid doesn't it?
586 I: No, it's very interesting
587 P: 'cos the doctors ... the nurses used to say to me, " wait until the doctor sees them ",
588 but I couldn't explaint to them, why I'd had it done. It made me sort of different, I
589 was getting something for myself, even though it was causing pain I knew the pain
590 would stop
591 I: Was it because you were in control?
592 P: Yeah, I was in control of all that pain
593 I: So did you have one done first just because it was the 'in-thing' to have done
594 & then because of how it felt ..
595 P: Yeah, because I'd put it off for years, 'cos I'd always liked them, I had one done
596 last year, "God that hurt" but it stopped & then I got to the point where I wanted
597 that pain because I knew it was going to stopa couple of hours later. It sounds
598 strange.
599 I: So how may did you have done?
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P: Three
I: And would you consider having another one done?
P: Yeah, with all.I 'm going through I'm trying to stop myself getting another one. The
only way I can see it, it's like hurting yourself but ... because you know you can
control the pain ...
I: Did you feel quite elated when the pain stopped?
P: Yeah, yeah
I: Is it a nice sensation? You'd have the pain & then it's gone?
P: Yeah, then it had gone
I: So you get a buzz from it?
Yeah
And is that the first time you've had a 'high', if you like, for a long time?
P: Yeah, it made me happy, I thought "Oh God, I'm not in pain ''. I know it sounds
weird, but like, that really hurts but, god the pain had gone
I: Does it distract you from the pain of your arthritis? Is the pain ••
P: Yeah, 'cos you're concentrating on a different pain
I: So you were distracted from the pain in your joints, so you weren't aware of
the joint pain?
P: No, 'cos the pain was there, at the tattoo (touches tattoo). You're saying "she's
mad!"
I: Do you not think it sounds like it makes sense?
P: It does to me. But then like every time we go on holiday I think "Oh, I'll get a
another tattoo &1'11get it in a different place & see if ..what it hurts ". It wasn't
"oh, look at the pictures" It was" I wonder how much it's going to hurt?"
because I knew at the end of the day "God, the pain's gone, look I had pain there,
but it's gone"
I: And then did you become aware of your joint pain again?
P: Yeah
I: So you have distraction for what, a few hours?
P: Yeah, because, like, when it's done it really hurts, or when he's doing it, it really
hurts, you know, it's like lots of needles, but it's a different pain, it's a pain you
know that's going to go
I: So it's worth putting up with that pain so you don't feel the joint pain for even
just a short period?
P: Yeah, so it ...it takes your mind of it, 'cos you're hurting somewhere else
I: How did you feel when you became aware again of your joint pain?
P: It didn't bother me, it didn't bother me for the next couple of days, 'cos you know
you've got different pain, 'cos all the pains in your joints feel like the same pain &
you know it's arthritis pain & you think "Oh, I've got something different". Feels
like a different pain, that's not arthritis pain, I know that's going to go away.
I: So did that feel quite strange - having a differeDt sensation after so many
years of constant pain?
P: Yeah, arthritis pain isjust one type of pain
I: Can you describe it?
P: It's just sharp, constant. It's like stupid leaflets, you know like you get those
leaflets you get at the doctors & they say "how does the pain start/" & "when
does the pain stop?" Stupid questions, you know, who's making them up?
I: So people don't understand?
P: No, they haven't got a clue. They don't know, they don't know. It feels, that thing
with the questions, like, ifwe ask enough questions we'll understand how the 'rey
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650 feeling. I think ...I think what it boils down to, isjust depression, that's the way it
651 makes you feel. I just feel down all the time.
652 I: Do you feel depressed?
653 P: Yeah
654 I: Have you had a diagnosis of depression?
655 P: My GP reckons, but I'm not going to take any thing for it, I won't, I take enough
656 tablets, I don't want to take anymore, I don't want to go down that road.
657 I: So how do you try & cope with it then? Do you have your own sort of strategy'
658 for dealing with it?
659 P: Things like books, reading, likes of them, puzzles, I constantly try & take my mind
660 off it & think of something else, everybody else's problems, everything is a
661 problem that has got to be worked out, something that will keep my mind ticking
662 over, my mind isjust constantly on the go, something that's not quite physical,
663 more mental than physical which I know I can do
664 I: So 1S that how you occupy quite a lot of your time? You mentioned your
665 puzzles and ..
666 P: Yeah
667 I: and games & stuff, is that how you get through your day?
668 P: Yeah
669 I: You mentioned reading, is that one of your main pass-times?
670 P: If I pick a book up, I can't put it down (laughs)
671 I: Does that give you a lot of pleasure? I mean is reading a source of pleasure or
672 is it just because you feel that you can't do something else?
673 P: I enjoy reading
674 I: Ifyou read a lot, have you spent time trying to read up about your condition?
675 Are you one of these people that's gone out & tried to get information?
676 P: Yeah a little. Ifind it helps. It's like when I started my injections they give you a
677 video to watch, but I don't think they should give you that
678 I: Why was that?
679 P: Just ... they show you everything, it makes it too real
680 I: Is it a case of you don't want to know that much? Being told you need the
681 injection & the possible side-effects, that's all you need to know?
682 P: Yeah, you don't need to know
683 I: Did it almost put you off wanting to take your injections?
684 P: I was ready to say "No" to the nurse when she turned up, but she sits there
685 watching & makes you do it, so it's easier to do it & get it over with, but then
686 that's another thing I've got to worry about now. It's like the nurses, they say "Oh,
687 it's no problem, just poke it in, put the stuff in, take it out, end of story. it's not that
688 big a needle" It is when you've got to do it yourself. Then you know you've got
689 them in the house (the needles) with the kids. Everything just seems to turn into a
690 worry.
691 I: The treatment regime sounds, from what you've said, that it does throw up
692 quite a lot of concerns for you, both in having to actually inject, taking the
693 tablets & the long-term prospects of all the drugs?
694 P: It's having to take them all the time. It's a case ofifyou miss them, you know
695 you've got to pay for it
696 I: How about the economic cost of having a long-term condition like this? In
697 terms of, you know, prescriptions, & constant visits to the hospital, not being
698 able to work, I mean has that been a major impact on your life?
699 P: You have to make do
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I: Is it something you worry about, or because you were off having the kids at
tbe time was it not such a big issue?
P: No, because it's something you get used to, but there's never like spare money
in case you think "what if I go really bad" I can't go & spend this amount of
money because I've got to go to hospital next week, or what if they take me into
hospital, because afew months ago it got really bad & he wanted to take me in/or
two weeks & I turned around & said "No, I've got kids, it's not an option"
I: Do you feel that having a family actually impacts on how you deal with your
treatment? I mean, ifyou hadn't have bad kids, would you have gone into
hospital?
P: Yeah
I: And you felt that you needed to be there, in hospital?
P: It's got to the point now where the doctor says «we want to do this, we want to do
that", I'll go "just do it, ifit's going to work, do it", "take these tablets", I say "if
they're going to work, do it, do it, if you've got a miracle cure give me it". It's like
they were doing a drugs test & J said "I'll do it, I don't want to know the side-
effects are or that, I'lljust do it"
I: You'D do anything to get some relief?
P: Yeah, if they could, say to me you can start again, get a job ...
I: is that a chance to be back to what you consider 'normal'?
P: I'd love to be going out working, I know they say some people play on it & all that,
like, get to sit in the house all day & that it's better than going to work it's daft, but
I'd love to go to work.
I: Is part of that because of the social contact, you know, you've got people
around you?
P: Yeah, it's just, J think that's what my husband can't understand, like his work, he's
meeting diffirent people all the time, even though he says "My work is boring, you
don't understand", I say "No, it's a different face all the time". People see him/or
him, like he's the happy-go-lucky one, no problems, no ...but I think that bit 0/ it he
doesn't get
I: So tbat's bow you want to be looked at?
P: No, I just want to be me. I don't want to be, like, "are you alright to do this, Sue?
Are you alright to do that? Or you find people will ask someone else because they
know you can't.
I: Do you feel that you won't ever be you whilst you've got this condition?
P: Mmm, yeah, it's not going to happen is it? Unless I can control it, mind you I've
forgotten what that means, it's been that long
I: Do you feel that even though you're doing your drug treatments, that you still
can't control it & that you're administering to it rather than controlling it?
P: Yeah, even the doctors have said.they reckon like the level in your blood is
supposed to be about 5, mine was reaching about 188, they've got it down to 90.
That's like proving to the doctor that I am in pain, but he's trying everything he
can, he's tried me on everything. I'm just awkward. I mean I don't think it's like
the doctor's fault or anything, hut I still think, even though, like i/ ..they don't
understand it
I: You say you don't think it's the doctor's fault?
P: They've tried everything they can try.
I: You don't feel they're letting you down?
P: No, no, Dr T is a brilliant doctor, he's done everything/or me, but there's only so
much they can do isn't there? It's my body's fault, ifmy body is not taking to the
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drugs it's not their fault is it? I think that's what makes me angry as well, my
mum's blaming herself, but I'm blaming me. I keep thinking I must have done
something or, but I can't think what
I: Why, because you've got this arthritis? .
P: Yes, I 'feel like I'm being punished for something, I don't even know what, I don't
do drugs, I don't drink, don't smoke, you know I do everything right & yet I'm still
being punished when there's all these people walking around, drug dealers, people
taking drugs & that. They don't know they're born. I foellike I'm being punished.
I: You mention the need to blam~ there a couple of times, do you really think
you have to blame somebody for this? Does it not just happen?
P: I know itjust happens but youfee that angry that you want to ...you need something
to blame, there's got to be a reason for it, there must be. Like, I'm angry that when
I got the psoriasis the hospital never mentioned it, that this could happen. I think to
myself, "well, I could have taken cod-liver oil & maybe helped this for 12years".
Maybe they should warn people, because Iwas never told nothing.
I: Have you since asked why you weren't told?
P: 0, I asked once & they just said "Oh, we don't, we just don't mention it"
I: So does your psoriasis tend to flare at the same time as your arthritis? Do the
two go together?
P: I had psoriasis for years before they even said I had arthriris, I had psoriasis from
when I was was 15. Inever had any problems up until I was about 27 & then my
knee started, I don't even know what triggered it off. I can't think of anything
that's triggered it off.
I: But now if you get a flare up of psoriasis, does your arthritis kick-in as well?
P: No, because that's just constant anyway
I: So the two don't tend to flare together?
P:No
I: And is the psoriasis, when it flares, visible?
P: It's on my knee (rolls up trousers to show me)
P: Do you get affected on your face?
P: Only over the last month or so I've been getting it under my nose. I've never, ever
suffered with it on my face, it's always been..I've been able to cover it ip. You
never, ever see me in a skirt, never, it's always trousers
I: Is that because you don't want it visible?
P: Yeah, plus all my knees are always swollen, you know, with the arthritis.
I: Are you quite conscious about your image?
P: Yeah, like about three months ago I started losing my hair, you can see my fringe
isjust growing back, so that was another thing to worry about, losing my hair, but
the doctors just said that's because I wasn't well & it came out as hair loss. Every
corner you turn there's something else waitingfor you, around the corner.
I: You've had a lot to contend with
P: When it happens you think "what's going on", you try & cope because you know
there is nothing they can do
I: Is there a sense that you ••• because you learn & have adapted to changes in
your lifestyle because of the condition, do you feel that that you can cope with
things that are being thrown at you, like your hair dropping out?
P: You've got to, you've got no choice, you've got to teach yourself to do it or you're
just going to get yourself more & more worked up to the point where you're going
to snap & it's happened
I: What, that you snapped?
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P: Yeah, I just got to the point where Ifelt as though I wanted to go to bed, fall asleep
& not wake up (cries) so you can't let yourself get that far, but then when you go
into hospital you can't explain this to the doctors. It's like, you think if you tell
them they're not going to believe you
I: Do you not think there must be other people that feel the same way & that
Maybe they have heard that before?
P: You don't tend to think of other people when you go there, it feels like you're the
only person with it
I: Feel like you're alone?
P: When I go to the hospital it's all old people, you're sitting there & you're watching
. them & you can see the way their fingers have bent & all that, & it's starting to
happen to my toes &you think "I don't want to be like that when I'm older ",
That's what you start thinking, that's why I don't want to be old, old people scare
me now. You think "if I'm struggling now, what am I going to be like when I'm
old?n .
I:.Growing old frightens you, the prospect of it?
P: Yeah, I don't like being around old people, you know like pensioners who are
struggling anyway. You see them at hospital & all their hands are twisted with the
arthritis. I couldn't cope, I'd rather not be here.
I: You've mentioned that a few times, is it something that has gone through your
mind?
P: Yeah, it's 'cos I've got the kids, there's no point really is there?
I: What about your husband?
P: He knows my life..you want a life, you want a proper life don't you?, not just
Same everyday then worrying about what you're going to do & then if you feel
alright, going out & then halfway through the day you think "I'm in agony, I'll
have to go home ". go home & take my tablets, go home & do my injection
I: Do family life & your marriage not give you some sense that life is worth
living?
P: Iflellike I'm letting the kids down, but I don't want them having' someone in my
place, I always think they're never going to call someone-else' mum' or that. You
feel like they're missing out, even though they say they're not, you feel like they
must be missing out on something. It's like the youngest will say can we go out &
I'll say "sorry babe we can't, I'm too sore today, you'll have to wait/or another
day" & she 'IIjust go "OK".
I: Have they learnt to cope with it, I mean something like that if they want to go
somewhere do they say they'll organise to go with a friend?
P: It doesn't bother them, if I say I can't they say "OK, don't worry about it ", but
then Ifeel like I'm letting them down, I can't do it. But then when they're 18, or
left home, they're sorted then ...you know while I've got them here I've got
something, I've got to get up & do things. It's like, I don't force myself, but you
know you've got to get up & you've got to do them & you've got to look after them
so you've got a purpose
I: So you feel that your purpose in life at the minute is•••
P: Looking after the kids
I: That's your reason to get up in the morning?
P: Yeah, so what's going to happen when they ...
I: Is that a source of worry to you, about how, if you think further ahead, how
you might actually feel when they're not here, when they're away or married?
P: It's like my eldest daughter now, she's got her first boyfriend & I can't let go. He
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